Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1Abbreviated Title: EP0057 in Advanced Cancers
NIH Protocol #: 16-C-0107 
Version Date: 08/16/2024
Study ID: [REMOVED]
Title: A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with 
Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers 
NCI Principal Investigator: [INVESTIGATOR_148322], MBBS, M.D. 
Developmental Therapeutics Branch (DTB)
Center for Cancer Research (CCR)
National Cancer Institute (NCI)
[ADDRESS_729196], Room 4-5330
Bethesda, MD [ZIP_CODE]
Phone: [PHONE_3302]
E-mail: [EMAIL_2187]
Drug Name: [CONTACT_151658]0057 (formerly CRLX101) Olaparib
IND Number: 130102 130102
Sponsor: Center for Cancer Research Center for Cancer Research
Manufacturer: Ellipses Pharma Limited [COMPANY_008]
Supplier: Ellipses Pharma Limited [COMPANY_008]
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2PRÉCIS 
Background:
•Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis.
•Although highly responsive to chemotherapy initially, SCLC relapses quickly and 
becomes refractory to treatment within a few months.
•Urothelial Carcinoma (UC) of the Bladder is the fourth most common malignancy in men 
and the ninth most common in women.
•Prostate cancer is the most common cancer among men in the [LOCATION_002]. While 
prostate cancer is initially responsive to androgen deprivation therapy (ADT), the median 
duration of sensitivity is 24-36 months. Moreover, patients develop resistance to current 
treatment options. 
•The use of PARP inhibitors in combination with chemotherapy builds upon pre-clinical 
data in lung cancer and other cancers supporting the notion that PARP inhibitors 
potentiate the effect of DNA damaging therapi[INVESTIGATOR_014]. 
•Despi[INVESTIGATOR_555505], human studies combining 
PARP inhibitors and camptothecins have not translated into clinical benefit due to 
enhanced toxicity with the combination.
•One approach to improve ability to combine camptothecins with agents that sensitize 
their activity like PARP inhibitors is to use alternative formulations that minimize 
toxicity to the normal tissues.
•EP0057 is a nanoparticle drug conjugate composed of 20 (S)-camptothecin (a potent and 
highly selective topoisomerase I inhibitor) conjugated to a linear, cyclodextrin-
polyethylene glycol-based polymer.
•Olaparib is a PARP inhibitor indicated as monotherapy in patients with deleterious or 
suspected deleterious germline BRCA mutated advanced ovarian cancer who have been 
treated with three or more prior lines of chemotherapy. Olaparib has an established safety 
profile and it is under investigation in a number of different cancers.
Objectives:
•Phase I: To determine the MTD/recommended Phase 2 dose (RP2D) of EP0057 in 
combination with olaparib in patients with refractory cancers.
•Phase II: To determine the antitumor activity of olaparib plus EP0057 with respect to 
progression free survival at 16 weeks in SCLC patients with resistant or sensitive relapse.
•Expansion Cohorts: To determine overall response rate of EP0057 plus olaparib in 
patients with mCRPC and urothelial carcinoma.
Eligibility:
Phase I
•Adult patients ≥18 years of age
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
3•Histologically or cytologically confirmed, advanced solid tumor that is refractory to 
standard therapy and/or for whom no further standard therapy is available
•ECOG Performance Status of 0, 1 or 2
Phase II
•Adult patients ≥ 18 years old
•Have a pathologically (histology or cytology) confirmed diagnosis of SCLC
•Disease progression on or after at least one platinum-based standard chemotherapy 
regimen and/or an immune-checkpoint inhibitor for either limited or extensive stage 
disease. 
•Have measurable disease per RECIST 1.1 
•ECOG performance status of 0, 1 or 2
Phase II Expansion Cohorts
•Have a pathologically (histology or cytology) confirmed diagnosis of urothelial 
carcinoma or metastatic, progressive, castrate resistant prostate cancer (mCRPC)
•Disease progression on or after at least one platinum-based standard chemotherapy 
regimen and/or an immune-checkpoint inhibitor (except prostate cohort)
•Have measurable disease per RECIST 1.1 (except prostate cohort)
•Prior treatment with enzalutamide and/or abiraterone (prostate cancer cohort only)
•Patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]) (Prostate 
cohort only)
Design:
•Patients meeting eligibility criteria will receive EP0057 (IV Q 2weeks) plus olaparib (PO 
BID days 3-13 and days 17-26 administered in 28-day cycles, until disease progression or 
development of intolerable side effects. The MTD of the combination will be used in 
Phase II. 
•Patients in Phase II will receive, the RP2D at DL4R EP0057 12 mg/m2 and olaparib 250 
mg BID. 
•Blood, tumor and hair samples will be collected at multiple time points for PK, PD 
analyses. Hair sample collection is optional. Tumor biopsies are optional for SCLC and 
UC patients and mandatory for mCRPC patients (only baseline biopsy is mandatory).
•Toxicity will be graded according to CTCAE version 4.0. 
•Tumor assessments will be made using CT scans (chest, abdomen and pelvis) at baseline 
and after every 2 cycles (3 cycles for mCRPC) according to RECIST version 1.1. 
•After discontinuation of study treatment, follow-up for survival will be carried out every 
3 months. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
4Trial schema and dose escalation
Provisional Dose levelsEP0057, mg/m2
(IV q 2 weeks D1 and D15)Olaparib tablet, mg
(PO BID Days 3-13* and 17-
26*) 
1 12 100
2 12 150
3 12 200
4 12 300**
4R(educed)  (MTD/RP2D) 12 250
5 (Not explored) 15 300
5B (Not explored) 15 300
28-day cycles; biopsies pre-treatment and on day 4 ([ADDRESS_729197]- olaparib) and at disease 
progression. 
* There should be a minimum 48-hour window between EP0057 and olaparib except dose 
level 5B which allows the interval to be abbreviated to 24 hours. 
The recommended phase 2 dose (RP2D) may be lower than, or equal to, the MTD. Phase II 
portion of this study may start with RP2D, and/or at MTD.
** An additional dose level (4R) of 250 mg has been evaluated with DLTs in 1 of 6 patients as 
there were 2 or more DLTs among 6 patients treated at dose level 4.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
5

Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
6TABLE OF CONTENTS 
PRÉCIS............................................................................................................................................2
TABLE OF CONTENTS.................................................................................................................6
STATEMENT OF COMPLIANCE...............................................................................................12
1 INTRODUCTION ..................................................................................................................13
1.1 Study Objectives .............................................................................................................13
1.1.1 Primary Objectives...................................................................................................13
1.1.2 Secondary Objectives...............................................................................................13
1.1.3 Exploratory Objectives ............................................................................................13
1.2 Background and Rationale ..............................................................................................13
1.2.1 Small Cell Lung Cancer...........................................................................................13
1.2.2 Urothelial Carcinoma (UC) of the Bladder..............................................................14
1.2.3 Castrate resistant prostate cancer (mCRPC)............................................................16
1.2.4 PARP as a Therapeutic Target in Small Cell Lung Cancer.....................................18
1.2.5 PARP Inhibitors and DNA Damaging Chemotherapy are Synergistic ...................19
1.2.6 Safely combining PARP Inhibitors with Camptothecins.........................................19
1.2.7 EP0057 Preclinical Toxicology ...............................................................................21
1.2.8 EP0057 phase I clinical trial ....................................................................................21
1.2.9 Adverse Events with EP0057 (CRLX101) Monotherapy........................................22
1.2.10 Adverse Events Associated with EP0057 (CRLX101) Combination Therapy .......28
1.2.11 EP0057 (CRLX101) Clinical Development Overview............................................33
1.2.12 Preclinical Data of EP0057 (CRLX101) plus Olaparib...........................................34
1.2.13 Hypothesis................................................................................................................35
1.2.14 Rationale ..................................................................................................................36
1.2.15 Rationale for Amendment C ....................................................................................36
1.2.16 Rationale for Amendment E ....................................................................................36
1.2.17 Rationale for mCRPC cohort accrual closure (amendment version date: 
07/27/2021)............................................................................................................................37
1.2.18 Rationale for urothelial carcinoma cohort accrual closure (amendment version date: 
08/17/22)................................................................................................................................37
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT ........................................................37
2.1 Eligibility Criteria ...........................................................................................................37
2.1.1 Inclusion Criteria - Phase I ......................................................................................37
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
72.1.2 Inclusion Criteria - Phase II SCLC ..........................................................................39
2.1.3 Inclusion Criteria for Urothelial Carcinoma Expansion Cohort (accrual to the 
cohort ended with amendment version 08/17/2022)..............................................................40
2.1.4 Inclusion Criteria for mCRPC Expansion Cohort (accrual to the mCRPC cohort 
ended with amendment version 7/27/2021)...........................................................................42
2.1.5 Exclusion Criteria - Phase I and II SCLC and UC Expansion Cohort (note: accrual 
to the UC cohort ended with amendment version 08/17/2022) .............................................43
2.1.6 Exclusion Criteria - mCRPC Expansion Cohort (accrual to the mCRPC cohort 
ended with amendment version 7/27/2021)...........................................................................44
2.2 Recruitment Strategies ....................................................................................................46
2.3 Screening Evaluation ......................................................................................................47
2.3.1 Screening activities performed prior to obtaining informed consent.......................47
2.3.2 Screening activities performed after a consent for screening has been signed........47
2.4 Participant Registration and Status Update Procedures..................................................48
2.4.1 Screen Failures.........................................................................................................48
2.4.2 Treatment Assignment Procedures ..........................................................................48
2.5 Baseline Evaluation.........................................................................................................48
3 STUDY IMPLEMENTATION ..............................................................................................49
3.1 Study Design...................................................................................................................49
3.1.1 Dose Limiting Toxicity............................................................................................50
3.1.2 Dose Escalation........................................................................................................51
3.2 Drug Administration .......................................................................................................52
3.2.1 EP0057.....................................................................................................................52
3.2.2 Olaparib....................................................................................................................53
3.3 Dose Modifications .........................................................................................................53
3.3.1 General Recommendation for Dose Modification...................................................53
3.3.2 Dosing Delays/Dose Modifications and Management of Toxicities .......................54
3.3.3 General Recommendations for Dose Modification and Management of Non-
Hematologic Adverse Events.................................................................................................57
3.3.4 Management of the hypersensitivity/infusion reactions ..........................................[ADDRESS_729198] and Compensation ..................................................................................................63
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
83.5.1 Costs.........................................................................................................................63
3.5.2 Compensation ..........................................................................................................63
3.5.3 Reimbursement ........................................................................................................63
3.6 Criteria for Removal from Protocol Therapy and Off Study Criteria.............................63
3.6.1 Criteria for Removal from Protocol Therapy...........................................................63
3.6.2 Off-Study Criteria ....................................................................................................63
4 CONCOMITANT MEDICATIONS/MEASURES................................................................64
4.1 Supportive Care...............................................................................................................65
4.1.1 Other Concomitant Medications..............................................................................65
4.1.2 Palliative radiotherapy .............................................................................................66
4.1.3 Administration of other anti-cancer agents..............................................................66
4.1.4 Medications that may NOT be administered ...........................................................66
4.1.5 Overdose ..................................................................................................................66
4.2 Highly Effective methods of birth control ......................................................................66
4.2.1 Acceptable non-hormonal birth control methods ....................................................67
4.2.2 Acceptable hormonal methods.................................................................................67
5 CORRELATIVE STUDIES FOR RESEARCH ....................................................................68
5.1 Biospecimen Collection ..................................................................................................68
5.1.1 Phase I and Phase II Cohorts ...................................................................................68
5.1.2 UC Expansion Cohort..............................................................................................74
5.1.3 mCRPC Expansion Cohort ......................................................................................85
5.2 Sample Storage, Tracking and Disposition.....................................................................87
5.2.1 DTB Clinical Translational Unit..............................................................................87
5.2.2 Clinical Pharmacology Program (Figg Lab)............................................................88
5.2.3 Redon (Aladjem) Lab ..............................................................................................89
5.2.4 Paul Meltzer Lab......................................................................................................89
5.2.5 Laboratory of Genitourinary Cancer Pathogenesis (Kathleen Kelly Siebenlist).....89
5.2.6 Urologic Oncology Branch Molecular Therapeutics Facility (Donald Bottaro) .....89
5.2.7 Laboratory of Pathology ..........................................................................................90
5.2.8 Laboratory of Pathology NCI COMPASS Program................................................90
5.2.9 Future Use/IRB Reporting/Protocol Completion/Sample Destruction....................90
5.3 Samples for Genetic/Genomic Analysis .........................................................................91
5.3.1 Description of the scope of genetic/genomic analysis.............................................91
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
95.3.2 Certificate of Confidentiality ...................................................................................91
5.3.3 Management of Results............................................................................................91
6 DATA COLLECTION AND EVALUATION ......................................................................92
6.1 Data Collection ...............................................................................................................92
6.2 Data Sharing Plans ..........................................................................................................92
6.2.1 Human Data Sharing Plan........................................................................................92
6.2.2 Genomic Data Sharing Plan.....................................................................................93
6.3 Response Criteria ............................................................................................................93
6.3.1 Definitions................................................................................................................93
6.3.2 Disease Parameters ..................................................................................................93
6.3.3 Methods for Evaluation of Measurable Disease ......................................................94
6.3.4 Response Criteria.....................................................................................................96
6.3.5 Response Criteria for mCRPC Cohort.....................................................................98
6.3.6 Duration of Response...............................................................................................99
6.3.7 Progression-Free Survival........................................................................................99
6.3.8 Response Review.....................................................................................................99
6.4 Toxicity Criteria..............................................................................................................99
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN..100
7.1 Definitions.....................................................................................................................100
7.2 OHSRP Office of Compliance and Training / IRB Reporting......................................100
7.2.1 Expedited Reporting ..............................................................................................100
7.2.2 IRB Requirements for PI [INVESTIGATOR_10021] ..................................100
7.3 NCI Clinical Director Reporting...................................................................................100
7.4 NIH Required Data and Safety Monitoring Plan ..........................................................100
7.4.1 Principal Investigator/Research Team ...................................................................100
8 SPONSOR PROTOCOL/SAFETY REPORTING...............................................................101
8.1 Definitions.....................................................................................................................101
8.1.1 Adverse Event........................................................................................................101
8.1.2 Serious Adverse Event (SAE)................................................................................[ADDRESS_729199] ...............................................................................102
8.2 Assessment of Safety Events ........................................................................................102
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
108.3 Reporting of Serious Adverse Events ...........................................................................102
8.4 Waiver of expedited reporting to CCR/OSRO .............................................................103
8.5 Safety Reporting Criteria to the Pharmaceutical Collaborators....................................103
8.5.1 Ellipses Reporting Requirements...........................................................................103
8.5.2 [COMPANY_008] Reporting Requirements ...................................................................103
8.6 Reporting Pregnancy.....................................................................................................105
8.6.1 Maternal  exposure ................................................................................................105
8.6.2 Paternal exposure...................................................................................................105
8.7 Regulatory Reporting for Studies Conducted Under CCR-Sponsored IND.................105
8.8 Sponsor Protocol Deviation Reporting .........................................................................106
9 CLINICAL MONITORING.................................................................................................106
10 STATISTICAL CONSIDERATIONS .................................................................................107
10.1 Phase I and Phase II...................................................................................................107
10.2 Phase II Expansion Cohorts ......................................................................................109
10.2.1 Expansion Cohort (Urothelial Carcinoma) ............................................................109
10.2.2 Expansion Cohort (mCRPC) .................................................................................109
10.3 Sample Size Determination .......................................................................................111
11 COLLABORATIVE AGREEMENTS.................................................................................111
11.1 Cooperative Research and Development Agreement (CRADA) ..............................111
11.1.1 BlueLink (CRADA #[ZIP_CODE])..................................................................................111
11.1.2 Astra Zeneca (CRADA #[ZIP_CODE])............................................................................[ADDRESS_729200] Selection ................................................................................111
12.2 Participation of Children ...........................................................................................111
12.3 Evaluation of Benefits and Risks/Discomforts .........................................................[ADDRESS_729201] Policy .........................................................................................114
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1113.4 Confidentiality and Privacy.......................................................................................114
14 PHARMACEUTICAL INFORMATION ............................................................................115
14.1 EP0057 (IND#130102)..............................................................................................115
14.1.1 Description.............................................................................................................115
14.1.2 Supplier/How Supplied..........................................................................................115
14.1.3 Handling and Dispensing.......................................................................................116
14.1.4 Preparation .............................................................................................................116
14.1.5 Storage and Stability..............................................................................................116
14.1.6 Dosage and Administration....................................................................................117
14.1.7 Premedication and Hydration ................................................................................117
14.1.8 Return and Retention of EP0057 ...........................................................................117
14.1.9 Toxicity..................................................................................................................117
14.2 Olaparib (AZD2281; Olaparib; IND#130102)..........................................................117
14.2.1 Source ....................................................................................................................117
14.2.2 Pre-clinical experience...........................................................................................118
14.2.3 Toxicology and safety pharmacology summary....................................................118
14.2.4 Approved indications and clinical experience .......................................................118
14.2.5 Indications and Usage............................................................................................118
14.2.6 Dosage and Administration....................................................................................118
14.2.7 Tablet Dosage Forms and Strengths ......................................................................118
14.2.8 Warnings and Precautions......................................................................................119
14.2.9 Adverse Reactions .................................................................................................119
14.2.10 Drug Interactions ...................................................................................................121
15 REFERENCES .....................................................................................................................122
16 APPENDICES ......................................................................................................................128
16.1 Appendix A: Performance Status Criteria.................................................................128
16.2 Appendix B : List of drugs that may have potential CYP3A4 interactions ..............129
16.2.1 CYP3A4 Substrates ...............................................................................................129
16.2.2 CYP3A4 Inhibitors ................................................................................................130
16.2.3 CYP3A4 Inducers ..................................................................................................135
16.3 Appendix C : Patient’s Pi[INVESTIGATOR_13355]: Olaparib..............................................................140
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
12STATEMENT OF COMPLIANCE
The trial will be carried out in accordance with International Council for Harmonisation Good 
Clinical Practice (ICH GCP) and the following: 
•[LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) 
National Institutes of Health (NIH)-funded investigators and clinical trial site staff who are 
responsible for the conduct, management, or oversight of NIH-funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board (IRB) for review and approval. Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled. Any 
amendment to the protocol will require review and approval by [CONTACT_52590]. In addition, all changes to the consent form will be IRB-approved; an 
IRB determination will be made regarding whether a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
131 INTRODUCTION
1.1 STUDY O BJECTIVES
1.1.1 Primary Objectives
[IP_ADDRESS] Phase I: To determine the MTD/recommended Phase 2 dose (RP2D) of EP0057 plus 
olaparib in patients with refractory cancers.
[IP_ADDRESS] Phase II: To determine the antitumor activity of olaparib plus EP0057 with respect to 
progression free survival 16 weeks in SCLC patients with resistant or sensitive relapse
[IP_ADDRESS] Phase II Expansion Cohorts: To determine overall response rate of EP0057 plus 
olaparib in patients with mCRPC and urothelial carcinoma
1.1.2 Secondary Objectives
Phase I and Phase II Cohorts:
[IP_ADDRESS] To evaluate the pharmacokinetic profile of EP0057 (both the total drug and released 
camptothecin) and olaparib in plasma. 
[IP_ADDRESS] To evaluate the pharmacodynamic (PD) activity of EP0057 in blood, surrogate tissue 
and tumor biopsy specimens.
[IP_ADDRESS] To determine the duration of response (DOR), overall survival (OS), and progression-
free survival (PFS) of the combination.
[IP_ADDRESS] To further explore safety for combination.
Phase II Expansion Cohorts:
[IP_ADDRESS] To determine safety and progression-free survival (PFS) in patients with mCRPC and 
urothelial carcinoma.
[IP_ADDRESS] To determine duration of response and PSA responses in patients with mCRPC.
1.1.3 Exploratory Objectives
Phase I and Phase II Cohorts:
[IP_ADDRESS] To explore possible correlations between clinical response and biomarkers
Phase II Expansion Cohorts:
[IP_ADDRESS] To determine correlation between molecular markers and clinical outcomes (ORR and 
PFS) in urothelial carcinoma patients. 
[IP_ADDRESS] To explore pharmacodynamic changes in immune characteristics in tumor, circulating 
tumor cells (CTCs), and PBMCs in response to treatment of patients with mCRPC
1.2 BACKGROUND AND RATIONALE
1.2.1 Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Annually there are 
approximately 34,000 new cases in the [LOCATION_002] alone. SCLC is characterized by [CONTACT_148377], high growth fraction and early and widespread metastatic involvement. 
Approximately two thirds of patients present with extensive-stage disease with tumor 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
14involvement of contralateral lung, liver, adrenal glands, brain, bones and/or bone marrow. The 
median survival of patients with extensive-stage SCLC (ES-SCLC) ranges from 8 to 13 months. 
Less than 5% of patients survive two years and less than 2% of patients survive five years after 
diagnosis.
Standard therapy for patients with ES-SCLC consists of platinum and etoposide followed by 
[CONTACT_555555] a response (2). Although highly responsive to 
chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few 
months. There is only one FDA approved treatment for patients with relapsed SCLC after first-
line chemotherapy: topotecan, a camptothecin which inhibits relegation of topoisomerase I-
mediated single-strand DNA breaks leading to lethal double-strand DNA breaks. In patients with 
disease that is refractory to or relapsed after first-line chemotherapy, the median survival ranges 
from [ADDRESS_729202] been found to be independent predictors of 
probability of responding to second-line chemotherapy (3).
The standard treatment of ES-SCLC today reflects the prevailing state-of-the-art from the early 
1980s. Among the many strategies that have been evaluated unsuccessfully over the last three 
decades are dose-dense chemotherapy regimens, addition of a third drug to standard two drug 
chemotherapi[INVESTIGATOR_014], alternating non-cross resistant chemotherapy regimens, maintenance therapy 
and more recently targeted therapi[INVESTIGATOR_014]. Not unexpectedly, the outcomes for these patients have not 
significantly changed over this time. Clearly there is a critical need for newer therapeutic 
approaches for patients with SCLC. 
1.2.2 Urothelial Carcinoma (UC) of the Bladder
In the [LOCATION_002], urothelial carcinoma (UC) of the bladder is the fourth most common 
malignancy in men and the ninth most common in women, with 76,960 new cases and 31,540 
deaths estimated for 2016 (4). Although UC is a chemo-sensitive malignancy, there is no FDA-
approved second-line therapy that have demonstrated a survival benefit in patients who have 
progressed after first-line platinum-based chemotherapy. Second-line trials with cytotoxic agents 
have generally yielded discouraging response rates with a median progression-free survival 
(PFS) of 2–3 months and a median overall survival (OS) of 6–9 months (5-9). 
Two immune-checkpoint inhibitors have been FDA-approved as second-line therapy for patients 
with metastatic UC after disease progression following or during platinum-containing 
chemotherapy. Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) humanized 
monoclonal antibody, showed an overall response rate (ORR) confirmed by [CONTACT_555556] 14.8% (95% CI: 11.1-19.3) in all treated patients (10) and nivolumab, a PD-1 humanized 
monoclonal antibody, that has demonstrated ORR of 19.6% (95% CI, 15.1 - 24.9). The estimated 
median duration of response was 10.3 months with nivolumab ( 11). Unfortunately, only a subset 
of patients with metastatic UC benefit from immune-checkpoint inhibitors highlighting the need 
to develop novel therapi[INVESTIGATOR_555506]. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
15Specific genes involved in the DNA damage response (DDR) are mutated in UC increasing the 
genomic instability of cancer cells. Nickerson and colleagues at the National Cancer Institute, the 
TCGA, and other investigators have recognized that a marked number of somatic and germline 
mutations in genes encoding proteins involved in the DNA-repair pathway are present in UC 
(roughly 30% of cases) (Table 1) (12-14) These events may render UC particularly sensitive to 
inhibition of PARP in homologous recombination DNA repair, creating opportunities for 
synthetic lethality or synergistic cytotoxicity (potentiate the effect of other DNA damaging 
therapi[INVESTIGATOR_014]).
Table 1. Summary of observed somatic/germline mutations frequencies in UC of the bladder
Yap, K.L.; et al.
(Whole-exome sequencing)
Somatic Mutations % (n)Nickerson, M.; et 
al.
(Exome and Sanger 
sequencing of 
tumor-normal DNA)
Somatic Mutations 
% (n)Nickerson, M.; et 
al.
(Exome and 
Sanger 
sequencing of 
tumor-normal 
DNA)
Germline 
Mutations % (n)
TP53 40.7% (33/81) 9.2% (5/54) -
KDM6A 17% (21/81) 22.2% (12/54) 3.7% (2/54)
BAP1 NA 15% (8/54) 1.8% (1/54)
TSC1 12.3% (10/81) 3.7% (2/54) -
ATM 12.3% (10/81) 7.4% (4/54) 1.8% (1/54)
UNC5C 9.9% (8/81) NA -
BRCA2 8.6% (7/81) 1.8% (1/54) 9.2% (5/54)
ERCC2 6.2% (5/81) NA -
FANCD2 4.9% (4/81) NA -
PALB2 4.9% (4/81) 3.7% (2/54) 5.5% (3/54)
BRAC1 3.7% (3/81) 3.7% (2/54) 1.8% (1/54)
PARP inhibitors (PARPi) such as olaparib are highly effective in combination with 
camptothecins in tumors with and without defects in homologous recombination. (15-17) In the 
case of UC, studies of human xenograft in vivo models and clinical studies have confirmed 
activity of irinotecan (CPT) and its combinations in human urothelial tumors. In the clinical 
setting, gemcitabine combined CPT has demonstrated to be with manageable toxicities in 
cisplatin-ineligible patients with locally-advanced or metastatic UC(18). Other clinically 
evaluated combination with irinotecan includes mitomycin, fluorouracil, and CPT in cisplatin-
pretreated and cisplatin-ineligible metastatic UC patients. This regimen demonstrated modest 
activity with an overall response rate of 19%(19).
EP0057 is a novel nanoparticle consisting of camptothecin (10% by [CONTACT_8497]) conjugated to a 
biocompatible copolymer of cyclodextrin and polyethylene glycol designed to maximize CPT 
efficacy without problematic hematologic toxicity. This offers a unique opportunity to revisit the 
use of topoisomerase-1 inhibitors for urothelial carcinoma treatment. 
The observation that the administration of an agent that acts to inhibit the repair of single strand 
DNA damage, such as olaparib, will potentiate DNA damage and increase the potency of 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
16topoisomerase-1 inhibitors (10, 12, 20) provided rational for EP0057 being assessed in 
combination with olaparib at the National Institute of Health ([STUDY_ID_REMOVED]). Initial safety 
results are favorable at dose level 2 in this Phase I study.
Given the high proportion of DNA-repair abnormalities and sensitivity to CPT of UC, our intent 
is to examine the clinical activity of EP0057 in combination with olaparib in patients with UC.
[IP_ADDRESS] Rationale for expansion cohort in patients with metastatic/advanced urothelial 
carcinoma
As of Amendment C we propose an expansion to our current study protocol # 16-C-0107 
[[STUDY_ID_REMOVED]] for [ADDRESS_729203] one platinum-based chemotherapy and/or an immune-
checkpoint inhibitor. To be eligible for this expansion cohort, patients must have histologically 
confirmed diagnosis of UC and at least one measurable site of disease (according per RECIST 
criteria v 1.1).
This study will provide further insight into the potential increased efficacy of EP0057 in 
combination with olaparib in UC patients with manageable toxicity. Primary end-point is ORR. 
Secondary end-points are PFS and safety. Exploratory end-point include correlation between 
molecular markers and clinical outcomes (ORR and PFS).
1.2.3 Castrate resistant prostate cancer (mCRPC)
Prostate cancer is the most common cancer among men in the [LOCATION_002] with an estimated 
161,360 new cases and 26,730 deaths in 2017 (21). While prostate cancer is initially responsive 
to androgen deprivation therapy (ADT), the median duration of sensitivity is 24-36 months,(22) 
and a majority of men will go on to develop castration-resistant disease. Over the last several 
years, the landscape of treatment in metastatic castration-resistant prostate cancer (mCRPC) has 
heralded new treatment options including potent hormonal agents abiraterone(23, 24) and 
enzalutamide(25, 26). Both abiraterone and enzalutamide have shown overall survival (OS) 
benefits in mCRPC, but unfortunately, men will develop resistance to these agents and to 
chemotherapeutic agents such as docetaxel. Furthermore, emerging data suggests that DNA 
repair mutations are present in 25-30% of tumors(27) and up to ~12% of patients with mCRPC 
may have germline mutations (28). Therefore, therapi[INVESTIGATOR_555507].
[IP_ADDRESS] DNA Damage Repair
Next generation sequencing (NGS) techniques have been used to characterize recurrent 
mutations and genomic alterations in advanced prostate cancer (29) which include alterations in 
key genes important for DNA repair such as BRCA2. An international consortium of 8 medical 
center clinical sites conducted prospective whole-exome and trascriptome sequencing of bone or 
soft tissue tumor biopsies in 150 patients with mCRPC (27). Informative mutations were 
frequent, with clinically actionable alterations often seen in the DNA repair pathway (19%). 
Aberrations of BRCA2 and BRCA1 were observed with BRCA2 alterations in 19/150 (12.7%) 
of cases. Pathogenic germline BRCA2 mutations were found in 8 patients (5.3%) with a 
subsequent somatic event that resulted in biallelic loss. Events were also noted in BRCA1. 
Overall, 19.3% of patients harbored aberrations in DNA repair pathway involving BRCA2, 
BRCA1, and ATM. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
17Early clinical data has supported DNA repair defects as a target in mCRPC. In the phase II 
TOPARP-A study, fifty patients with mCPRC were treated with a single agent PARP inhibitor, 
olaparib(30). All patients had been treated previously with docetaxel, 49 patients (98%) had been 
previously treated with abiraterone or enzalutamide, and 29 patients (58%) with cabazitaxel. In 
33% (16/49) of evaluable patients, NGS revealed homozygous deletions and/or deleterious 
mutations in DNA repair genes, with the majority in BRCA2 and ATM. Of these 16 patients, 14 
(88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic 
somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations. The specificity of 
the biomarker suite was 94%. In the 7 patients with BRCA2 loss, 57% (4/7) were somatic 
aberrations and 43% (3/7) were germline. Targeting genetic defects in DNA repair genes in 
mCRPC offer possibilities for treatment options in heavily pre-treated patients and larger 
confirmatory trials are underway.
Recent data shows DNA damage plays an important role in priming the type I interferon (INF) 
system, where DNA damage results in enhanced production of type I IFNs via the cystolic DNA 
sensor STING (stimulator of interferon genes) which can prime the innate immune system for an 
amplified response ( 31). STING is a signaling molecule which is involved in controlling the 
transcription of host defense genes including Type I IFNs following recognition of aberrant 
DNA species and also self-DNA as a result of DNA damage (32). Instigating DNA damage can 
lead to nuclear DNA leakage into the cytosol and trigger STING-dependent cytokine activity 
(32). Loss of DNA repair mechanisms, via PARP inhibition, may enable DNA to leak into the 
cytoplasm to activate STING leading to production of Type I IFNs which exert potent effects on 
the priming of anti-tumor T cells (32).
[IP_ADDRESS] Camptothecin Derivatives Investigated in Prostate Cancer
Camptothecin (CPT) is a potent Top1 inhibitor that failed clinical development due to poor 
solubility and high systemic toxicity. CPT derivatives such as irinotecan and topotecan have 
clinical utility for the treatment of a limited subset of advanced solid tumors. Both irinotecan and 
topotecan demonstrated improvements in plasma solubility but decreased target affinity 
compared to CPT. The primary cellular target of CPT is the Top1-DNA cleavage complex. CPT 
stabilizes the Top1-DNA cleavage complex during DNA replication and prevents Top1-mediated 
DNA relegation, leading to double strand breaks. The accumulation of double-strand breaks via 
CPT leads to apoptosis.
Camptothecin has shown activity in several prostate cancer cell lines (e.g. PC3, DU145, 
LNCaP).( 33-35) The administration of CPT in LNCaP cells was shown to down-regulate 
expression of the AR and PSA.(36) Camptothecin was shown to suppress the expression of 
matrix-metalloproteinase-9 (MMP-9) and VEGF through inhibition of NF-κB activity in DU145 
cells.(37)
Synergistic activity between camptothecin and olaparib has been shown in DU145 prostate 
cancer cells. The combination’s activity is independent of defects in homologous recombination 
(e.g. BRCA1, BRCA2, etc.) and is due to catalytic PARP inhibitory activity.(1)
[IP_ADDRESS] Rationale for the expansion cohort in patients with mCRPC
The rationale for combination of a PARP inhibitor, olaparib, and EP0057, is based upon the 
potential complementary mechanisms of action of the two therapi[INVESTIGATOR_014]. Synergy between 
camptothecin and PARP inhibitors has been established.(38) PARP1 plays a role in the repair of 
topoisomerase I-induced DNA damage. By [CONTACT_555557], via olaparib, the potency of 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729204] the hypothesis that the EP0057 in combination 
with olaparib could yield durable responses in mCRPC. Increased DNA damage should 
complement the activity of topoisomerase I inhibitor EP0057 in mCRPC.
1.2.4 PARP as a Therapeutic Target in Small Cell Lung Cancer
Poly-(ADP)-ribose polymerases (PARPs) are a large family comprising of proteins that are 
critical regulatory components in DNA damage repair, maintenance of genomic integrity and 
other cellular processes (39). PARP-1 and PARP-2 are activated by [CONTACT_25505]-strand DNA breaks 
(SSB). When SSBs are formed, PARP binds at the end of broken DNA strands, activating its 
enzymatic activity. Activated PARP catalyzes addition of long polymers of ADP-ribose (PAR). 
This lengthening PAR chain (PARylation) builds up a large negatively charged structure at the 
SSB which recruits other DNA repair enzymes that collectively repair DNA breaks via base 
excision repair (BER). PARP inhibition by [CONTACT_555558]-strand breaks (DSB). The activity of PARP inhibitors are best established in 
cancers with mutations in BRCA1/2 and other DNA repair genes that result in synthetic lethality 
in the setting of PARP inhibition (which provides a second “hit” to the DNA repair machinery). 
Olaparib monotherapy was recently FDA-approved for patients with advanced, BRCA-mutated 
ovarian cancer who have received three or more lines of chemotherapy.
Drugs that target DNA damage response (DDR), including PARP inhibitors, have shown 
promising activity against SCLC in pre-clinical models and in early clinical trials. Proteomic 
profiling of a large panel of SCLC cell lines led to the observation that PARP1, Chk1, and 
several other DNA repair proteins are expressed at high levels in SCLC (40). These studies also 
confirmed PARP1 overexpression in patient tumors at the protein level by 
[CONTACT_555559]. Based on this finding, several PARP inhibitors 
were tested in pre-clinical models of SCLC. Olaparib, rucaparib, and talazoparib (previously 
BMN-673) all demonstrated striking single agent activity in a majority of SCLC cell lines tested. 
Furthermore, the addition of a PARP inhibitor to standard chemotherapi[INVESTIGATOR_014] (e.g., cisplatin, 
etoposide and/or topotecan) and radiation further potentiated their effect (41). In animal models 
including xenografts and patient-derived xenografts (PDXs), talazoparib has demonstrated 
significant anti-tumor activity as a single agent, comparable or superior to cisplatin (42). 
Following these observations, several clinical trials were initiated to investigate the effects of 
PARP inhibition in SCLC patients. The first two studies to complete enrollment investigated the 
use of PARP inhibitors in relapsed SCLC. In the first study, single-agent talazoparib (BMN-673) 
was tested in an expansion cohort of patients with platinum-sensitive SCLC relapse 
([STUDY_ID_REMOVED]). Preliminary data from this trial demonstrated 2/[ADDRESS_729205] 
confirmed partial responses and 3/23 with stable disease lasting more than 24 weeks (clinical 
benefit rate of 25%). More than half of patients treated had some tumor volume reduction as 
their best response (43). In the second study, the oral alkylating drug temozolomide with or 
without veliparib (ABT-888) was studied in 100 patients with sensitive or refractory relapse 
([STUDY_ID_REMOVED]). This trial recently completed enrollment and analysis of the results are 
ongoing.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729206] of other DNA damaging therapi[INVESTIGATOR_014]. Supporting this hypothesis, PARP inhibition has 
been reported to down regulate key components of the DNA repair machinery and enhanced the 
efficacy of chemotherapy in preclinical SCLC models (40). PARP inhibition sensitizes cancer 
cells both to cytotoxic chemotherapy, such as alkylators (temozolomide, cyclophosphamide) or 
camptothecins (irinotecan, topotecan) and to ionizing radiation- all of which induce DNA 
damage requiring BER (44). PARP inhibitors are highly effective in combination with 
camptothecins in tumors with and without defects in homologous recombination (1, 15, 16, 45). 
The Pommier laboratory has demonstrated highly synergistic activity of olaparib in combination 
with camptothecins (Figure 1) ( 1). They observed that the synergistic activity is due to its 
catalytic PARP inhibitory activity rather than due to trappi[INVESTIGATOR_48817]-DNA complexes. 
 
Despi[INVESTIGATOR_555505], human studies combining PARP 
inhibitors and camptothecins have not translated into clinical benefit due to enhanced toxicity 
with the combination ( 46, 47). In combination with chemotherapy, olaparib and veliparib 
enhanced the myelosuppression of their chemotherapy partners. In these studies, unacceptable 
toxicity necessitated dose reductions to sub-therapeutic levels. 
1.2.6 Safely combining PARP Inhibitors with Camptothecins
One approach to safely combine camptothecins with agents that sensitize their activity like 
PARP inhibitors is to use alternative formulations that could minimize toxicity to the normal 
tissues.
EP0057 (formerly named CRLX101 and IT-101) is a nanoparticle-drug conjugate (NDC) 
composed of 20(S) -camptothecin conjugated to a linear, cyclodextrin-polyethylene glycol-based 
polymer (Poly-CD-PEG-Camptothecin) (EP0057 Investigators Brochure) In solution, EP0057 
self-assembles into nanoparticles and releases CPT over prolonged periods of time (48) (49).Figure 1: Synergistic activity of 
camptothecins and olaparib in DT40 
cells with a synergistic combination 
index (<0.3), even when the doses of 
individual agents are low (1).
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
20Camptothecin (CPT) is a potent topoisomerase I (Top1) inhibitor that failed clinical development 
due to poor solubility and high systemic toxicity. CPT derivatives such as irinotecan and 
topotecan demonstrate clinical utility for the treatment of advanced solid tumors. The primary 
cellular target of CPT, the Top1–DNA cleavage complex, is stabilized, preventing Top1-
mediated DNA relegation. Exposure of cancer cells to CPT leads to replication-mediated 
accumulation of DNA double-strand breaks and subsequent apoptosis. 
EP0057 localizes to the tumor and is retained for a prolonged duration by a mechanism referred 
to as enhanced permeability and retention (EPR) wherein macromolecules penetrate and are 
trapped in tumor tissue due to the abnormally leaky vasculature of tumors. EP0057 provides 
sustained release of CPT from polymer in the tumor for prolonged periods while sustaining low 
unconjugated (released) CPT concentrations in the blood. Animal xenograft models of cancer 
indicate that EP0057 accumulates in solid tumors and releases CPT over a period of several days 
to give sustained inhibition of its target ( 49). Sustained release of camptothecin from polymer in 
the tumor and low unconjugated camptothecin concentrations in the blood could optimize the 
cell cycle specific antitumor activity associated with the prolonged drug exposure in tumor tissue 
and improve tolerability associated with low systemic exposure. Drug localization analyses have 
been conducted in tumor from subjects with HER-[ADDRESS_729207]-treatment normal tissue. Images show bright, punctuate CPT signal specific to tumor tissue 
following treatment with EP0057 and rare events of CPT signal co-localized with anti-PEG 
signal as demonstrated in Figure 2.
Figure 2: Immunofluorescence Visualization in Gastric Cancer Tumor and Adjacent Normal Tissue after 
First Dose with EP0057 in Subjects on the Gastric Investigator-Sponsored Trial
 
Left: Tumor pre-treatment; Middle: Tumor [ADDRESS_729208]-treatment; Right: Healthy adjacent tissue [ADDRESS_729209]; 
Green dots = CPT from nanoparticles
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
211.2.7 EP0057 Preclinical Toxicology
Dose-limiting toxicity in rat and dog were largely body weight losses. Reductions in neutrophil 
and platelet counts were observed in the acute dog toxicity study and reversible reductions in 
neutrophil and platelet counts were observed at the mid dose in the sub-acute multi-dose dog 
toxicity study (EP0057 Investigators Brochure). Reversible reductions in neutrophil and 
increases in platelet counts were observed at the high dose in the sub-acute multi-dose rat 
toxicity study.
1.2.8 EP0057 phase I clinical trial
Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-
escalation study, in which EP0057 was administered intravenously over 60 min among two 
dosing schedules, initially weekly at 6, 12, and 18 mg/m2 and later bi-weekly at 12, 15, and 18 
mg/m2. The MTD was determined at 15 mg/m2 bi-weekly, and an expansion phase 2a study was 
completed. Sixty-two patients (31 male; median age 63 years, range 39-79) received treatment. 
Bi-weekly dosing was generally well tolerated with myelosuppression being the dose-limiting 
toxicity. Among all phase 1/2a patients receiving the MTD (n=44), most common grade 3/4 
adverse events were neutropenia (Grade 3 neutropenia = 9% and no grade 4) and fatigue (Grade 
3 fatigue = 9%, no grade 4). Evidence of systemic plasma exposure to both the polymer-
conjugated and unconjugated CPT was observed in all treated patients. Mean elimination 
unconjugated CPT Tmax values ranged from 17.[ADDRESS_729210] overall response was stable disease in 28 patients (64 
%) treated at the MTD and 16 (73 %) of a subset of NSCLC patients. Median progression-free 
survival (PFS) for patients treated at the MTD was 3.7 months and for the subset of NSCLC 
patients was 4.4 months. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
221.2.9 Adverse Events with EP0057 (CRLX101) Monotherapy
Table 2. Treatment-emergent AEs Related to EP0057 (CRLX101) Monotherapy in Cerulean-sponsored Studies (as of 12 March 2016)
15 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
At Least 1 TEAE Related 
to Study Drug88 (62.4) 21 
(14.9)5 (83.3) 3 (50.0) 10 
(100.0)5 (50.0) 5 (100.0) 1 (20.0) 3 (100.0) 3 (100.0) 2 (66.7) 0 3 (100.0)2 (66.7)116 
(67.8)35 
(20.5)
Anaemia 25 (17.7) 1 ( 0.7) 1 (16.7) 0 1 (10.0) 0 0 0 3 (100.0) 1 (33.3) 0 0 1 (33.3)1 (33.3)31 (18.1) 3 ( 1.8)
Fatigue 17 (12.1) 4 ( 2.8) 3 (50.0) 2 (33.3) 6 (60.0) 1 (10.0) 2 (40.0) 0 2 (66.7) 1 (33.3) 0 0 1 (33.3)031 (18.1) 8 ( 4.7)
Cystitis 19 (13.5) 1 ( 0.7) 1 (16.7) 0 3 (30.0) 0 2 (40.0) 0 1 (33.3) 0 0 0 1 (33.3)027 (15.8) 1 ( 0.6)
Nausea 20 (14.2) 1 ( 0.7) 0 0 3 (30.0) 0 2 (40.0) 0 1 (33.3) 0 1 (33.3) 0 0027 (15.8) 1 ( 0.6)
Haematuria 11 ( 7.8) 1 ( 0.7) 2 (33.3) 0 3 (30.0) 0 0 0 2 (66.7) 1 (33.3) 0 0 0018 (10.5) 2 ( 1.2)
Neutropenia 9 ( 6.4) 6 ( 4.3) 0 0 0 0 0 0 3 (100.0) 3 (100.0) 0 0 1 (33.3)1 (33.3)13 ( 7.6) 10 ( 5.8)
Diarrhoea 8 ( 5.7) 0 0 0 0 0 2 (40.0) 1 (20.0) 0 0 0 0 2 (66.7)012 ( 7.0) 1 ( 0.6)
Vomiting 5 ( 3.5) 1 ( 0.7) 1 (16.7) 0 4 (40.0) 0 0 0 1 (33.3) 0 1 (33.3) 0 0012 ( 7.0) 1 ( 0.6)
Dysuria 6 ( 4.3) 0 3 (50.0) 1 (16.7) 1 (10.0) 0 0 0 1 (33.3) 0 0 0 0011 ( 6.4) 1 ( 0.6)
Constipation 3 ( 2.1) 0 1 (16.7) 0 2 (20.0) 0 3 (60.0) 0 0 0 0 0 009 ( 5.3) 0
Thrombocytopenia 4 ( 2.8) 1 ( 0.7) 0 0 0 0 1 (20.0) 0 2 (66.7) 2 (66.7) 0 0 2 (66.7)2 (66.7)9 ( 5.3) 5 ( 2.9)
Alopecia 7 ( 5.0) 0 0 0 0 0 0 0 0 0 0 0 1 (33.3)08 ( 4.7) 0
Decreased appetite 3 ( 2.1) 0 1 (16.7) 0 2 (20.0) 0 0 0 2 (66.7) 0 0 0 008 ( 4.7) 0
Leukocyturia 4 ( 2.8) 0 2 (33.3) 0 1 (10.0) 0 0 0 1 (33.3) 0 0 0 008 ( 4.7) 0
Leukopenia 4 ( 2.8) 0 0 0 1 (10.0) 0 0 0 3 (100.0) 2 (66.7) 0 0 008 ( 4.7) 2 ( 1.2)
Neuropathy peripheral 5 ( 3.5) 1 ( 0.7) 0 0 0 0 1 (20.0) 0 0 0 0 0 006 ( 3.5) 1 ( 0.6)
Proteinuria 3 ( 2.1) 0 1 (16.7) 0 0 0 1 (20.0) 0 1 (33.3) 0 0 0 006 ( 3.5) 0
Pyrexia 4 ( 2.8) 0 0 0 2 (20.0) 0 0 0 0 0 0 0 006 ( 3.5) 0
Dyspnoea 3 ( 2.1) 1 ( 0.7) 0 0 0 0 1 (20.0) 0 0 0 0 0 1 (33.3)1 (33.3)5 ( 2.9) 2 ( 1.2)
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2315 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
Urinary tract infection 3 ( 2.1) 0 1 (16.7) 0 0 0 0 0 0 0 1 (33.3) 0 005 ( 2.9) 0
Alanine aminotransferase 
increased4 ( 2.8) 0 0 0 0 0 0 0 0 0 0 0 004 ( 2.3) 0
Dehydration 2 ( 1.4) 1 ( 0.7) 1 (16.7) 0 1 (10.0) 1 (10.0) 0 0 0 0 0 0 004 ( 2.3) 2 ( 1.2)
Haemoglobin decreased 2 ( 1.4) 0 0 0 0 0 0 0 0 0 1 (33.3) 0 1 (33.3)04 ( 2.3) 0
Neutrophil count 
decreased3 ( 2.1) 3 ( 2.1) 0 0 0 0 0 0 0 0 0 0 1 (33.3)1 (33.3)4 ( 2.3) 4 ( 2.3)
Pain in extremity 3 ( 2.1) 0 1 (16.7) 0 0 0 0 0 0 0 0 0 004 ( 2.3) 0
White blood cell count 
decreased3 ( 2.1) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 1 (33.3)1 (33.3)4 ( 2.3) 2 ( 1.2)
Abdominal pain 3 ( 2.1) 0 0 0 0 0 0 0 0 0 0 0 003 ( 1.8) 0
Aspartate 
aminotransferase 
increased3 ( 2.1) 0 0 0 0 0 0 0 0 0 0 0 003 ( 1.8) 0
Asthenia 2 ( 1.4) 1 ( 0.7) 1 (16.7) 0 0 0 0 0 0 0 0 0 003 ( 1.8) 1 ( 0.6)
Blood creatinine increased 3 ( 2.1) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 003 ( 1.8) 1 ( 0.6)
Chills 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 1 (33.3)03 ( 1.8) 0
Dizziness 2 ( 1.4) 0 0 0 0 0 0 0 1 (33.3) 0 0 0 003 ( 1.8) 0
Micturition urgency 2 ( 1.4) 0 0 0 1 (10.0) 0 0 0 0 0 0 0 003 ( 1.8) 0
Abdominal distension 1 ( 0.7) 0 0 0 1 (10.0) 0 0 0 0 0 0 0 002 ( 1.2) 0
Bladder spasm 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Blood alkaline 
phosphatase increased2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Bone pain 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Cough 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2415 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
Cystitis haemorrhagic 0 0 1 (16.7) 0 1 (10.0) 1 (10.0) 0 0 0 0 0 0 002 ( 1.2) 1 ( 0.6)
Dysgeusia 1 ( 0.7) 0 0 0 1 (10.0) 0 0 0 0 0 0 0 002 ( 1.2) 0
Dyspepsia 0 0 1 (16.7) 0 1 (10.0) 0 0 0 0 0 0 0 002 ( 1.2) 0
Flatulence 0 0 1 (16.7) 0 0 0 1 (20.0) 0 0 0 0 0 002 ( 1.2) 0
Hyperglycaemia 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Hypersensitivity 1 ( 0.7) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 1 (33.3)1 (33.3)2 ( 1.2) 2 ( 1.2)
Hypokalaemia 1 ( 0.7) 0 0 0 0 0 0 0 1 (33.3) 0 0 0 002 ( 1.2) 0
Infusion related reaction 1 ( 0.7) 1 ( 0.7) 0 0 0 0 1 (20.0) 0 0 0 0 0 002 ( 1.2) 1 ( 0.6)
Insomnia 1 ( 0.7) 0 0 0 0 0 0 0 1 (33.3) 0 0 0 002 ( 1.2) 0
Lymphocyte count 
decreased0 0 0 0 2 (20.0) 2 (20.0) 0 0 0 0 0 0 002 ( 1.2) 2 ( 1.2)
Myalgia 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Nocturia 1 ( 0.7) 0 1 (16.7) 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Oedema peripheral 0 0 1 (16.7) 0 0 0 0 0 0 0 0 0 1 (33.3)02 ( 1.2) 0
Pollakiuria 0 0 0 0 2 (20.0) 0 0 0 0 0 0 0 002 ( 1.2) 0
Rash 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Urinary retention 2 ( 1.4) 0 0 0 0 0 0 0 0 0 0 0 002 ( 1.2) 0
Abdominal pain upper 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Acute kidney injury 0 0 0 0 0 0 1 (20.0) 0 0 0 0 0 001 ( 0.6) 0
Acute respi[INVESTIGATOR_13086]1 ( 0.7) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Adrenal insufficiency 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Angina pectoris 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Anxiety 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2515 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
Atrial flutter 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Back pain 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Bacteriuria 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Bladder discomfort 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Bladder pain 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Bronchospasm 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Candida infection 0 0 0 0 0 0 1 (20.0) 0 0 0 0 0 001 ( 0.6) 0
Cystitis noninfective 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Cytokine release 
syndrome1 ( 0.7) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Dry mouth 0 0 1 (16.7) 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Dysphagia 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Dysphonia 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Dyspnoea exertional 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Electrocardiogram qt 
prolonged1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Epi[INVESTIGATOR_3940] 0 0 0 0 1 (10.0) 0 0 0 0 0 0 0 001 ( 0.6) 0
Febrile neutropenia 0 0 0 0 1 (10.0) 1 (10.0) 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Gait disturbance 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Gastric haemorrhage 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Gastrointestinal disorder 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Gastrointestinal pain 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Glucose tolerance 
impaired0 0 0 0 1 (10.0) 0 0 0 0 0 0 0 001 ( 0.6) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2615 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
Headache 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Herpes zoster 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hiccups 0 0 0 0 1 (10.0) 0 0 0 0 0 0 0 001 ( 0.6) 0
Hypercreatininaemia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hyperkalaemia 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Hypertension 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hypoglycaemia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hypomagnesaemia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hypotension 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Hypoxia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Lip swelling 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Lymphadenopathy 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Lymphopenia 1 ( 0.7) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Mucosal inflammation 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Musculoskeletal 
discomfort1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Nitrituria 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Ocular discomfort 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Pancytopenia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Paraesthesia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Pelvic pain 1 ( 0.7) 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Penile pain 0 0 0 0 1 (10.0) 1 (10.0) 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Platelet count decreased 0 0 0 0 1 (10.0) 1 (10.0) 0 0 0 0 0 0 001 ( 0.6) 1 ( 0.6)
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2715 mg/m2 Q2W 
(MTD)
(N=141)6 mg/m2 QW
(N=6)12 mg/m2 QW
(N=10)15 mg/m2 QW
(N=5)18 mg/m2 QW
(N=3)12 mg/m2 Q2W
(N=3)18 mg/m2 Q2W
(N=3)Total
(N=171)
MedDRA Preferred 
TermaAll 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)All 
Grades
n (%)Grade 
3/4
n (%)
Polydipsia 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Polyuria 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Pyelonephritis chronic 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Rash generalised 0 0 0 0 0 0 0 0 0 0 0 0 1 (33.3)1 (33.3)1 ( 0.6) 1 ( 0.6)
Rash maculo-papular 0 0 0 0 0 0 1 (20.0) 0 0 0 0 0 001 ( 0.6) 0
Rash papular 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Right ventricular 
dysfunction1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Sinus tachycardia 0 0 1 (16.7) 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Stomatitis 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Tachycardia 0 0 0 0 0 0 0 0 0 0 0 0 1 (33.3)01 ( 0.6) [ADDRESS_729211] 
infection0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Urethritis 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Urine flow decreased 0 0 0 0 1 (10.0) 0 0 0 0 0 0 0 001 ( 0.6) 0
Urobilinogen urine 
increased1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Urticaria 0 0 0 0 0 0 0 0 0 0 0 0 1 (33.3)01 ( 0.6) 0
Ventricular extrasystoles 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Vertigo 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Vision blurred 0 0 0 0 0 0 0 0 1 (33.3) 0 0 0 001 ( 0.6) 0
Weight decreased 1 ( 0.7) 0 0 0 0 0 0 0 0 0 0 0 001 ( 0.6) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
281.2.10 Adverse Events Associated with EP0057 (CRLX101) Combination Therapy
Table 3. Treatment-Emergent AEs Related to EP0057 (CRLX101) + bevacizumab combination therapy in Cerulean-sponsored Studies (as of 12 March 
2016)
12 mg/m2 QW +
bevacizumab Q2W
(N=7)15 mg/m2 QW +
bevacizumab Q2W
(N=4)15 mg/m2 Q2W +
bevacizumab Q2W
(N=55)Total
(N=66)
MedDRA Preferred TermaAll Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)
At Least 1 TEAE Related to Study Drug 3 (42.9) 0 1 (25.0) 0 47 (85.5) 13 (23.6) 51 (77.3) 13 (19.7)
Fatigue 2 (28.6) 0 1 (25.0) 0 23 (41.8) 4 ( 7.3) 26 (39.4) 4 ( 6.1)
Nausea 2 (28.6) 0 0 0 16 (29.1) 0 18 (27.3) 0
Constipation 0 0 0 0 10 (18.2) 0 10 (15.2) 0
Anaemia 2 (28.6) 0 0 0 5 ( 9.1) 2 ( 3.6) 7 (10.6) 2 ( 3.0)
Decreased appetite 0 0 0 0 7 (12.7) 0 7 (10.6) 0
Cystitis noninfective 1 (14.3) 0 0 0 5 ( 9.1) 0 6 ( 9.1) 0
Diarrhoea 1 (14.3) 0 0 0 5 ( 9.1) 1 ( 1.8) 6 ( 9.1) 1 ( 1.5)
Headache 0 0 0 0 6 (10.9) 1 ( 1.8) 6 ( 9.1) 1 ( 1.5)
Cystitis 0 0 0 0 5 ( 9.1) 1 ( 1.8) 5 ( 7.6) 1 ( 1.5)
Dysuria 0 0 0 0 5 ( 9.1) 0 5 ( 7.6) 0
Haematuria 1 (14.3) 0 0 0 3 ( 5.5) 0 4 ( 6.1) 0
Vomiting 2 (28.6) 0 0 0 2 ( 3.6) 1 ( 1.8) 4 ( 6.1) 1 ( 1.5)
Weight decreased 0 0 0 0 4 ( 7.3) 0 4 ( 6.1) 0
Aspartate aminotransferase increased 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Asthenia 0 0 0 0 3 ( 5.5) 1 ( 1.8) 3 ( 4.5) 1 ( 1.5)
Chills 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Dizziness 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Dyspepsia 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Dyspnoea 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Epi[INVESTIGATOR_3940] 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Hypersensitivity 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
2912 mg/m2 QW +
bevacizumab Q2W
(N=7)15 mg/m2 QW +
bevacizumab Q2W
(N=4)15 mg/m2 Q2W +
bevacizumab Q2W
(N=55)Total
(N=66)
MedDRA Preferred TermaAll Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)
Hypokalaemia 1 (14.3) 0 0 0 2 ( 3.6) 0 3 ( 4.5) 0
Hyponatraemia 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Insomnia 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Onychoclasis 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Stomatitis 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) [ADDRESS_729212] infection 0 0 0 0 3 ( 5.5) 0 3 ( 4.5) 0
Abdominal pain 1 (14.3) 0 0 0 1 ( 1.8) 0 2 ( 3.0) 0
Flushing 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Hiccups 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Hypertension 0 0 0 0 2 ( 3.6) 2 ( 3.6) 2 ( 3.0) 2 ( 3.0)
Infusion related reaction 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Mucosal inflammation 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Myalgia 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Neutropenia 0 0 0 0 2 ( 3.6) 1 ( 1.8) 2 ( 3.0) 1 ( 1.5)
Neutrophil count decreased 0 0 0 0 2 ( 3.6) 1 ( 1.8) 2 ( 3.0) 1 ( 1.5)
Night sweats 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Oedema peripheral 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Proteinuria 0 0 0 0 2 ( 3.6) 0 2 ( 3.0) 0
Acidosis 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Acute kidney injury 1 (14.3) 0 0 0 0 0 1 ( 1.5) 0
Alanine aminotransferase increased 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Arthralgia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Asymptomatic bacteriuria 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Blood alkaline phosphatase increased 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Blood bilirubin increased 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
3012 mg/m2 QW +
bevacizumab Q2W
(N=7)15 mg/m2 QW +
bevacizumab Q2W
(N=4)15 mg/m2 Q2W +
bevacizumab Q2W
(N=55)Total
(N=66)
MedDRA Preferred TermaAll Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)
Blood phosphorus decreased 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Blood urine present 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Cheilitis 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Cognitive disorder 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Confusional state 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Cough 1 (14.3) 0 0 0 0 0 1 ( 1.5) 0
Dysgeusia 1 (14.3) 0 0 0 0 0 1 ( 1.5) 0
Dysphonia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Gingival bleeding 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hyperkeratosis 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hypoaesthesia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hypoalbuminaemia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hypocalcaemia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hypomagnesaemia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Hypophosphataemia 0 0 0 0 1 ( 1.8) 1 ( 1.8) 1 ( 1.5) 1 ( 1.5)
Influenza like illness 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Leukopenia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Lung infection 0 0 0 0 1 ( 1.8) 1 ( 1.8) 1 ( 1.5) 1 ( 1.5)
Micturition urgency 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Musculoskeletal discomfort 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Nail infection 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Oedema 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Pain 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Palmar-plantar erythrodysaesthesia 
syndrome0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
3112 mg/m2 QW +
bevacizumab Q2W
(N=7)15 mg/m2 QW +
bevacizumab Q2W
(N=4)15 mg/m2 Q2W +
bevacizumab Q2W
(N=55)Total
(N=66)
MedDRA Preferred TermaAll Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)
Paronychia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Peripheral sensory neuropathy 1 (14.3) 0 0 0 0 0 1 ( 1.5) 0
Pollakiuria 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Procedural headache 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Pyrexia 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Rash 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Retching 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Sinus congestion 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Skin irritation 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Thrombocytopenia 1 (14.3) 0 0 0 0 0 1 ( 1.5) 0
Tongue ulceration 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Upper gastrointestinal haemorrhage 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Urine analysis abnormal 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Visual impairment 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
White blood cell count decreased 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
White blood cells urine positive 0 0 0 0 1 ( 1.8) 0 1 ( 1.5) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
32Table 4. Treatment-emergent AEs Related to EP0057 (CRLX101) + paclitaxel combination therapy in Cerulean-sponsored Studies (as of 12 March 
2016)
12 mg/m2 Q2W +
paclitaxel QW
(3 out of 4 weeks)
(N=3)15 mg/m2 Q2W +
paclitaxel QW
(3 out of 4 weeks)
(N=6)Total
(N=9)
MedDRA Preferred TermaAll Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)All Grades
n (%)Grade 3/4
n (%)
Subjects With at Least 1 TEAE Related to 
Study Drug3 (100.0) 2 ( 66.7) 6 (100.0) 3 ( 50.0) 9 (100.0) 5 ( 55.6)
Fatigue 3 (100.0) 0 3 ( 50.0) 0 6 ( 66.7) 0
Neutrophil count decreased 3 (100.0) 2 ( 66.7) 3 ( 50.0) 2 ( 33.3) 6 ( 66.7) 4 ( 44.4)
Nausea 2 ( 66.7) 0 2 ( 33.3) 0 4 ( 44.4) 0
Infusion related reaction 1 ( 33.3) 0 2 ( 33.3) 0 3 ( 33.3) 0
Alopecia 1 ( 33.3) 0 1 ( 16.7) 0 2 ( 22.2) 0
Headache 0 0 2 ( 33.3) 0 2 ( 22.2) [ADDRESS_729213] infection 1 ( 33.3) 0 1 ( 16.7) 0 2 ( 22.2) 0
Vomiting 1 ( 33.3) 0 1 ( 16.7) 0 2 ( 22.2) 0
Alanine aminotransferase increased 0 0 1 ( 16.7) 0 1 ( 11.1) 0
Anemia 1 ( 33.3) 0 0 0 1 ( 11.1) 0
Aspartate aminotransferase increased 0 0 1 ( 16.7) 0 1 ( 11.1) 0
Constipation 1 ( 33.3) 0 0 0 1 ( 11.1) 0
Cystitis noninfective 1 ( 33.3) 0 0 0 1 ( 11.1) 0
Dizziness 0 0 1 ( 16.7) 0 1 ( 11.1) 0
Dyspnea 1 ( 33.3) 0 0 0 1 ( 11.1) 0
Hypertension 0 0 1 ( 16.7) 1 ( 16.7) 1 ( 11.1) 1 ( 11.1)
Insomnia 0 0 1 ( 16.7) 0 1 ( 11.1) 0
Peripheral sensory neuropathy 1 ( 33.3) 0 0 0 1 ( 11.1) 0
Sinusitis 0 0 1 ( 16.7) 0 1 ( 11.1) 0
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
331.2.11 EP0057 (CRLX101) Clinical Development Overview
As of [ADDRESS_729214] been 5 clinical trials sponsored by [CONTACT_555560]: CRLX-001, 
CRLX-002, CRLX101-208, CRLX101-209, and CRLX101-102. 
•Studies CRLX-[ADDRESS_729215] been completed; studies CRLX101-208, 
CRLX101-209, and CRLX101-102 are ongoing. 
•246 subjects received CRLX101/EP0057 at doses ranging from 6 to 18 mg/m2 in the 
[ADDRESS_729216] been 7 Investigator-sponsored trials (ISTs) with EP0057 (named CRLX101 at the 
time), (see Table 4 for details); as of [ADDRESS_729217] 1 dose of 
EP0057 in the ISTs at doses ranging from 12 to 15 mg/m2. 
•A total of [ADDRESS_729218] 1 dose of CRLX101. 
When tested in the QOW schedule, the MTD/RP2D of EP0057 monotherapy was 
determined to be 15 mg/m2. 
•EP0057 has been generally well-tolerated, and has shown preliminary antitumor 
activity in subjects with solid tumors such as with gastroesophageal, lung, and 
ovarian cancers.
As of [ADDRESS_729219] been 6 clinical trials sponsored by [CONTACT_555561] (prior to 
17 April 2017) and BlueLink Genetics (as of 17 April 2017). Overall, [ADDRESS_729220] 1 dose of EP0057 at doses ranging from 6 to 18 mg/m2 in these [ADDRESS_729221] 1 dose of EP0057 at starting doses ranging from 12 to 15 mg/m2. When 
tested in the every-other-week schedule, the MTD/recommended phase 2 dose (RP2D) of 
EP0057 monotherapy was determined to be 15 mg/m2. EP0057 has been generally well-
tolerated, and has shown preliminary antitumor activity in subjects with solid tumors.
Overall Safety Assessment from these trials indicated:
•Infusion-related reactions, cystitis, hematologic toxicity, and gastrointestinal disorders 
have been recognized as the risks associated with EP0057. 
•Infusion-related hypersensitivity reactions have been well managed with the mandatory 
premedication and slower rate of infusion. 
•Cystitis symptoms have been well managed with IV hydration before and after the 
EP0057 infusion. In addition, the impact of urine alkalization (oral and/or IV) on the 
incidence and severity of cystitis in subjects treated with EP0057 continue to be 
evaluated. 
EP0057 is contraindicated for subjects who have a history of infusion-related hypersensitivity 
reactions to a topo-[ADDRESS_729222] to nursing mothers are 
unknown. Olaparib
Olaparib is a PARP inhibitor indicated as monotherapy in patients with deleterious or suspected 
deleterious germline BRCA mutated (as detected by [CONTACT_13247]-approved test) advanced ovarian 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729223] been treated with three or more prior lines of chemotherapy. Olaparib has an 
established safety profile and it is under investigation in a number of different cancers. 
Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5’diphosphoribose [poly (ADP 
ribose] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral 
therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy 
and other anti-cancer agents.
PARP inhibition is a novel approach to targeting tumors with deficiencies in DNA repair 
mechanisms. PARP enzymes are essential for repairing DNA single strand breaks (SSBs). 
Inhibiting PARPs leads to the persistence of SSBs, which are then converted to the more serious 
DNA double strand breaks (DSBs) during the process of DNA replication. During the process of 
cell division, DSBs can be efficiently repaired in normal cells by [CONTACT_555562] (HR). Tumors with HR deficiencies (HRD), such as serous ovarian cancers and SCLC 
cannot accurately repair the DNA damage, which may become lethal to cells as it accumulates. 
In such tumor types, olaparib may offer a potentially efficacious and less toxic cancer treatment 
compared with currently available chemotherapy regimens. 
Olaparib has been shown to inhibit selected tumor cell lines in vitro and in xenograft and primary 
explant models as well as in genetic BRCA knock-out models, either as a stand-alone treatment 
or in combination with established chemotherapi[INVESTIGATOR_014]. Cells deficient in homologous recombination 
DNA repair factors, notably BRCA1/2, are particularly sensitive to olaparib treatment. 
PARP inhibitors such as olaparib may also enhance the DNA damaging effects of chemotherapy 
(50-52). For further information, please refer to the current version of the olaparib Investigator 
Brochure.
1.2.12 Preclinical Data of EP0057 (CRLX101) plus Olaparib
In vivo studies (conducted by [CONTACT_38966]) show that concurrent combination of EP0057 and 
olaparib resulted in a dose-dependent decrease in hematological parameters in preclinical rat 
bone marrow model (53). However, combination with delay (24h+) between EP0057 and 
olaparib provided sparing effect on peripheral blood cells (nadir and recovery) (Figure 3). 
The combination of EP0057 with olaparib (starting 24 hours after EP0057) administered for 14 
days had significantly more anti-tumor activity than olaparib administered for 2 days and 
provided greater efficacy than EP0057 alone (Figure 4). The combination was also significantly 
more efficacious than topotecan (standard-of-care for SCLC). 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
35Figure 3: Hematological response to sequenced 
versus concurrent combination schedule in Wistar 
rat. Animals were treated with a single dose of 
EP0057 and either simultaneously or with 24h and 
48h delay with daily olaparib. Peripheral blood was 
collected from tail vain and analysis was performed 
on the Siemens Advia 2120i hematology analyzer.
Figure 4: In vivo efficacy of 
EP0057 combination with 
various duration of 
olaparib dosing in SCLC 
xenograft model. Mice 
implanted with NCI-H417a 
tumor cells were dosed with 
single dose of EP0057 + 
olaparib for [ADDRESS_729224] not translated into clinical benefit due to enhanced toxicity 
with the combination. EP0057 (and free camptothecin) is cleared out more slowly from tumor 
cells compared to plasma/bone marrow and induces sustained activation of DNA damage 
response in tumor. Of note, in preclinical models, most EP0057 is cleared from the bone marrow 
by 24 hours; in contrast, durable topoisomerase [ADDRESS_729225] 
combined with low systemic exposure lends EP0057 to combinations with PARP inhibitors 
where both drugs can potentially be used at effective doses. Based on preclinical studies, PARP 
inhibitors used 48 hours after EP0057 administration will provide synergy while minimizing risk 
of myelosuppression.

Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
361.2.14 Rationale
PARP inhibitors are highly synergistic in combination with camptothecins in preclinical models. 
However, this has not translated to clinical effectiveness, primarily due to enhanced toxicity 
which precludes administration of effective doses of either the PARP inhibitor or chemotherapy. 
Major dose limiting toxicity of this combination is myelosuppression. EP0057 is a nanoparticle 
drug conjugate with a camptothecin payload that provides durable inhibition of topoisomerase I 
(Top1) specifically in the tumor. EP0057 is cleared from the bone marrow relatively quickly. 
These properties allow combination of EP0057 with PARP inhibitors where both drugs can 
potentially be used at doses close to the MTD of each. Based on preclinical studies, PARP 
inhibitors used 48 hours after EP0057 and continued for 11 days will provide maximum synergy 
while minimizing risk of myelosuppression. 
Since the safety of this combination is not established, we propose a phase I trial where 
escalating doses of olaparib will be combined with EP0057 administered at 80% of its MTD (12 
mg/kg IV q2 weeks). The starting dose of olaparib is [ADDRESS_729226] of its single-
agent maximum tolerated dose (MTD; 300 mg tablet BID). 
1.2.15 Rationale for Amendment C
This is a phase I/II trial of EP0057, a nanoparticle drug conjugate plus olaparib. The goal of 
phase I this to determine the MTD/recommended Phase 2 dose (RP2D) of EP0057 in 
combination with olaparib in patients with refractory cancers. The goal of the existing phase II 
trial is to determine the antitumor activity of olaparib plus EP0057 with respect to progression 
free survival at [ADDRESS_729227] 3 patients who enrolled at dose level 1 (EP0057 12 mg/m2 
IV q2weeks plus olaparib 100 mg tablet PO BID). At dose level 2 (EP0057 12 mg/m2 plus 
olaparib 150 mg), five patients were enrolled. Two patients in this cohort were not evaluable due 
to early and rapid disease progression prior to completion of DLT assessment period. At dose 
level 3 (EP0057 12 mg/m2 plus olaparib 200 mg), three patients enrolled with no DLTs. Two 
patients started on dose level 4 (EP0057 12 mg/m2 plus olaparib 300 mg), on 4/4/[ADDRESS_729228] not been 
dose-limiting and managed with dose delays/ growth factors. One patient at dose level 3 required 
dose delays for ANC not recovering to 1500 prior to the next cycle. Two patients treated at dose 
level 3 and two patients who recently enrolled at dose level 4 remain on treatment. Among 8 
evaluable patients with multiple histologies, 6 patients had progressive disease, one patient with 
cervical cancer had stable disease with -17% reduction in target tumor lasting 6 months, and 
another patient with refractory small cell lung cancer has ongoing stable disease at 3 months.
1.2.16 Rationale for Amendment E
Summary of Dose Escalation and Determination of MTD/Recommended Phase II Dose
Twenty-four patients were enrolled between May 2016 and December 2017. All patients had 
received one or more lines of prior systemic therapy and had evidence of disease progression at 
enrollment. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
37Patients across different dose levels received the same dose of EP0057 (EP0057 12mg/m2 Q2W) 
and increasing doses of olaparib. There were no DLTs at DL1 (n=3; olaparib 100 mg BID), DL2 
(n=5, 2 patients were not evaluable for DLT; olaparib 150 mg BID), or DL3 (n=3; olaparib 200 
mg BID). One patient at DL4 (olaparib 300 mg BID) experienced a DLT- grade 4 neutropenia 
not recovering within 7 days. This cohort was expanded with 5 additional patients. One 
additional patient had a DLT at this dose level- inability to begin subsequent treatment course 
within 28 days of the scheduled date, due to neutropenia. Therefore, DL4 was considered too 
toxic and 3 patients were enrolled at DL4R with lower dose of olaparib 250 mg BID. One of the 
3 patients enrolled at DL4R with lower dose of olaparib had a DLT- grade 4 neutropenia that did 
not resolve within 7 days. This cohort was expanded with 3 additional patients. No DLTs were 
observed in the additional patients, which established DL4R (EP0057 12 mg/m2 and olaparib 
250 mg) as the MTD/RP2D. 
1.2.17 Rationale for mCRPC cohort accrual closure (amendment version date: 07/27/2021)
Accrual to the mCRPC cohort is to cease with amendment version date 7/27/2021. Accrual to 
this cohort has been slow given the recent FDA approval of olaparib for prostate cancer. 
Additionally, underlying conditions such as history of pelvic irradiation or surgery predispose the 
prostate cancer cohort to cystitis and hematuria.
1.2.18 Rationale for urothelial carcinoma cohort accrual closure (amendment version date: 
08/17/22)
Accrual to this cohort has been slow due to currently active protocols competing for the same 
patient population. There are also protocols in development which the team believes are better 
suited for these patients. The decision was made to close cohort accrual on this trial to prioritize 
current and upcoming studies.
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT 
2.1 ELIGIBILITY CRITERIA
2.1.1 Inclusion Criteria - Phase I
[IP_ADDRESS] Patients must have histologically or cytologically confirmed advanced solid tumor that 
is resistant or refractory to standard therapy. 
[IP_ADDRESS] A minimum of 2 weeks will be required from any prior therapy, including 
chemotherapy, immunotherapy and/or radiation. In addition, recovery to Grade ≤ 1 
from all reversible toxicities related to prior therapy is required at study entry.
[IP_ADDRESS] Patients do not need to have measurable disease to enroll on phase I. 
[IP_ADDRESS] Age >18 years. 
[IP_ADDRESS] ECOG performance status ≤2 (Appendix A , Section 16.1).
[IP_ADDRESS] Patients with treated brain metastases (surgery, whole or stereotactic brain radiation) are 
allowed provided the lesions have been stable for at least 2 weeks and the patient is off 
steroids or is on a stable dose of steroids. Patients with brain metastases should not 
require use of enzyme-inducing antiepi[INVESTIGATOR_006] (e.g., carbamazepi[INVESTIGATOR_050], phenytoin, or 
phenobarbital) within [ADDRESS_729229] dose and during study. Use of newer 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
38antiepi[INVESTIGATOR_555508]-drug interactions (DDIs) is 
allowed.
[IP_ADDRESS] Patients must have normal organ and marrow function as defined below: 
leukocytes >3,000/mcL
absolute neutrophil count >1,500/mcL without growth factor support
platelets >100,000/mcL without growth factor 
support
hemoglobin ≥9 g/dL, and no blood transfusion within 4 
weeks.
OR
hemoglobin >10 g/dL, and no blood transfusion within 2 
weeks.
total bilirubin ≤1.[ADDRESS_729230] (unless Gilbert’s Disease)
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal (≤ 
5X ULN if liver mets)
creatinine ≤ ULN
OR
creatinine clearance >51 mL/min (calculated using the Cockroft-
Gault formula) for patients with creatinine 
levels above institutional normal.
[IP_ADDRESS] Individuals who can father children and their partners must agree to use highly effective 
contraception (refer to section 4.2 for details) prior to study entry, for the duration of 
study participation and for [ADDRESS_729231] totally/truly abstain from any form of sexual intercourse, 
throughout their participation in the study and for at least [ADDRESS_729232] dose of olaparib. Individuals of 
childbearing potential (IOCBP) are defined as being physically capable of becoming 
pregnant unless unable have children because of surgery or other medical reasons 
(effective tubal ligation, ovaries or the uterus removed, or are post-menopausal). Post-
menopausal is defined as:
oAmenorrheic for 1 year (12 months in a row) or more following 
cessation of exogenous hormonal treatments,
oLH and FSH levels in the post-menopausal range for individuals 
under 50,
oradiation-induced oophorectomy with last menses >1 year ago,
ochemotherapy-induced menopause with >[ADDRESS_729233] 
menses,
oor surgical sterilization of participant (bilateral oophorectomy or 
hysterectomy) and/or partner.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] Negative urine pregnancy test ≤3 days prior to C1D1 (IOCBP)
[IP_ADDRESS] Patient is willing and able to comply with the protocol for the duration of the study 
including undergoing treatment and scheduled visits and examinations including follow 
up. 
2.1.2 Inclusion Criteria - Phase II SCLC 
[IP_ADDRESS] Age >18 years. 
[IP_ADDRESS] Patients must have histologically or cytologically confirmed diagnosis of SCLC from a 
CLIA-certified laboratory. 
[IP_ADDRESS] Have received and progressed during or after a platinum-based standard chemotherapy 
regimen and/or an immune-checkpoint inhibitor 
[IP_ADDRESS] Patients could have received any number of therapi[INVESTIGATOR_555509], including re-treatment with original frontline regimen. A minimum of 2 weeks 
will be required from any prior therapy, including chemotherapy, immunotherapy 
and/or radiation. In addition, recovery to Grade ≤ 1 from all reversible toxicities related 
to prior therapy is required at study entry. No previous irradiation to the site of 
measurable or evaluable disease, unless that site had subsequent evidence of 
progression.
[IP_ADDRESS] Patients must have measurable disease as per Response Evaluation Criteria in Solid 
Tumors, version (RECIST 1.1). See Section 6.3 for the evaluation of measurable 
disease.
[IP_ADDRESS] Radiographic evidence of disease progression after initial therapy should have been 
documented.
[IP_ADDRESS] ECOG performance status ≤2 (see Appendix A , Section 16.1).
[IP_ADDRESS] Patients with treated brain metastases (surgery, whole or stereotactic brain radiation) are 
allowed provided the lesions have been stable for at least 2 weeks and the patient is off 
steroids or is on a stable dose of steroids. Patients with brain metastases should not 
require use of enzyme-inducing antiepi[INVESTIGATOR_006] (e.g., carbamazepi[INVESTIGATOR_050], phenytoin, or 
phenobarbital) within [ADDRESS_729234] dose and during study. Use of newer 
antiepi[INVESTIGATOR_555508]-drug interactions (DDIs) is 
allowed. 
[IP_ADDRESS] Patients must have normal organ and marrow function as defined below: 
leukocytes >3,000/mcL
absolute neutrophil count >1,500/mcL without growth factor support
platelets >100,000/mcL without growth factor 
support
hemoglobin ≥9 g/dL, and no blood transfusion within 4 
weeks.
OR
hemoglobin >10 g/dL, and no blood transfusion within 2 
weeks.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
40total bilirubin ≤1.[ADDRESS_729235] (unless Gilbert’s Disease)
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal (≤ 
5X ULN if liver mets)
creatinine ≤ ULN
OR
creatinine clearance >51 mL/min (calculated using the Cockroft-
Gault formula) for patients with creatinine 
levels above institutional normal.
[IP_ADDRESS] Individuals who can father children and their partners must agree to use highly effective 
contraception (refer to section 4.2 for details) prior to study entry, for the duration of 
study participation and for [ADDRESS_729236] totally/truly abstain from any form of sexual intercourse, 
throughout their participation in the study and for at least [ADDRESS_729237] dose of olaparib. Individuals of 
childbearing potential (IOCBP) are defined as being physically capable of becoming 
pregnant unless unable to have children because of surgery or other medical reasons 
(effective tubal ligation, ovaries or the uterus removed, or are post-menopausal). Post-
menopausal is defined as:
oAmenorrheic for 1 year (12 months in a row) or more following 
cessation of exogenous hormonal treatments,
oLH and FSH levels in the post-menopausal range for individuals 
under 50,
oradiation-induced oophorectomy with last menses >1 year ago,
ochemotherapy-induced menopause with >[ADDRESS_729238] 
menses,
oor surgical sterilization of participant (bilateral oophorectomy or 
hysterectomy) and/or partner.
2.1.3 Inclusion Criteria for Urothelial Carcinoma Expansion Cohort (accrual to the cohort 
ended with amendment version 08/17/2022)
[IP_ADDRESS] Patients must have a histologically confirmed diagnosis of urothelial carcinoma of the 
bladder, urethra, ureter, or renal pelvis from a CLIA-certified laboratory, with 
measurable disease by [CONTACT_393] (version 1.1) including lymphadenopathy and visceral 
metastatic disease
[IP_ADDRESS] Adult patients ≥ 18 years of age. 
[IP_ADDRESS] Patient must have received at least one platinum based regimen of chemotherapy and/or 
an immune-checkpoint inhibitor if appropriate with progressive disease.
[IP_ADDRESS] Prior antiangiogenic and radiation therapy are permitted (2-week washout from therapy 
is required). 
[IP_ADDRESS] Bisphosphonates and denosumab are permitted if on a stable dose for ≥4 weeks. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] ECOG 0–2 
[IP_ADDRESS] Patients must have normal organ and marrow function as defined below: 
leukocytes >3,000/mcL
absolute neutrophil count >1,500/mcL without growth factor support
platelets >100,000/mcL without growth factor 
support
hemoglobin ≥9 g/dL, and no blood transfusion within 4 
weeks.
OR
hemoglobin >10 g/dL, and no blood transfusion within 2 
weeks.
total bilirubin ≤1.[ADDRESS_729239] (≤ 3 × ULN for subjects with 
Gilbert’s Disease)
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal (≤ 
5X ULN if liver mets)
creatinine ≤ ULN
OR
creatinine clearance >51 mL/min (calculated using the Cockroft-
Gault formula) for patients with creatinine 
levels above institutional normal.
PT/INR and aPTT   within 1.[ADDRESS_729240] institutional limits, except 
where a lupus anti-coagulant has been 
confirmed
[IP_ADDRESS] Individuals who can father children and their partners must agree to use highly effective 
contraception (refer to section 4.2 for details) prior to study entry, for the duration of 
study participation and for [ADDRESS_729241] totally/truly abstain from any form of sexual intercourse, 
throughout their participation in the study and for at least [ADDRESS_729242] dose of olaparib. Individuals of 
childbearing potential (IOCBP) are defined as being physically capable of becoming 
pregnant unless unable have children because of surgery or other medical reasons 
(effective tubal ligation, ovaries or the uterus removed, or are post-menopausal). Post-
menopausal is defined as:
oAmenorrheic for 1 year (12 months in a row) or more following 
cessation of exogenous hormonal treatments,
oLH and FSH levels in the post-menopausal range for individuals 
under 50,
oradiation-induced oophorectomy with last menses >1 year ago,
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
42ochemotherapy-induced menopause with >[ADDRESS_729243] 
menses,
oor surgical sterilization of participant (bilateral oophorectomy or 
hysterectomy) and/or partner.
[IP_ADDRESS] Patients must be able to tolerate oral medications and not have gastrointestinal illnesses 
that would preclude absorption of olaparib. 
[IP_ADDRESS] Ability to understand and the willingness to sign a written informed consent document. 
[IP_ADDRESS] Willingness to release archival tissue sample for research purposes, if available
2.1.4 Inclusion Criteria for mCRPC Expansion Cohort (accrual to the mCRPC cohort ended 
with amendment version 7/27/2021)
[IP_ADDRESS] Patients must have metastatic, progressive, castrate resistant prostate cancer (mCRPC).
[IP_ADDRESS] Documented histopathological confirmation of prostate cancer from a CLIA-certified
laboratory.
[IP_ADDRESS] All patients must have at least one lesion deemed safe to biopsy and be willing to 
undergo a mandatory baseline biopsy.
[IP_ADDRESS] Patients must have received prior treatment with enzalutamide and/or abiraterone with 
the exception of patients who were treated with docetaxel and androgen deprivation 
therapy for metastatic castrate-sensitive prostate cancer and progressed on docetaxel 
treatment or who progress within one month of the last docetaxel dose.
[IP_ADDRESS] Patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l])
[IP_ADDRESS] Patients must have undergone bilateral surgical castration or must agree to continue on 
GnRH agonists/antagonists for the duration of the study.
[IP_ADDRESS] ECOG performance status ≤ 2
[IP_ADDRESS] Patients must have adequate bone marrow, hepatic, and renal function with: 
leukocytes >3,000/mcL
absolute neutrophil count >1,500/mcL without growth factor support
platelets >100,000/mcL without growth factor 
support
hemoglobin ≥9 g/dL, and no blood transfusion within 4 
weeks.
OR
hemoglobin >10 g/dL, and no blood transfusion within 2 
weeks.
total bilirubin ≤1.[ADDRESS_729244] (≤ 3 × ULN for subjects with 
Gilbert’s Disease)
AST(SGOT)/ALT(SGPT) <3 X institutional upper limit of normal (≤ 
5X ULN if liver mets)
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
43creatinine ≤ ULN
OR
creatinine clearance >51 mL/min (calculated using the Cockroft-
Gault formula) for patients with creatinine 
levels above institutional normal.
[IP_ADDRESS] Men must be at least 18 years of age.
[IP_ADDRESS] Patient must be capable of understanding and complying with protocol requirements 
and is willing to give informed consent.
[IP_ADDRESS] Individuals who can father children and their partners must also agree to use adequate 
contraception (refer to section 4.2 for details) prior to the study and for the duration of 
study participation and for [ADDRESS_729245] dose of olaparib 
[IP_ADDRESS] Patients who were treated for metastatic castrate-sensitive prostate cancer with 
docetaxel and androgen deprivation therapy who progress on docetaxel treatment or 
who progress within one month of the last docetaxel dose are eligible. 
2.1.5 Exclusion Criteria - Phase I and II SCLC and UC Expansion Cohort (note: accrual to the 
UC cohort ended with amendment version 08/17/2022)
[IP_ADDRESS] Patients who are receiving any other investigational agents.
[IP_ADDRESS] Persistent toxicities (≥ CTCAE grade 2) with the exception of alopecia and neuropathy, 
caused by [CONTACT_48834]
[IP_ADDRESS] Patients who have had prior treatment with olaparib or other camptothecin inhibitors 
(UC expansion Cohort Only).
[IP_ADDRESS] Patients with myelodysplastic syndrome/acute myeloid leukemia or active pneumonitis; 
or baseline features suggestive of myelodysplastic syndrome or acute myelogenous 
leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicated.
[IP_ADDRESS] Hypersensitivity to study therapi[INVESTIGATOR_555510]
[IP_ADDRESS] Patients unable to swallow orally administered medication and patients with 
gastrointestinal disorders likely to interfere with absorption of the study medication.
[IP_ADDRESS] History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to EP0057 and/or olaparib or other agents used in study.
[IP_ADDRESS] Patients receiving any medications or substances that are strong and moderate inhibitors 
or inducers of CYP3A are ineligible. Lists including medications and substances known 
or with the potential to interact with the CYP3A isoenzymes are provided in Appendix 
B, Section 16.2.
[IP_ADDRESS] Pregnant individuals are excluded from this study because EP0057 and/or olaparib are 
agents with the potential for teratogenic or abortifacient effects. Because there is an 
unknown but potential risk for adverse events in nursing infants secondary to treatment 
of the mother with EP0057 and/or olaparib, breastfeeding should be discontinued if the 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
44mother is treated with EP0057 and/or olaparib. These potential risks may also apply to 
other agents used in this study.
[IP_ADDRESS] HIV-positive patients on combination antiretroviral therapy are ineligible because of the 
potential for pharmacokinetic interactions with EP0057 and/or olaparib. In addition, 
these patients are at increased risk of lethal infections when treated with marrow-
suppressive therapy. Appropriate studies will be undertaken in patients receiving 
combination antiretroviral therapy when indicated. 
[IP_ADDRESS] Prolongation of QT/QTc interval (QTc interval >500 msec) using the Fredericia method 
of QTc analysis or family history of long QT syndrome. If single reading is above these 
minimum ranges, then repeat test in triplicate and evaluate eligibility based on average 
value
[IP_ADDRESS] Any chronic or concurrent acute liver disease.
[IP_ADDRESS] History of stroke, transient ischemic attack (TIA), or myocardial infarction, within 6 
months prior to C1D1
[IP_ADDRESS] Uncontrolled concurrent disease or illness including but not limited to:
•symptomatic congestive heart failure, unstable angina pectoris, clinically significant 
cardiac arrhythmia
•unstable or untreated cardiac conditions or ejection fraction of <50% as determined by 
[CONTACT_6751] (ECHO) or multiple gated acquisition scan (MUGA)
•uncontrolled diabetes mellitus
•psychiatric illness that would limit compliance with study requirements, as determined by 
[CONTACT_737] 
[IP_ADDRESS] Other severe, acute, or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or study drug 
administration or that may interfere with the interpretation of study results and, in the 
judgment of the investigator, would make the patient inappropriate for the study.
2.1.6 Exclusion Criteria - mCRPC Expansion Cohort (accrual to the mCRPC cohort ended 
with amendment version 7/27/2021)
[IP_ADDRESS] Patients who have had prior treatment with olaparib or other camptothecin inhibitors.
[IP_ADDRESS] The patient has received chemotherapy, radiotherapy, biologic agents or enzalutamide 
within [ADDRESS_729246] dose of study treatment (nitrosoureas or mitomycin 
within 6 weeks). However, for patients receiving abiraterone, they must discontinue the 
medication at least [ADDRESS_729247] dose of study treatment. 
[IP_ADDRESS] The patient has received any other type of investigational agent within [ADDRESS_729248] dose of study treatment. 
[IP_ADDRESS] The patient has received radionuclide treatment within [ADDRESS_729249] dose of 
the study treatment
[IP_ADDRESS] Patients with evidence of CNS metastasis or leptomeningeal disease within 1 year prior 
to enrollment will be excluded from this clinical trial because of their poor prognosis 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
45and because they often develop progressive neurologic dysfunction that would 
confound the evaluation of neurologic and other adverse events. Patients with a remote 
history of brain metastases may be considered if they received sterilizing therapy to the 
CNS (resection or radiation) and have been CNS progression-free for the 1-year period. 
Baseline imaging to rule out brain metastases is not required for screening, but should 
be performed prior to study enrollment if clinically indicated.
[IP_ADDRESS] Patients receiving any medications or substances that are strong and moderate inhibitors 
or inducers of CYP3A are ineligible. Lists including medications and substances known 
or with the potential to interact with the CYP3A isoenzymes are provided in Appendix 
B, Section 16.2.
[IP_ADDRESS] The patient has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all 
prior therapi[INVESTIGATOR_014], including surgery, except alopecia and other non-clinically significant 
AEs.
[IP_ADDRESS] Uncontrolled concurrent disease or illness including but not limited to:
•symptomatic congestive heart failure, unstable angina pectoris, clinically significant 
cardiac arrhythmia
•unstable or untreated cardiac conditions or ejection fraction of <50% as determined 
by [CONTACT_6751] (ECHO) or multiple gated acquisition scan (MUGA)
•uncontrolled diabetes mellitus
•psychiatric illness that would limit compliance with study requirements, as 
determined by [CONTACT_737] 
[IP_ADDRESS] Any of the following within [ADDRESS_729250] dose of study treatment:
•unstable angina pectoris
•stroke (including TIA, or other ischemic event)
•myocardial infarction
[IP_ADDRESS] Other clinically significant disorders such as:
•active infection requiring intravenous treatment within 7 days of starting protocol 
treatment
•serious non-healing wound/ulcer/bone fracture (excluding stable compression 
fracture) within [ADDRESS_729251] dose of study treatment
[IP_ADDRESS] HIV-positive patients on combination antiretroviral therapy are ineligible because of the 
potential for pharmacokinetic interactions with the study agent. 
[IP_ADDRESS] HBV-or HCV-positive patients are ineligible
[IP_ADDRESS] Prolongation of QT/QTc interval (QTc interval >500 msec) using the Fredericia method 
of QTc analysis or family history of long QT syndrome. If single reading is above these 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729252] in triplicate and evaluate eligibility based on average 
value
2.2 RECRUITMENT STRATEGIES
It is expected that participants for this single site study will be enrolled from across the United 
States though there is no exclusion for participants from foreign countries. 
Recruitment strategies that can be used for this study may include:
1. The study will be publicized on 
a. NIH official websites; (e.g., www.clinicaltrials.gov, NCI cancer clinical trial 
listing (PDQ), and CCR)
b. NIH moderated social media platforms [e.g., Facebook, X, Instagram]. These 
sites comply with government terms of service per the NIH Social Media 
Guidelines)
c. Research Match https://www.researchmatch.org/about/
d. Newsletters
The protocol may be abstracted into a plain language announcement-information to be abstracted 
includes-study title; purpose of the study; protocol summary; basic eligibility criteria; study site 
location(s); and how to contact [CONTACT_555563]) and posted/distributed on the above 
media without IRB approval. Should we add additional descriptive information about the study to 
these announcements, we will seek IRB approval.
2. Television advertisements/radio advertisements
a. Clinical Center TV (CCTV) – Clinical Center Television - CCTV | NIH Clinical 
Center - America's Research Hospi[INVESTIGATOR_555511].
3. Newspaper advertisements
4. Videos
5. Publicly posted recruitment flyers and posters
6. Brochures
7. Clinical Center Office of Patient Recruitment Services (OPR) including OPR 
a. Listservs (Email list of those interested in receiving study recruitment updates.) 
Includes the OPR Protocols and OPR Healthy Volunteers listservs and 3 NIH 
listservs (NIH Post bac, NIH Clinical Fellows & NIH Study Volunteers)
8. Recruitment Letters 
a. Doctor to patient informational letter: distribution of letters to private health 
care physicians who will then share the letters with potential participants. This 
information will be made available in electronic and/or a hard copy as needed. 
(Note: if material is not to be shared with participants, these are not submitted 
to the IRB)
b. Investigator to potential participant letters.
Prior to the distribution of any individual recruitment materials not included in item #1, 
such materials will be submitted for IRB review, as appropriate. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729253] has signed a consent include the 
following: 
•Email, written, in person or telephone communications with prospective participants 
•Review of existing medical records to include H&P, laboratory studies, etc.  
•Review of existing MRI, x-ray, or CT images, etc.
•Review of existing photographs or videos
•Review of existing pathology specimens/reports from a specimen obtained for diagnostic 
purposes
A waiver of consent for these activities has been requested in Section 12.4.1.
2.3.2 Screening activities performed after a consent for screening has been signed
The following activities will be performed only after the participant has signed the study consent 
OR the consent for study 01-C-0129 (provided the procedure is permitted on that study) on 
which screening activities may also be performed. Assessments performed at outside facilities or 
on another NIH protocol within the timeframes below may also be used to determine eligibility 
once a participant has signed the consent.
Screening must be completed within 2 weeks prior to C1D1. 
•History and physical exam (including height, weight, vital signs and performance status)
•Blood tests (for organ function)
oComplete blood count (CBC/Diff)
oAcute care panel (sodium, potassium, chloride, total CO2 (Bicarbonate), 
creatinine, glucose, urea nitrogen)
oHepatic panel (alkaline phosphatase, ALT/GPT, AST/GOT, total bilirubin, direct 
bilirubin)
oProthrombin time (PT)
oPartial thromboplastin time (PTT)
oViral Markers Protocol Screen (HBsAg, anti-HCV, anti-HIV) within 3 months of 
C1D1.
•Collection of pathology reports from any certified laboratory for confirmation of 
diagnosis (may be done prior to the two week screening window).
•CT chest/abdomen/pelvis (mCRPC patients will have baseline CT scans and technetium-
99 bone scan imaging within 30 days prior to initiation of therapy)
•Electrocardiogram
•Echocardiogram within 4 weeks prior to C1D1
•Urine or serum HCG for IOCBP (to be performed within 3 days prior to C1D1)
•Serum testosterone level (mCRPC patients only)
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
482.4 PARTICIPANT REGISTRATION AND STATUS UPDATE PROCEDURES
Registration and status updates (e.g., when a participant is taken off protocol therapy and when a 
participant is taken off-study) will take place per CCR SOP ADCR-2, CCR Participant 
Registration & Status Updates found at 
https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=73203825.
2.4.1 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details and eligibility criteria.
2.4.2 Treatment Assignment Procedures
Cohorts
Number Name [CONTACT_62578]
1 Phase I Phase I subjects
2 Phase II SCLC expansion Phase II expansion cohort of subjects with SCLC 
3 Phase II urothelial carcinoma 
expansionPhase II expansion cohort of subjects with urothelial carcinoma
4 Phase II mCRPC expansion Phase II expansion cohort of subjects with mCRPC
Arms
Number Name [CONTACT_62578]
1 Phase I EP0057 + olaparib
2 Phase II EP0057 + olaparib at MTD/RP2D
Arm Assignment
All subjects in cohort 1 will be enrolled on arm 1. All subjects in cohorts 2-4 will be enrolled on 
arm 2. There is no randomization.
Note: Accrual to cohort 4 (mCRPC) ended with amendment version 7/27/2021. Accrual to 
cohort 3 (urothelial carcinoma) ended with amendment version 8/17/2022.
2.5 BASELINE EVALUATION
Please refer to the Study Calendar (Section 3.4).
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
493 STUDY IMPLEMENTATION
3.1 STUDY DESIGN
This is a phase I / II open label single center trial. Patients will be enrolled to the phase I portion 
of the study to determine the maximum tolerated dose (MTD) or recommended phase 2 dose 
(RP2D). The RP2D is EP0057 12mg/m2 and olaparib 250 mg BID. In phase II, up to 27 
evaluable patients with SCLC will be enrolled (Amendment H). To further evaluate clinical 
response rate to EP0057, up to 34 evaluable patients will be enrolled into a urothelial carcinoma 
cohort and 25 evaluable patients enrolled into an mCRPC expansion cohort as described in 
section 10. 
Patients meeting the eligibility criteria will receive EP0057 (IV Q 2weeks) plus olaparib (PO 
BID days 3-13* and days 17-26* administered in 28-day cycles, until disease progression or 
development of intolerable side effects. 
* There should be at least a 48-hour window between EP0057 and olaparib with the exception of 
dose level 5B in which the window is reduced to [ADDRESS_729254] a mandatory baseline biopsy. If an SCLC patient opts for a biopsy, it will be performed at 
the following time points: pre-treatment, on cycle [ADDRESS_729255] scans (chest, abdomen and pelvis) at baseline and after every [ADDRESS_729256] not seen dose limiting toxicities, specifically myelosuppression. 
With amendment A, we would like to dose escalate olaparib from 200 mg to 300 mg between 
dose levels 3 and 4. This represents a 50% increase in the dose of olaparib (compared with 25% 
increase proposed in the earlier schema from 200 to 250 mg). If olaparib 300 mg is not tolerated 
(2 or more DLTs), dose escalation will be stopped and [ADDRESS_729257] dose level (dose level 5) is well tolerated, the 
interval between EP0057 and olaparib will be abbreviated at the next dose level (dose level 5B) 
from 48 hours to 24 hours. 
With amendment E, patients are to be enrolled at RP2D (DL 4R, EP0057 at 12 mg/m2 and 
olaparib at 250 mg) in Phase II part of the trial as Phase I part of the study is now completed; it 
was determined that olaparib at the dose level 4R, 250 mg, is well tolerated. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
50Provisional Dose levelsEP0057, mg/m2
(IV q 2 weeks
D1 and D15)Olaparib tablet, mg
(PO BID Days 3-13* and 17-26*) 
1 12 100
2 12 150
3 12 200
4 12 300**
4R(educed)  (MTD/RP2D) 12 250
5 (Not explored) 15 300
5B (Not explored) 15 300
28-day cycles; biopsies pre-treatment and on day 4 ([ADDRESS_729258]- olaparib) and at disease 
progression; 
* There should be a minimum 48-hour window between EP0057 and olaparib except dose 
level 5B which allows the interval to be abbreviated to 24 hours. 
The recommended phase 2 dose (RP2D) may be lower than, or equal to, the MTD. Phase II 
portion of this study may start with RP2D, and/or at MTD.
** An additional dose level (4R) of 250 mg has been evaluated with DLTs in 1 of 6 patients as 
there were 2 or more DLTs among 6 patients treated at dose level 4.
With amendment version 07/27/2021, accrual to the mCRPC cohort is to cease given the 
incidence and possibly the severity of hematuria/cystitis in participants with GU malignancies 
and slow cohort accrual following FDA approval of Olaparib for prostate cancer.
Accrual to the urothelial carcinoma cohort ended with amendment version 08/17/2022.
3.1.[ADDRESS_729259] 
cycle unless otherwise indicated. DLTs will be defined using the National Cancer Institute (NCI) 
CTCAE (Version 4). The following events, occurring during cycle 1 of the study combination, 
will be considered DLTs if deemed drug-related:
•Grade 4 neutropenia complicated by [CONTACT_411] ≥  38.5 °C (i.e. febrile neutropenia) and/or 
documented infection; 
•Grade 4 neutropenia that does not resolve within 7 days* 
•Grade 4 thrombocytopenia that does not resolve within 7 days* or any grade 3-4 
thrombocytopenia complicated with hemorrhage; 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
51•Grade 4 anemia that does not resolve within 7 days despi[INVESTIGATOR_11920] (withholding 
study drug and red blood cell transfusions); 
•Inability to begin subsequent treatment course within 28 days of the scheduled date, due 
to study drug toxicity; 
•Any grade 3-4 non-hematologic toxicity (except fatigue/asthenia < 2 weeks in duration; 
mucositis in subjects who have not received optimal therapy for mucositis; vomiting or 
diarrhea lasting less than 72 hours whether treated with an optimal anti-emetic or anti-
diarrheal regimen or not; or alkaline phosphatase changes). 
*Note: In the event of a Grade [ADDRESS_729260] will be closely monitored until resolution to Grade 3 or less.
3.1.2 Dose Escalation
Dose escalation will proceed in groups of 3–[ADDRESS_729261] 2 (of ≤6) patients have DLT as a result of the drug. If a patient did 
not experience DLT and did not finish cycle [ADDRESS_729262] a DLT will be replaced. 
The theoretical maximum number of subjects required to determine the MTD in the phase 1 
portion of the study is 30 subjects (6 per dose level), although it is expected that as few as 15 
subjects in 4 dose levels would be required to reach an MTD.
The recommended phase 2 dose (RP2D) may be lower than, or equal to, the MTD. Phase II 
portion of this study may start with RP2D, and/or at MTD.
Dose escalation will follow the rules outlined in the Table 5 below.
Table 5. Dose Escalation Guidelines 
Number of Patients with 
DLT
at a Given Dose LevelEscalation Decision Rule
0 out of 3 Enter up to 3 patients at the next dose level
> 2 Dose escalation will be stopped. This dose level will 
be declared the maximally administered dose 
(highest dose administered). Up to three (3) 
additional patients will be entered at the next lowest 
dose level if only 3 patients were treated previously 
at that dose.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
521 out of 3 Enter up to 3 more patients at this dose level.
•If 0 of these 3 patients experience DLT, proceed 
to the next dose level.
•If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared 
the maximally administered dose. UP to three (3) 
additional patients will be entered at the next 
lowest dose level if only 3 patients were treated 
previously at that dose.
<[ADDRESS_729263] be entered at 
the recommended phase 2 dose.
3.2 DRUG A DMINISTRATION
3.2.1 EP0057
EP0057 will be diluted with 5% dextrose for injection (D5W) to a total volume of 500 mL and 
should be infused intravenously as described in section 14.1.6 over 60-75 minutes. Nothing else 
should be added to the bag.
The EP0057 infusion should begin immediately after preparation and diluted EP0057 infusion 
solution not used within 6 hours should be destroyed following institutional practices. 
[IP_ADDRESS] Premedication Prior to EP0057 Treatment and Pre and Post Hydration
Subjects will receive up to 1,000 ml of 0.9% normal saline solution IV hydration before and after 
administration of EP0057 to reduce risk of cystitis adverse reaction. Hydration levels should be 
adjusted as needed by [CONTACT_555564].
Hypersensitivity reaction (HSR) have been observed in a small number of subjects treated with 
EP0057. Most HSR associated with EP0057 are mild and moderate, reversible upon study drug 
interruption. In general, subjects restarted EP0057 infusion at a slower infusion rate without 
recurrence. In addition to the mandatory premedication to prevent HSR, the duration of EP0057 
infusion must be prolonged from 1 hour to approximately 2 hours. 
Appropriate resuscitation equipment should be available in the room and a physician readily 
available during the period of study drug infusion.
Subjects should be pre-medicated with the following 3 drug classes 30-120 minutes* prior to 
start of EP0057 infusion to reduce likelihood of hypersensitivity adverse reactions:
▪a corticosteroid (dexamethasone 20 mg IV) 30-120 minutes prior to start of EP0057 
▪an antihistamine (diphenhydramine 50 mg PO)
▪an H2 antagonist (ranitidine 50 mg IV) 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729264] are to be administered to 
reduce the potential for nausea. Suggested antiemetics include dolasetron (PO), granisetron (PO 
or IV) or ondansetron (PO or IV) 30-120 minutes prior to starting EP0057 infusion.
The example medications, route of administration, and dose indicated should be the medication-
of-choice if clinically feasible. It is acknowledged that the premedication regimen may be altered 
for patient safety during the study (for example, if a patient experiences a 
hypersensitivity/infusion reaction related to study drug, the premedication regimen may be 
altered for subsequent cycle dosing based on the investigator’s discretion).
* Contact [CONTACT_555565]-medications exceeds 120 minutes.
3.2.2 Olaparib
Olaparib tablet at the appropriate dose level will be given orally on days 3-13* and days 17-26* 
twice daily (*there should be at least a 48-hour window between olaparib and EP0057 except 
dose level 5B which allows the window to be abbreviated to 24 hours). The correct number of 25 
mg, 100 mg, 150 mg or 200 mg tablets comprising the appropriate dose should be taken at the 
same times each day with approximately 240 mL of water. A light snack (biscuits/ toast) is 
advised at the time of dosing to help alleviate nausea but no specific timing needs to be observed. 
The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided.
Olaparib will be dispensed at the start of each cycle. Patients will be provided with a pi[INVESTIGATOR_69642] 
(Appendix C , Section 16.3), instructed in its use, and asked to bring it with them to each 
appointment.
For Phase II, it is recommended, but not required, that growth factors be given prophylactically 
starting cycle [ADDRESS_729265] dose reduction Second dose 
reduction
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
54-1 100 mg twice daily 75 mg twice daily 50 mg twice daily
1 100 mg twice daily 75 mg twice daily 50 mg twice daily
2 150 mg twice daily 100 mg twice daily 75 mg twice daily
3 200 mg twice daily 150 mg twice daily 100 mg twice daily
4 and 5 300 mg twice daily 250 mg twice daily 200 mg twice daily
4R (RP2D) [ADDRESS_729266] dose reduction Second dose 
reduction
-1 9 mg/m2 q 2weeks 6 mg/m2 q 2weeks 4 mg/m2 q 2weeks
1-4 & 4R 12 mg/m2 q 2weeks 9 mg/m2 q 2weeks 6 mg/m2 q 2weeks
5 15 mg/m2 q 2weeks 11 mg/m2 q 2weeks 7 mg/m2 q 2weeks
3.3.2 Dosing Delays/Dose Modifications and Management of Toxicities
•In the case of toxicity, appropriate medical treatment should be used (including anti-emetics, 
anti-diarrheals, etc.). 
•Once a patient has a dose reduction for toxicity, the dose will not be increased. 
•A maximum of 2 dose reductions is permitted 
•If either agent is discontinued due to toxicity, the patient may continue on the other agent.
•Participants continuing to experience toxicity at the off treatment visit will be contact[CONTACT_555566]. Patients must 
remain on the study to have additional assessment.
•For AEs that are unrelated to the study drugs, study drug may be held for up to 21 days at the 
discretion of the PI. 
•The associate investigator and/or PI [INVESTIGATOR_555512].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] Hematologic toxicities
Table 8. Dose Modification and Management of Hematologic Adverse Events
Observation Action
On day 1 and 15 
Absolute neutrophil count (ANC) ≥ 
1500/mcL
AND
Platelets ≥ 75,000/mcL
AND
Hemoglobin ≥  8 g/dLNo interruption.
On day 1 and 15 
ANC < 1500/mcL
OR
Platelets < 75,000/mcL
OR
Hemoglobin < 8 g/dLIf any weekly evaluation demonstrates grade ≥  3 
neutropenia or grade ≥ [ADDRESS_729267] occurrence, hold the drug(s) causing the 
toxicity for up to 21 days until ANC ≥ 1500/mcL, 
platelets ≥ 75,000/mcL, and hemoglobin ≥ 9 g/dL.
The associate investigator and/or PI [INVESTIGATOR_555513]-
initiation.
On second occurrence, hold the drug(s) causing the 
toxicity for up to 21 days until ANC ≥ 1500/mcL, 
platelets ≥ 75,000/mcL, and hemoglobin ≥ 9 g/dL. 
Initiate appropriate medical therapy. Treatment with 
olaparib or EP0057 may be restarted at one dose 
level (DL) lower. 
Patients whose counts have not recovered to ANC ≥  
1500/mcL, platelets ≥ 75,000/mcL, and hemoglobin 
≥ 9 g/dL after [ADDRESS_729268] occurrence, hold the drug(s) causing the 
toxicity for up to 21 days until ANC ≥ 1500/mcL, 
platelets ≥ 75,000/mcL, and hemoglobin ≥ 9 g/dL. 
Initiate appropriate medical therapy. Treatment with 
olaparib or EP0057 may be restarted at one DL 
lower. 
On second occurrence, discontinue the drug(s) 
causing the toxicity. Follow patient until 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
56Table 8. Dose Modification and Management of Hematologic Adverse Events
Observation Action
resolution/stabilization of toxicity. 
Patients whose counts have not recovered to ANC ≥  
1500/mcL, platelets ≥ 75,000/mcL, and hemoglobin 
≥ 9 g/dL after 21 days should be removed from the 
drug causing the toxicity. See section [IP_ADDRESS] for 
exceptions.
Toxicities requiring more than 2 dose 
reductionsRemove patient from the drug causing the toxicity.
•Treatment may be delayed for a maximum of 21 days after holding the treatment for 
toxicities that develop and do not resolve as defined above (the following AE’s are exempt 
from hold: lymphopenia, or leukopenia in the absence of grade 3 or higher neutropenia).
•Weekly blood counts will be obtained during the first cycle, and then at day 1 and 15 of 
subsequent cycles.
•Management of prolonged hematological toxicities while on study treatment
If a patient develops prolonged hematological toxicity such as:
≥2 week interruption/delay in study treatment due to CTC grade 3 or worse anemia 
and/or development of blood transfusion dependence
≥3 week interruption/delay in study treatment due to CTC grade 3 or worse neutropenia 
(ANC < 1,000/mcL)
≥3 week interruption/delay in study treatment due to CTC grade 3 or worse 
thrombocytopenia (Platelets < 50,000/mcL)
Weekly differential blood counts including reticulocytes (calculate reticulocyte index 
(RI), RI = reticulocyte count x hematocrit (Hct)/normal Hct; a value of [ADDRESS_729269]) and peripheral blood smear should be performed. If any blood parameters 
remain clinically abnormal after [ADDRESS_729270] for further investigations. Bone marrow analysis and/or blood 
cytogenetic analysis should be considered at this stage according to standard 
hematological practice. 
Development of a confirmed myelodysplastic syndrome or other clonal blood disorder 
should be reported as an SAE. Study treatment should be discontinued if diagnosis of 
myelodysplastic syndrome is confirmed. 
[IP_ADDRESS] Neutropenia
•Phase I: Growth factors to prevent neutropenia will not be administered during the DLT 
period in phase I but may be used thereafter to prevent/treat neutropenia. Please note that G-
CSF should not be used within at least [ADDRESS_729271] dose of EP0057 administration.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] Thrombocytopenia
•Thrombocytopenia will be treated conservatively. In the absence of bleeding, or a necessary 
invasive procedure, platelet transfusions should be given for a platelet count ≤ 10,000/mcL.
•If invasive procedure(s) is (are) planned, or the patient develops bleeding, platelet 
transfusions should be administered in accordance with the standard of practice, usually 
maintaining a platelet count above 50,000/mcL.
[IP_ADDRESS] Anemia
•Symptomatic anemia should be treated with red blood cell transfusion and is recommended if 
the hemoglobin falls below 8 g/dL or the patient is symptomatic.
3.3.3 General Recommendations for Dose Modification and Management of Non-
Hematologic Adverse Events 
•The management of general AEs not otherwise specified in the following sections should be 
as per Table 9. 
•At the discretion of the investigator, the study drugs may be held or dose modified 
independently if the observed toxicity is attributed to only one of the drugs, while the patient 
continued to receive the drug not associated with the observed toxicity. 
•Dose modifications for nausea, vomiting, and diarrhea will be made only if they are 
refractory to treatment. The time a given drug is held should not exceed 21 days.
Table 9. General Management of Adverse Events (Non-Hematologic)
Observation Action
Grade 1 or 2 AEs resolves promptly (within 
48 hours) with supportive care Maintain dose level (DL)
Any ≥ grade 3 non-hematologic* Hold study drug(s) causing the toxicity for up 
to 21 days until toxicity resolves to ≤ grade 1. 
Treatment with olaparib or EP0057 may be 
restarted at one DL lower, as per the dose 
reduction guidelines. 
Grade [ADDRESS_729272] 
reduced DLRemove patient from the drug causing the 
toxicity.
Toxicities requiring more than 2 dose 
reductions Remove patient from the drug causing the 
toxicity.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
58*Except fatigue/asthenia < 2 weeks in duration; mucositis in subjects who have not received 
optimal therapy for mucositis; vomiting or diarrhea lasting less than 72 hours whether treated 
with an optimal anti-emetic or anti-diarrheal regimen or not; or alkaline phosphatase changes
•Management of new or worsening pulmonary symptoms
If new or worsening pulmonary symptoms (e.g. dyspnea) or radiological abnormality occurs, an 
interruption in olaparib dosing is recommended and a diagnostic workup (including a high 
resolution CT scan) should be performed, to exclude active pneumonitis. Following 
investigation, if no evidence of abnormality is observed on CT imaging and symptoms resolve, 
then olaparib treatment can be restarted, if deemed appropriate by [CONTACT_093]. 
3.3.4 Management of the hypersensitivity/infusion reactions
Table 10. Management of the hypersensitivity/infusion reactions
Hypersensitivity reaction
Grade 1 or 2 Stop infusion immediately, continue hydration fluids and provide 
medications as indicated per institutional guidelines. 
If symptoms resolve within 1-2 hours, at Investigator’s discretion may 
re-start study drug administration at slower rate (i.e. 2x slower rate) 
and increase rate slowly to complete administration of full dose.
OR
Hold dose administration on day of event, and resume treatment at 
next scheduled day at same dose level.
At Investigator’s discretion may administer subsequent dose using a 
desensitization protocol as per institutional guidelines.
Grade 3 or 4 Stop infusion immediately and administer medical support as 
indicated per institutional guidelines. 
Hold dose administration on day of event.
Review with study Principal Investigator [INVESTIGATOR_555514]. Confirm that rate of 
administration was appropriate and premeds were given as suggested.
Administration of EP0057 should be over 2 hours (using the following infusion schedule) with 
additional pre-medications (dexamethasone 20mg IV, ranitidine 50mg IV, acetaminophen 
650mg PO, ondansetron 16mg PO or IV and Benadryl 50mg PO). 
 EP0057 in 500ml 5% dextrose IV infusion
15mL/hr for 15 minutes, then increase to
30mL/hr for 15 minutes, then increase to
60mL/hr for 15 minutes, then increase to
120mL/hr for 15 minutes, then increase to
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
59240mL/hr for 15 minutes, then increase to
480mL/hr for 15 minutes, then increase to
528mL/hr for 30 minutes to complete infusion
3.3.5 Dose Modification for Surgical Procedures or Palliative Radiation
•Olaparib should be stopped 3 days before surgery and re-started after wound has healed 
following recovery. 
•No stoppage of olaparib is required for any biopsy procedures.
•Olaparib should be discontinued for a minimum of 3 days before a patient undergoes 
therapeutic palliative radiation treatment.
3.3.6 Laboratory safety assessment
Full hematology assessments for safety (hemoglobin, red blood cells [RBC], platelets, mean cell 
volume [MCV], mean cell hemoglobin concentration [MCHC], mean cell hemoglobin [MCH], 
white blood cells [WBC], absolute differential white cell count (neutrophils, lymphocytes, 
monocytes, eosinophils and basophils) and absolute neutrophil count or segmented neutrophil 
count and Band forms should be performed weekly during Cycle 1, at each subsequent visit, and 
when clinically indicated. If absolute differentials are not available, percentage differentials are 
acceptable. Coagulation [activated partial thromboplastin time (APTT) and international 
normalized ratio (INR)] will be performed at baseline and if clinically indicated. Patients taking 
warfarin may participate in this study; however, it is recommended that prothrombin time (INR 
and APTT) be monitored carefully at least once per week for the first month, then monthly if the 
INR is stable.
Biochemistry assessments for safety include an acute care panel and hepatic panel. These tests 
should be performed weekly during Cycle 1, at each subsequent visit, and when clinically 
indicated. The mCRPC cohort will have additional assessments specified in 3.4.
Urine or serum HCG for IOCBP (to be performed within 3 days of C1D1) is to be performed at 
screening only. 
Bone marrow or blood cytogenetic samples may be collected for patients with prolonged 
hematological toxicities.
Additional analyses may be performed if clinically indicated.
Any clinically significant abnormal laboratory values should be repeated as clinically indicated.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
603.4 STUDY CALENDAR
On study assessments can be performed within ±7 days of the specified time, unless otherwise indicated. Treatments may be delayed 
up to 7 days to accommodate scheduling. 
Cycles = 28 days1
Procedure
Screening
Baseline2
Day 1 2 3 4 5 7 152821 28Cycle 222 
Day 1
End of 
Treatment/ 
Disease 
Progression [ADDRESS_729273] Therapy 
Follow-up4
History X X X
Physical exam3X X X X
PTT/PT 23X X
Viral Markers Protocol 
Screen17 X
CBC diff 5, 20X X X14X X X X
Acute Care Panel6,20X X X14X X X X
Hepatic Panel7, 20X X X14X X X X
Mineral Panel (mCRPC 
only) 24 X X
LDH, Creatine kinase, 
Uric Acid, Total Protein 
(mCRPC only)XX
Pregnancy test8X X X
CT scan12X15X X
CT c/a/p and bone scan 
(mCRPC only)X XX25
X
PSA (mCRPC only) X X25X
Clinical disease 
assessmentX X X
ECG X X X27X27X27
Echocardiogram21X
Whole blood, plasma, 
hair26 and saliva for 
correlative studies9, 29Refer to tables in section 5. Table 11– Phase 1 and Phase 2 SCLC; Table 13 – UC 
expansion; Table 14 – mCRPC expansion
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
61Cycles = 28 days1
Procedure
Screening
Baseline2
Day 1 2 3 4 5 7 152821 28Cycle 222 
Day 1
End of 
Treatment/ 
Disease 
Progression [ADDRESS_729274] be performed 
within 3 days prior to the initiation of study therapy. If the procedure was performed during the appropriate timeframe at screening, it is not 
necessary to repeat at baseline.
3 Symptom-directed physical examinations will be performed as clinically indicated in the investigator’s judgment
4 Follow-up for survival will be carried out every 3 months
5 Includes  Neutrophils, Lymphs, Monos, Eos, Basos, WBC, RBC, Hemoglobin, Hematocrit, RBC Indices, MCV, RDW, Platelet. Results should 
be available prior to administration of study drugs
6 Includes Sodium (NA), Potassium (K), Chloride (CL), Total CO2 (Bicarbonate), Creatinine, random Glucose, Urea or blood urea nitrogen 
[BUN], eGFR.
7 Includes Alkaline Phosphatase, ALT/GPT, AST/GOT, Total Bilirubin, Direct Bilirubin
8 Only for IOCBP; may be obtained up to 3 days prior to Day 1 of each cycle.
9 Blood, plasma, hair and saliva samples will be collected at multiple time points during cycles 1,2 and each cycle thereafter for hair collection (for 
specific timepoints on correlative samples collection please refer to section 5.1.1 for Phase I and Phase II cohorts, section 5.1.2 for UC expansion 
cohort and section 5.1.3 for mCRPC expansion cohort). C1D15 timepoint for correlative studies will only be done for Phase II SCLC cohort. Only 
whole blood will be drawn for that cohort at that timepoint. 
[ADDRESS_729275] treatment cycle (approximately [ADDRESS_729276] dose of olaparib) and at 
disease progression. In the mCRPC cohort, biopsy at baseline is mandatory. 
[ADDRESS_729277] a 48-hour window between EP0057 and olaparib except dose 
level 5B which allows the interval to be abbreviated to 24 hours. Olaparib can be taken continuously if EP0057 is missed for any reason. 
12 Performed after every 2 cycles
13 Approximately 4 weeks after treatment discontinuation
14 Only done in cycle 1
15 Only done in phase 2
16 Phase 1 portion of the study in cycles 1 and 6 only.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
6217 Within 3 months of C1D1.
19 D15 PKs can be obtained +/- [ADDRESS_729278]/abdomen/pelvis and technetium 99 bone scan every 3 cycles 
(every 12 weeks).
[ADDRESS_729279] two cycles of EP0057 for patients with any conduction abnormality on baseline 
ECG.
28 Day 15 assessments not required for patients on olaparib only.
29. This protocol targets patients with aggressive tumors and, historically, minimal tissue is available (majority of patients are unresectable at 
diagnosis). Hence, the priority is to perform biopsies followed by [CONTACT_555567]. In instances where research labs 
including PKs cannot be obtained due to scheduling conflicts, samples may be omitted or collected in a delayed fashion. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729280] to pay for these costs. 
Medicines that are not part of the study treatment will not be provided or paid for by [CONTACT_251703].  
3.5.2 Compensation
Participants will not be compensated on this study.
3.5.3 Reimbursement 
The NCI will cover the costs of some expenses associated with protocol participation. Some of 
these costs may be paid directly by [CONTACT_62539]/guardian as appropriate. The amount and form of these payments are determined by 
[CONTACT_62540]. 
3.[ADDRESS_729281] dose of study therapy.
3.6.1 Criteria for Removal from Protocol Therapy
•Progressive disease 
•Participant requests to be withdrawn from active therapy
•Unacceptable Toxicity as defined in Sections 3.1.1 and 3.3
•Toxicity related dose delay lasting longer than 21 days in which case patient will be 
removed from the drug causing the toxicity.
•Investigator discretion
•Requirement for any of the prohibited study drugs as described in Appendix B, 
Section 16.2 (Strong and moderate Inhibitors and Inducers of CYP3A)
•The subject becomes pregnant
•Active pneumonitis
3.6.2 Off-Study Criteria
•Participant requests to be withdrawn from study
•Investigator decision to end study
•Death
•Permanent loss of capacity to consent
•Screen failure
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
644 CONCOMITANT MEDICATIONS/MEASURES
•No other chemotherapy, hormonal therapy (HRT is acceptable) or other novel agent is to be 
permitted during the course of the study for any patient (the patient can receive a stable dose 
of corticosteroids during the study as long as these were started at least 4 weeks prior to 
treatment, as per exclusion criteria above). For the mCRPC cohort, patients may receive 
hormonal therapy in the form of GnRH agonists/antagonists as per eligibility criteria above 
and corticosteroids are permissible. 
•Live virus and bacterial vaccines should not be administered whilst the patient is receiving 
study medication and during the 30 day follow up period. An increased risk of infection by 
[CONTACT_367421].
•No concomitant use of alternative, complementary therapi[INVESTIGATOR_477262]-the-counter agents will 
be allowed without approval of the PI. All medications must be recorded in the case report 
form and be reviewed by [CONTACT_555568]. 
•Caution should be exercised in the concomitant use of any medication that may markedly 
affect renal function. Such medications may be used with caution as deemed essential for 
treatment, or if already in use prior to entry in the study without any effect on renal function. 
•Caution should be exercised in concomitant use of any medication that may significantly 
affect hepatic CYP450 drug metabolizing activity by [CONTACT_555569] (e.g. 
Phenytoin) or inhibition (e.g. ketoconazole, ritonavir, erythromycin) within [ADDRESS_729282] dose of olaparib and throughout the study period.
•Given this data, potent inhibitors or inducers of CYP3A4 (as outlined in Appendix B, 
Section 16.[ADDRESS_729283] not be used during this study. 
•CYP3A4 known potent inhibitors: wash-out period [ADDRESS_729284] 4.5x elimination half-
lives for drugs and metabolites known to inhibit CYP3A subfamily enzymes: Ketoconazole, 
itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
•CYP3A4 inducers (potential reduction in efficacy of olaparib) a wash-out period for [ADDRESS_729285] John’s Wart.
•Patients should avoid concomitant use of drugs, herbal supplements and/or ingestion of foods 
known to modulate CYP3A4 enzyme activity from the time they enter the screening period 
until [ADDRESS_729286] shown that the 
principal enzyme responsible for the formation of the 3 main metabolites of olaparib is 
CYP3A4 and consequently, this restriction is required to ensure patient safety.
•Olaparib inhibits CYP3A4 in vitro and is predicted to be a mild CYP3A inhibitor in vivo. 
Therefore, caution should be exercised when sensitive CYP3A substrates or substrates with a 
narrow therapeutic margin (e.g. simvastatin, cisapride, cyclosporine, ergot alkaloids, 
fentanyl, pi[INVESTIGATOR_3924], sirolimus, tacrolimus and quetiapi[INVESTIGATOR_050]) are combined with olaparib. 
•Substrates of UGT1A1 should also be given with caution in combination with olaparib (e.g. 
irinotecan, nintedanib, ezetimibe, raltegravir or buprenorphine).
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
65•Induction of CYP1A2, 2B6 and 3A4 has been shown in vitro with CYP3A4 CYP2B6 being 
most likely to be induced to a clinically relevant extent. The potential for olaparib to induce 
CYP2C9, CYP2C19 and P-gp is unknown. It cannot be excluded that olaparib upon co 
administration may reduce the exposure to substrates of these metabolic enzymes and 
transport protein. The efficacy of hormonal contraceptives may be reduced if co administered 
with olaparib.
•In vitro olaparib has been shown to be an inhibitor of P-gp, OATP1B1, OCT1, OCT2, OAT3, 
MATE1 and MATE2K and is a weak inhibitor of BRCP. It cannot be excluded that olaparib 
may increase the exposure to substrates of P-gp (e.g. statins, digoxin, dabigatran, colchicine), 
OATP1B1 (e.g. bosentan, glibenclamide, repaglinide, statins, and valsartan), OCT1 (e.g. 
metformin), OCT2 (e.g. serum creatinine), OAT3, MATE1 and MATE2K. In particular, 
caution should be exercised if olaparib is administered in combination with any statin.
4.[ADDRESS_729287] 
medical practice. 
The use of any natural/herbal products or other “folk remedies” should be discouraged.
Olaparib is an investigational drug for which no data on in vivo interactions are currently 
available. Based on in vitro data and clinical exposure data, olaparib is considered unlikely to 
cause clinically significant drug interactions through inhibition or induction of cytochrome P450 
enzyme activity. In vitro data have, however, also shown that the principal enzyme responsible 
for the formation of the [ADDRESS_729288] often 
previously been reported to be associated with clinically significant drug interactions:
•ketoconazole, itraconazole, ritonavir, idinavir, saquinavir, telithromycin, clarithromycin 
and nelfinavir 
For patients taking any of the above, the required wash-out period prior to starting olaparib is 
one week.
In addition, to avoid potential reductions in exposure due to drug interactions and therefore a 
potential reduction in efficacy, the following CYP3A4 inducers should be avoided:
•Phenytoin, rifampi[INVESTIGATOR_2513], rifapentine, rifabutin, carbamazepi[INVESTIGATOR_050], phenobarbitone, nevirapi[INVESTIGATOR_050], 
modafinil and St John’s Wort (Hypericum perforatum) 
For patients taking any of the above, the required wash-out periods prior to starting olaparib are:
•phenobarbitone 5 weeks, and for any of the others, 3 weeks.
4.1.1 Other Concomitant Medications
All medications (prescriptions or over-the-counter medications) continued at the start of the trial 
or started during the study or until [ADDRESS_729289] be documented.
Anticoagulant Therapy: Subcutaneous heparin is permitted.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729290] not receive any other concurrent anti-cancer therapy, including investigational 
agents, while on study treatment. Patients may continue the use of bisphosphonates for bone 
disease and corticosteroids for the symptomatic control of brain metastases provided the dose is 
stable before and during the study
4.1.4 Medications that may NOT be administered
•No other chemotherapy, immunotherapy, hormonal therapy or other novel agent is to be 
permitted while the patient is receiving study medication. For the mCRPC cohort, patients 
may receive hormonal therapy in the form of GnRH agonists/antagonists as per eligibility 
criteria above. 
4.1.[ADDRESS_729291] only be used in accordance with the dosing recommendations in this protocol. 
Any dose or frequency of dosing that exceeds the dosing regimen specified in this protocol 
should be reported as an overdose.
Adverse reactions associated with overdose should be treated symptomatically and should be 
managed appropriately.
4.2 HIGHLY EFFECTIVE METHODS OF BIRTH CONTROL
The study drugs used in the study are regarded as having with medium/high fetal risk.
Individuals of childbearing potential and their partners, who are sexually active, must agree to 
the use of one highly effective form of contraception and their partner must use a condom [as 
listed below]. This should be started from the signing of the informed consent and continue 
throughout the period of taking study treatment and for at least [ADDRESS_729292] dose of study 
drug(s), or they must totally/truly abstain from any form of sexual intercourse (see below).
Individuals who can father children must use a condom during treatment and for [ADDRESS_729293] dose of olaparib when having sexual intercourse with a pregnant woman or with a 
woman of childbearing potential. Their partners should also use a highly effective form of 
contraception if they are of childbearing potential (as listed below). Individuals who can father 
children should not donate sperm throughout the period of taking olaparib and for [ADDRESS_729294] dose of olaparib.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
674.2.1 Acceptable non-hormonal birth control methods
•Total/true abstinence: When the patient refrains from any form of sexual intercourse and 
this is in line with their usual and/or preferred lifestyle; this must continue for the total 
duration of the study treatment and for at least 6 months (for individuals able to bear 
children) or at least 3 months (for individuals able to father children) after the last dose of 
study treatment. Periodic abstinence (eg, calendar ovulation, symptothermal, post-
ovulation methods, or declaration of abstinence solely for the duration of a trial) and 
withdrawal are not acceptable methods of contraception.
•Vasectomised sexual partner PLUS condom (with participant assurance that partner 
received post-vasectomy confirmation of azoospermia).
•Tubal occlusion PLUS condom.
•Intrauterine device (provided coils are copper-banded) PLUS condom.
4.2.2 Acceptable hormonal methods
•Mini pi[INVESTIGATOR_555515]: Progesterone-based oral contraceptive pi[INVESTIGATOR_72908]. 
Cerazette ([COMPANY_006] Sharp & Dohme) is currently the only highly efficacious progesterone-
based pi[INVESTIGATOR_555516].
•Combined pi[INVESTIGATOR_555515]: Normal and low-dose combined oral pi[INVESTIGATOR_3353].
•Injection PLUS condom: Medroxyprogesterone injection (eg, Depo-Provera [[COMPANY_007]]).
•Implants PLUS condom: Etonorgestrel-releasing implants (eg, Nexplanon [[COMPANY_006] Sharp 
& Dohme]).
•Patch PLUS condom: Norelgestromin/ethinyl estradiol transdermal system (eg, Xulane).
•Intravaginal device (eg, ethinyl estradiol-/etonogestrel-releasing intravaginal devices such 
as NuvaRing [[COMPANY_006] Sharp & Dohme]) PLUS condom.
•Levonorgestrel-releasing intrauterine system (eg, Mirena [Bayer]) PLUS condom.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
685 CORRELATIVE STUDIES FOR RESEARCH
5.1 BIOSPECIMEN COLLECTION
5.1.1 Phase I and Phase II Cohorts
Table 11. Correlative studies 
Phase I
Sample Assay Time pointsType of 
tube/sample a Amount of blood
gH2AX (1) Pre-treatment on C1D1
(2) Pre-treatment C1D4 
(24hr after olaparib)
(3) At disease progression NA NA
SLFN11 IHC
SLFN11 gene expressionNA NAOptional Tumor 
(only in patients with 
SCLC)
Exome/RNAseq/ droplet digital 
PCRNA NA
Germline DNA (1) Pre-treatment Purple top EDTA 5 ml
Circulating tumor
DNA mutation analyses(1) Pre-treatment Lavender top tubes Three 10-ml
Immune subsets (Peripheral 
blood mononuclear cells)(1) Pre-treatment on C1D1
(2) Pre-treatment C1D3 
(pre-olaparib)
(3) C1D4 (24hr after 
olaparib)
(4) Pre-treatment C2D1CPT citrate 
blue/black tubesTwo 8-ml tubesWhole blood
(only in patients with 
SCLC)
Circulating tumor cells 
enumeration RAD51 foci(1) Pre-treatment on C1D1 
(2) Pre-treatment C2D1 
(3) At disease progressionLavender top tubes Two 10-ml
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
69Sample Assay Time pointsType of 
tube/sample a Amount of blood
Nanostring immune panel (770 
genes)(1) Pre-treatment on C1D1
(2) Pre-treatment C2D1
(3) At disease progressionPAXgene RNA One 2.5 ml
Nanostring DNA damage 
response panel (180 genes) 3,4(1) Pre-treatment on C1D1
(2) Pre-treatment C2D1
(3) At disease progressionPAXgene RNA One 2.5 ml
Whole Blood 
(in all phase I 
patients)gH2AX (1) Pre-treatment on C1D1 
(2) Pre-treatment C1D3 
(pre-olaparib) 
(3) C1D4 (24hr after 
olaparib)green top One 6-ml tube
Hair
(optional)gH2AX (1) Pre-treatment on C1D1
(2) Pre-treatment on C1D3 
(pre-olaparib)
(3) C1D4 (24hr after 
olaparib)
(4) End of each cycle (any 
time after the last dose of 
olaparib but prior to the next 
dose of EP0057)12 follicles 12 follicles
Plasma PK Refer to Table 12 Refer to Table 12
a. Please note that tubes and media may be substituted based on availability with the permission of the PI [INVESTIGATOR_555517].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
70Phase II SCLC only
Sample Assay Time points Type of tube a Amount 
of bloodLab/
Instruction
gH2AX(1) Pre-treatment C1D1
(2) Pre-treatment C1D4
 (24hr after olaparib)NA NA
SLFN11 IHC
SLFN11 gene expression(3) At disease progressionNA NATumor 
(Optional)
Exome/RNAseq/droplet 
digital PCRNA NA
Germline DNA Pre-treatmentLavender top 
EDTA5 ml
Immune subsets 
(Peripheral blood 
mononuclear cells)(1) Pre-treatment on C1D1
(2) Pre-treatment on C1D15
(3) Pre-treatment on C2D1
(4) At disease progressionCPT citrate 
blue/black 
tubesTwo 8-ml 
tubes
Circulating tumor cells 
enumeration(1) Pre-treatment C1D1
(2) Pre-treatment C2D1
(3) At disease progressionCellSave tubes One 10 ml
Nanostring immune panel 
(770 genes)(1) Pre-treatment C1D1
(2) Pre-treatment C2D1
(3) At disease progressionPAXgene RNAOne 2.5 
mlWhole Blood
Nanostring DNA Damage 
and Repair panel (180 
genes)(1) Pre-treatment C1D1
(2) Pre-treatment C2D1
(3) At disease progressionPAXgene RNAOne 2.5 
mlPlease call DTB 
Clinical 
Translational Unit 
when the samples 
are ready for pi[INVESTIGATOR_9696]-
up at [PHONE_3305]
10/12C208
Keep all tubes at 
room temperature
a. Please note that tubes and media may be substituted based on availability with the permission of the PI [INVESTIGATOR_555517].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
715.1.1.1γ-H2AX
Phosphorylated H2AX (γ-H2AX) plays an important role in the recruitment and/or retention of 
DNA repair and checkpoint proteins such as BRCA1, MRE11/RAD50/NBS1 complex, MDC1 
and 53BP1. DNA damage has been shown to increase H2AX phosphorylation in cancer cells 
following exposure to camptothecins. If olaparib is able to increase the degree of DNA damage 
due to EP0057, it may be detectable by [CONTACT_305693] H2AX phosphorylation. We plan to 
study patient PBMCs, hair follicles, and tumor biopsies if obtained. Tumor tissue (optional) and 
hair follicles will be obtained if patients are suitable candidates and willing to allow such 
sampling. The ideal biomarker would confirm that there was increased DNA damage following 
addition of olaparib relative EP0057 alone. This analysis will be exploratory only and data will 
be used in planning biomarker endpoints in subsequent trials with the combination of EP0057and 
olaparib.
Hair follicles will be collected at multiple time points per Table 11. At least [ADDRESS_729295]. Aladjem’s lab (DTB-
LMP/CCR/NCI, Bldg 37/ Rm 5056) to inform him when samples will be taken (Tel: 240-760-
7338 (L); [PHONE_3304] (Cell); [EMAIL_3031]). [CONTACT_148430] will provide tubes for 
collecting the plucked hairs. The tubes contain ice cold PBS labeled with the date/time of 
sampling, the protocol, and the unique identifier. [CONTACT_148430] will also provide forceps for 
plucking. [CONTACT_148430] should be notified of when the samples should be pi[INVESTIGATOR_100628]. 
Single hairs are plucked from the scalp with forceps. Plucked hairs from eyebrows will be 
collected only if scalp hairs cannot be provided. The aim is to acquire [ADDRESS_729296]. Aladjem’s lab, hairs will be fixed with 
paraformaldehyde and analyzed under a dissection microscope to select those containing a full 
intact follicle and sheath. Plucked hairs will be fluorescently stained for γ-H2AX and images will 
be recorded by [CONTACT_2329] a confocal microscope. 
Blood will be collected per Table 11. When the patient is scheduled, the DTB Clinical 
Translational Unit will be contact[INVESTIGATOR_530] [by [CONTACT_20143] [EMAIL_3032]]. Blood from heparinized 
syringe will be mixed with a 1:1 ratio of room temperature PBS and layered over a 1:1 blood-
PBS/Ficoll ratio in a conical centrifuge tube. The conical centrifuge tube should be centrifuged 
25 minutes at room temperature at approximately 1000 rpm. The cell layer resting above the 
Ficoll and containing the peripheral blood mononuclear cells (PBMCs) will be aspi[INVESTIGATOR_555518] a 15 ml conical tube for washing in 15 ml PBS. PBMCs will be fixed with 
paraformaldehyde, spun onto a microscope slide and stain for γH2AX  detection. Images from γ-
H2AX-stained PBMCs will be recorded by [CONTACT_2329] a confocal microscope.
[IP_ADDRESS] SLFN11
Expression of the gene SLFN11 has been found to correlate with the activity of topoisomerase 
inhibitors in studies using the National Cancer Institute cell line panel (NCI60) and the Cancer 
Cell Line Encyclopedia (CCLE) (54, 55). SLFN11 expression predicted sensitivity to DNA 
damaging chemotherapy including Top1 and Top2 inhibitors, alkylating agents, platinum 
derivatives, DNA synthesis and PARP inhibitors ( 54-56). In experiments using cells with 
endogenously high and low SLFN11 expression and siRNA- and Crispr-mediated silencing, 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729297] and cell death in response to 
DNA damaging agents in cancer cells (56). Data from the CCLE, the NCI60 and The Cancer 
Genome Atlas (TCGA) indicate a broad range of SLFN11 expression in lung cancers, raising the 
possibility that high SLFN11 expression might enrich for tumors that are more likely to respond 
to DNA damaging chemotherapy; conversely low SLFN11 expression may predict tumors that 
are likely resistant. Pre-treatment SLFN11 expression in tumor samples will be assessed (IHC 
and RNA) to assess in an exploratory manner, the potentially role of SLFN11 as a predictor of 
response to EP0057 plus olaparib. 
[IP_ADDRESS] Tumor biopsies and genomic DNA 
Biopsies will be done only in phase II part of the study and in SCLC patients in the phase I part 
of the study.
Paired tumor biopsies will be obtained by [CONTACT_555570] [C1D4 (24hr after olaparib)] and at disease 
progression per Table 11. The site of biopsy will be determined in discussion with interventional 
radiologist. If it can be safely obtained, 4 cores of tumor tissue will be collected. Two cores will 
be sent to pathology- one for confirmation of diagnosis and another will be used for making an 
FFPE block. The other 2 cores will be flash frozen at the time of biopsy. When the patient is 
scheduled, the DTB Clinical Translational Unit lab will be contact[INVESTIGATOR_530] [by [CONTACT_148406] 
[EMAIL_3032]]. Interventional Radiology will call the lab at [PHONE_3305] when the 
patient arrives in IR and a lab member will be present at Interventional Radiology for the 
procedure. The cores will be flash frozen, 2D barcoded, and stored in liquid nitrogen.
Formalin fixed paraffin embedded tumor tissue (FFPE) from the new biopsies and or from 
archived FFPE tissue from prior biopsies/surgical procedures will be sent to the DTB Clinical 
Translational Unit as described above. Genomic DNA and RNA will be extracted from the tumor 
and archived for genomic analysis. Tumor tissue when obtained before start of treatment will be 
used for the following assessments: γ-H2AX, SLFN11, and POLQ expression; post-treatment 
biopsy samples will be assessed for γ-H2AX expression. 
[IP_ADDRESS] Immune Subsets 
Little is known of the immunomodulatory effects of DNA damage-inducing cytotoxic therapy. 
Peripheral blood mononuclear cells (PBMC) will be obtained per Table 11 and will be assessed 
by [CONTACT_555571], myeloid-derived suppressor cells, effector and 
exhausted CD4+ and CD8+ T-cells, and CD14+ monocytes. Assessment will include functional 
markers, i.e. PD-1, Tim-3, CTLA-4, CD40, HLA-DR , and/or PD-L1. Members of the lab will 
procure the peripheral blood samples, enter the samples in a secure patient database, process the 
samples for viable cell storage, label each sample with a unique 2D barcode, and viably store the 
samples. They will prepare the samples for staining, stain and run the samples by 
[CONTACT_64392] (MACSQuant, Miltenyi Biotec, Bergisch Gladbach, DE), the 
data will be analyzed by [CONTACT_325204] v.X.0.6. Peripheral blood will be drawn into two 8-ml CPT 
citrate blue/black tubes for each time point. These assessments will be performed by [CONTACT_555572].
Accumulating evidence has revealed the interplay between the host immune system and 
anticancer therapi[INVESTIGATOR_014].(57, 58) Several classical chemotherapeutics and molecular-targeted 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729298] been reported to stimulate tumor-specific immune responses either by [CONTACT_555573] (ICD) or by [CONTACT_555574]. We propose to 
study the impact of combination therapy of EP0057 with olaparib on immune subsets and test for 
clinical relevance. These analyses offer the opportunity to obtain new insights into the 
immunomodulatory action of these combination therapi[INVESTIGATOR_014].
[IP_ADDRESS] Circulating Tumor Cells and Circulating Tumor DNA
Circulating tumor cells (CTCs), which can be prevalent in SCLC, present a readily accessible 
'liquid biopsy'. Peripheral blood will be collected per Table 11 to correlate circulating tumor cell 
(CTC) levels at baseline or levels pre- and post-therapy with clinical response and survival. 
CTCs will be assessed using ferrofluidic enrichment and multiparameter flow cytometric 
detection. CTCs will be identified as viable, nucleated cells, that positively express one or more 
epi[INVESTIGATOR_258696]. CTCs will 
be enumerated and if sufficient, additional characterization performed included RAD51 foci, 
gene expression by [CONTACT_325200], NanoString, whole transcriptome by [CONTACT_555575]. Peripheral blood will be drawn into two 10-ml lavender 
top tubes and one 2.5 ml PAXgene RNA tube for each time point. These assessments will be 
performed by [CONTACT_452670]. 
Circulating tumor DNA will be isolated from plasma separated from peripheral blood. Mutations 
identified by [CONTACT_555576]. Mutations will be assessed by [CONTACT_325198]. 
A multiplexed gene expression approach to profiling immune gene and DNA damage response 
signatures 
Peripheral immune and DNA damage response transcriptional signatures will be evaluated by [CONTACT_555577]® platform (NanoString 
Technologies, Seattle, WA). We will use the nCounter 770 gene PanCancer Immune Profiling 
Panel and the newly released 170 gene DNA Damage & Repair panel, built in collaboration with 
the Developmental Therapeutics Branch. Peripheral blood will be collected in a PAXgene tube 
(PreAnalytix; 2.5 cc peripheral blood per tube) per the manufacturer’s instructions. RNA will be 
isolated using the PAXgene Blood RNA Kit according to the manufacturer’s instructions. The 
peripheral gene signatures will be evaluated at baseline and post-therapy to look for correlates of 
clinical response.
[IP_ADDRESS] PK (Phase I only)
In Phase I only, blood samples for the determination of EP0057 and olaparib plasma levels will 
be obtained from participating patients via 6mL sodium heparin tube (BD, Franklin Lakes, NJ) 
per the table below. Samples will be obtained following the first dose on Cycle 1, day 1, and 
again on Cycle 6, day 1 in order to assess the extent of accumulation from repeated dosing at the 
time points specified below:
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
74Table 12. Phase I PK Sample Collection Timeline
sample cycle day time 
(approx.)hr post-EP0057 start post-olaparib
1 1 1 8:00a 0 hr (predose, may be drawn 24 hrs prior 
start of dosing)-
2 1 1 8:30a 0.5 hr [+/- 5 minutes] (mid-infusion) -
3 1 1 9:00a 1 hr [+/- 5 minutes] (end of infusion 
(EIO))-
4 1 1 10:00a 2 hr [+/- 5 minutes] ([ADDRESS_729299] EOI) -
5 1 1 11:00a 3 hr [+/- 5 minutes] ([ADDRESS_729300] EOI) -
6 1 1 9:00p 13 hr [+/- 60 minutes] ([ADDRESS_729301] EOI) -
7 1 2 9:00a 25 hr [+/- 60 minutes] ([ADDRESS_729302] EOI) -
8 1 3 10:00a 50 hr [+/- 120 minutes] ([ADDRESS_729303] EOI) 2 hr
9 1 15 8:00a 360 hr [+/- 5 days] ([ADDRESS_729304] EOI) -
10 6 1 8:00a 0 hr (predose, may be drawn 24 hrs prior 
start of dosing)-
11 6 1 8:30a 0.5 hr [+/- 5 minutes] (mid-infusion) -
12 6 1 9:00a 1 hr [+/- 5 minutes] (end of infusion 
(EIO))-
13 6 1 10:00a 2 hr [+/- 5 minutes] ([ADDRESS_729305] EOI) -
14 6 1 11:00a 3 hr [+/- 5 minutes] ([ADDRESS_729306] EOI) -
15 6 1 9:00p 13 hr [+/- 60 minutes] ([ADDRESS_729307] EOI) -
16 6 2 9:00a 25 hr [+/- 60 minutes] ([ADDRESS_729308] EOI) -
17 6 3 10:00a 50 hr [+/- 120 minutes] ([ADDRESS_729309] EOI) 2 hr
18 6 15 8:00a 360 hr [+/- 5 days] ([ADDRESS_729310] EOI) -
The PK samples will be placed immediately on wet ice and refrigerated. The date and exact time 
of each blood draw should be recorded on the sample tube and the PK sheet. Please e-mail the 
Blood Processing Core) BPC at [EMAIL_1227] at least 24 hours before 
transporting samples (the Friday before is preferred). For sample pi[INVESTIGATOR_7049], please page 102-
[ZIP_CODE]. For immediate help, call [PHONE_1158] (main blood processing core number) or, if no 
answer, [PHONE_1159] (main clinical pharmacology lab number). 
Bioanalytical measurements of EP0057 and olaparib will be measured by [CONTACT_555578]-
MS/MS assays optimized for each drug by [CONTACT_62545] (CPP). This data 
will be used to assess any drug-drug interactions are present between olaparib and EP0057, as 
well as to correlate adverse events and efficacy to each drug’s exposure. Neither olaparib nor 
camptothecin are extensively metabolized into pharmacologically active metabolites, therefore 
there are no relevant pharmacogenomic considerations regarding drug metabolizing enzymes or 
transporters with this combination.
5.1.2 UC Expansion Cohort
Tumor biopsies and blood samples will be obtained at the time points as described below. Archival 
tissue and blood or saliva will be collected at baseline and will be stored under uniform conditions 
or, preferably, processed immediately for DNA. Tumor biopsies (nodal or visceral) will be 
optional for molecular analyses and will be obtained at baseline, on-treatment (timing at the 
discretion of PI) and at disease progression. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
75In the case of tumor biopsy and limited material, tissue distribution should be prioritized as 
follows:
1. Storage and diagnosis confirmation ([CONTACT_408286])
2. MET analysis ([CONTACT_555608]) 
3. RNA sequencing ([CONTACT_555609])
4. Genetic/Genomic Analysis ([CONTACT_555609])
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729311] Description Amount/ 
Type/Tube/HandlingCollection 
TimeContact [CONTACT_555579]
(voluntary)3-4 coresBaseline (Pre-
Treatment),
On-treatment,
At Disease 
ProgressionEmail: Rene Costello, 
[EMAIL_10559] 
24 hours prior to anticipated collection
Call Rene Costello at [PHONE_11541] 
immediate pi[INVESTIGATOR_9696]-up of sample collection
day.3-[ADDRESS_729312]. Bottaro/Rene 
Costello (tech) ([PHONE_11541]), and [CONTACT_408283]’s lab (pager 102-[ZIP_CODE]).
The cores will be flash frozen, 2D 
barcoded, and stored in liquid nitrogen. 
The tumor tissue will be divided among 
three laboratories for storage and will 
be batched:
1.1 core: Laboratory of pathology 
(Maria Merino) will perform diagnosis 
confirmation.
2. 1-2 cores: Genitourinary 
Malignancies Branch. Molecular 
Pharmacology Section (Figg 
Laboratory) will store 1-2 core of fresh 
tumor per patient (for [CONTACT_555610] 
WES/RNA seq)
3. [ADDRESS_729313]. Don 
Bottaro (MET protein)
Samples will be sent in batches of [ADDRESS_729314]. Nickerson lab.
When the samples will be shipped, the 
Nickerson lab will be contact[CONTACT_555580] 
[EMAIL_10560] 
about the timing of the shipment and the 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729315] Description Amount/ 
Type/Tube/HandlingCollection 
TimeContact [CONTACT_555581].
Nickerson laboratory:
DNA Extraction and Staging 
Laboratory (DESL)
ATTN: Amy Hutchinson [ADDRESS_729316]
ATC, Room 149
Gaithersburg, MD [ZIP_CODE]
 Phone: [PHONE_11542]
Saliva 3ml Oragene saliva 
collection kits
(DNA Genotek)Baseline (or any 
time after consent 
is signed but 
preferably at 
baseline)Email: BPC 
[EMAIL_1227]
[ADDRESS_729317]. Figg’s Lab
Plasma and urine HGF 
and METOne 4mL EDTA tube and 
collect at least 20 mL of 
urine specimen container Baseline,
Day 1 Each 
CycleE-mail BPC 
[EMAIL_1227] at least 24 
hours before transporting samples (the 
Friday before is preferred).
For sample pi[INVESTIGATOR_9107], page 102-[ADDRESS_729318] on 
wet ice and store at 4°C in the 
refrigerator until processing for a 
maximum of 30-[ADDRESS_729319] urine to pH 7.5 with 
2 mol/L, ph 7.5 Trizma-HCL (Sigma, 
St. Louis, MO) using 50uL per 2 mL 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729320] Description Amount/ 
Type/Tube/HandlingCollection 
TimeContact [CONTACT_555582]. Centrifuge the conical at 
3000xg for 10 min at room temperature 
to remove cells and debris. Make as 
many 2 mL aliquots as possible. Store 
at -80C until requested by [INVESTIGATOR_124]. Don 
Bottaro’s lab
Comprehensive 
cytokine/chemokine 
studyOne 10mL EDTA tubeBaseline
C2D1
C3D1NIH CCR: E-mail BPC 
[EMAIL_1227] at least 24 
hours before transporting samples (the 
Friday before is preferred).
For sample pi[INVESTIGATOR_9107], page 102-[ADDRESS_729321] on 
wet ice and store at 4°C in the 
refrigerator until processing for a 
maximum of 30-60 min.
Immunologic Subsets Two 8 ml BD Vacutainer 
Cell
Preparation Tubes (CPT) 
citrate
(blue/black tiger top 
closure)C1D1 (Pre-
treatment)
C2D1 (Pre-
treatment)
Disease 
Progression NIH CCR:
When scheduled email
Sunmin Lee
([EMAIL_3032]),
Min-Jung Lee
([EMAIL_2652])
and when samples are ready call 240-
760-6330Invert several times and leave at room 
temperature for DTB Clinical 
Translational Unit member pi[INVESTIGATOR_555519] (770 genes)PAXgene tube 2.5 cc 
peripheral
blood per tubeC1D1 (Pre-
treatment)
C2D1 (Pre-
treatment)NIH CCR:
When scheduled email
Sunmin Lee
([EMAIL_3032]),
Min-Jung Lee
([EMAIL_2652])
and when samples are ready call 240-
760-6330Invert several times and place at room 
temp or refrigerate Store up to 3 days at 
room temperature (15–25°C); up to 5 
days at 2–8°C and 8 years at –20°C or –
70°C
Nanostring DNA
damage response
panel (180 genes)PAXgene tube 2.5 cc 
peripheral blood per tubePretreatment on 
C1D1
Pretreatment on 
C2D1NIH CCR:
When scheduled email
Sunmin Lee
([EMAIL_3032]),
Min-Jung Lee
([EMAIL_2652])Invert several times and place at room 
temp or refrigerate
Store up to 3 days at room temperature 
(15–25°C); up to 5 days at 2–8°C and 8 
years at –
20°C or –70°C
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729322] Description Amount/ 
Type/Tube/HandlingCollection 
TimeContact [CONTACT_555583] 240-
760-6330
CTC (DTB Clinical 
Translational Unit)CellSave tube 7.5 ccC1D1 (Pre-
treatment)
C2D1 (Pre-
treatment)
Disease 
ProgressionNIH CCR:
When scheduled email
Sunmin Lee
([EMAIL_3032]),
Min-Jung Lee
([EMAIL_2652])
and when samples are ready call 240-
760-6330Invert several times and leave at room 
temperature for DTB Clinical 
Translational Unit member pi[INVESTIGATOR_555520].
CTC (Epic Science) 10mL Streck Cell-Free 
DNA BCTC1D1 (Pre-
treatment)
C3D1 (Pre-
treatment) Have patient bring sample to clinic. 
Contact [CONTACT_555584], [PHONE_11543], for 
pi[INVESTIGATOR_9696]-up of specimen
Send notification to:
[EMAIL_3260]
Ship to:
Epic Science
Attn: (Partner Protocol #/Epic
internal ID)
[ADDRESS_729323] phone number is:
1-858-356-6610Confirm blood tube is not expi[INVESTIGATOR_5697]. 
Expi[INVESTIGATOR_555521]. 
•Ensure first 5ml blood is discarded 
or the blood for CTC analysis is not 
the first tube to be collected
•Draw whole blood sample into [ADDRESS_729324] tube (*see 
note regarding prevention of backflow).
Fill tube until blood low stops. NOTE: 
Epic requires a minimum of 4 mL blood 
per sample, but a full 10 mL tube of 
blood should be provided when 
possible.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729325] Description Amount/ 
Type/Tube/HandlingCollection 
TimeContact [CONTACT_555585]-free DNA One 10mL lavender top 
(EDTA) Tube (minimum 
of blood required 3 cc)Every 2weeks E-mail BPC 
[EMAIL_1227] at least 24 
hours before transporting samples (the 
Friday before is preferred).
For sample pi[INVESTIGATOR_9107], page 102-[ZIP_CODE] -
Figg lab
When the samples will be shipped, the 
Nickerson lab will be contact[CONTACT_555580]
[EMAIL_10560]
about the timing of the shipment and the 
number and type of samples with typed 
sample IDsAfter the tube has been filled with 
blood, immediately invert the tube 
several times to prevent coagulation.
Process within 2 hours following a 
double-spin protocol.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] MET studies for UC expansion cohort
Prior work from our group showed that MET overexpression in cancer cells is associated with 
increased proteolytic release of soluble MET (sMet) protein from the cell surface into blood and 
urine, a potentially useful biomarker of tumor aggressiveness and progression. (59)We also 
found that urinary sMET levels differentiated urothelial bladder cancer (N=141) and benign 
bladder pathology (N=64), (P=0.0093) and non-muscle-invasive (N=110) from muscle-invasive 
(N=31) disease (P<0.0001) ( 60). In an independent cohort of patients with metastatic (N=23) and 
muscle-invasive (N=8) (not metastatic) urothelial cancer, we found that sMET levels in urine 
samples from ileal conduits and neobladders were significantly higher than in normally voided 
urine, regardless of stage (N=31) (P=0.0489), and in patients with visceral metastasis (N=14) 
(P=0.0111) (data not shown). Serum sMET levels showed a trend toward higher values in 
patients with metastatic versus non-metastatic disease. The process that increases MET shedding 
in the urine and blood of patients with UC are likely multi-factorial and not fully understood. 
However, there is great excitement for the potential of MET as a potential biomarker of disease 
status and progression. We plan to analyze plasma and urine sMET during treatment and 
correlate the results with baseline clinical parameters and response to therapy. We also plan to 
analyze cMET by [CONTACT_555586] (RT-PCR).
[IP_ADDRESS] Circulating Tumor Cells (DTB Clinical Translational Unit)
Blood will be collected per Table 13 to correlate baseline or changes in CTCs with clinical 
outcome. CTCs will be investigated using ferrofluidic enrichment and multi-parameter flow 
cytometric analysis. CTCs will be identified by [CONTACT_555587][INVESTIGATOR_555522]45.
[IP_ADDRESS] Circulating Tumor Cells (Epic Science)
The patients on the bladder expansion cohort will also have CTC’s measured using fee-for-
service Epic Science’s “no cell left behind” platform. 
CTC Samples should be collected in the [ADDRESS_729326] at timepoints per 
Table 13 baseline and day 1 of cycle 2 and 3. These tubes are commercially available through 
Streck (Omaha, NE). 
IMPORTANT: The first [ADDRESS_729327] results. 
Prevention of Backflow: 
Since Streck Cell-Free DNA BCT tubes contain chemical additives, it is important to avoid 
possible backflow from the tube. To guard against backflow, observe the following precautions: 
•Keep patient’s arm in the downward position during the collection procedure. 
•Hold the tube with the stopper uppermost. 
•Release tourniquet once the blood starts to flow into the tube, or within 2 minutes of 
application. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
82•Tube contents should not touch stopper or the end of the needle during the collection 
procedure. 
Blood Collection Instructions: 
**Arrange for the same day shipment! 
•Confirm blood tube is not expi[INVESTIGATOR_5697]. Expi[INVESTIGATOR_162607]. 
•Draw whole blood sample into [ADDRESS_729328] tube (*see note 
regarding prevention of backflow). Fill tube until blood flow stops. NOTE: Epic requires 
a minimum of 4 mL blood per sample, but a full 10 mL tube of blood should be provided 
when possible. 
•Remove tube from adapter and immediately mix by [CONTACT_5237] [ADDRESS_729329] 
results. 
•Label the tube with subject’s identification and date and time of blood draw. Unlabeled 
blood tubes may not be processed. 
•Keep sample at room temperature and ship on day of collection in shipper with ambient 
gel packs. 
Specimen Shipment Logistics 
All shipments must include requisition forms that contain Patient ID, Collection Date and time, 
Collection Site (including address), Time Point (if applicable), and the appropriate trial code 
(CTEP # 9681/ Epic Internal ID: NE-003). Clinical sites should provide email notification of 
sample shipment to Epic Sciences on the day of collection. The email should contain: 
•Trial codes (CTEP # 9681/ Epic Internal ID: NE-003) 
•Patient ID 
•Collection date and time* 
•Time point/Visit 
•Tracking information 
If possible, include a scanned copy of the completed sample requisition form. Partner will be 
responsible for all blood collection supplies, shippi[INVESTIGATOR_179269], and shippi[INVESTIGATOR_555523]. 
* When collection time is not provided, Epic Sciences will assume the sample was collected at 
8:00AM (local time) on the date of collection.
Send notification to: [EMAIL_3260]  
Ship to: Epic Science
Attn: (CTEP # 9681/Epic internal ID: NE-003)
[ADDRESS_729330] phone number is: [PHONE_11544]
Holiday Outages 
In observance of the following holidays, Epic Sciences sample processing locations will be closed, 
and samples will be processed on the next business day. Epic holidays are reviewed regularly and 
are subject to change. Notification of any changes to the holiday schedule will be communicated 
promptly via email to the project stakeholders.
Epic Sciences ([LOCATION_003]) Holidays
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
83New Year’s Day or Business Day after New Year’s Day
President’s Day 
Memorial Day 
Business day before Independence Day 
Independence Day 
Labor Day 
Thanksgiving Day 
Day after Thanksgiving Day 
Business day before Christmas or Christmas Day 
[IP_ADDRESS] Nanostring immune panel & Nanostring DNA damage response panel (UC Expansion 
Cohort)
Peripheral immune and DNA damage response transcriptional signatures will be evaluated by [CONTACT_555577]® platform (NanoString 
Technologies, Seattle, WA). We will use the nCounter 770 gene PanCancer Immune Profiling 
Panel and the newly released 170 gene DNA Damage & Repair panel, built in collaboration with 
the Developmental Therapeutics Branch. Peripheral blood will be collected in a PAXgene tube 
(PreAnalytix; 2.5 cc peripheral blood per tube) per the manufacturer’s instructions. RNA will be 
isolated using the PAXgene Blood RNA Kit according to the manufacturer’s instructions. The 
peripheral gene signatures will be evaluated at baseline and post-therapy to look for correlates of 
clinical response.
[IP_ADDRESS] Whole exome sequencing and RNA sequencing for UC expansion cohort
Recent data indicate that subsets of bladder cancer have dysfunctions in genes related to DNA 
damage repair pathways. Analysis of DNA copy number and mutation status of UC by [CONTACT_555588] 30% (germline or somatic 
mutations) of the cases included had BRCA pathway alterations (12). Nickerson and colleagues 
also found multiple germline and somatic mutations in genes encoding BRCA pathway proteins 
in bladder cancer, including BRCA1, BRCA2, ATM, BAP1, and PALB2. (14) Based on these 
data, exome sequencing will be done for bladder cancer cohort to investigate potential predictive 
biomarkers with particular focus on abnormalities in DNA-repair genes. Molecular finding will 
be correlate with response and time-to-event outcomes.
Inhibition of PARP1 could lead to an increase in SSBs, and if left unrepaired or additional DNA 
damaged is conferred – for example adding chemotherapy- these SSBs would lead to the 
formation of increased DSBs and in turn increased cell death.(61, 62) However, cells contain 
alternative mechanism for DNA damage repair in the absence of PARP activity. In this regard, 
differential expression of proteins involved in such alternative DNA repair mechanisms would 
further enhance the efficacy of PARP inhibitors. We propose to analyze DNA damage response 
transcriptional signatures in peripheral blood of our cohort of patients to correlate with response 
to olaparib. We hypothesize that differential expression of genes involved in DNA damage 
response and repair processes influence the response to olaparib. This part will be performed in 
collaboration with Michael Nickerson in the Genetics Branch/CCR/NCI.
[IP_ADDRESS] Circulating Tumor Cell DNA
FM panel and targeted sequencing results will be used to identify germline and somatic cancer-
gene alterations associated with tumor cells. This data will be used to design a patient-specific 
targeted sequencing panel to detect and monitor mutation load based on sequencing read counts in 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
84blood before, during and after treatment using whole blood DNA and Illumina and Ion Torrent 
sequencing.
Peripheral blood will be collected in EDTA-containing (lavender tops) tube at designated time 
points (see Table 13). Blood samples for isolation of DNA containing circulating tumor cell DNA 
will be processed per guidelines in Table [ADDRESS_729331]. Figg’s laboratory (Section 
5.2.2). 
DNA will be shipped to [CONTACT_555610]’s Laboratory for analysis in batches of 5-10 samples. 
[IP_ADDRESS] Blood Serum for Cytokine Analysis by [CONTACT_555589]: UC Cohort 
Blood Serum will be collected for cytokine analysis by [CONTACT_555589] (to be stored in Figg’s lab) at 
baseline and Day [ADDRESS_729332]. Figg’s lab to pi[INVESTIGATOR_7049].
i. Blood Serum: Collect 7-10 mLs blood in one (1) serum separator tube (SST) or red top 
tube with no preservatives. 
ii. Allow the blood to clot by [CONTACT_239965] 30 minutes.
iii. Separate serum from cells by [CONTACT_38298] 4 degrees C for 10 minutes at 1200 x g.
iv. Pi[INVESTIGATOR_555524] (2) aliquots of serum 1.5mLs each into two 2mL cryovials.
v. Freeze immediately at -[ADDRESS_729333]. Cao’s lab.
[IP_ADDRESS] Urine Cytology Tumor DNA (in patients with intact primary tumors only) by [CONTACT_555590]: UC Cohort
Urine will be collected for urine cytology tumor DNA by [CONTACT_555591] (to be stored in Figg’s 
lab). Page 102-[ADDRESS_729334]. Figg’s lab to pi[INVESTIGATOR_7049].
Urine Cytology tumor DNA Standard Operating Procedure
Objective: To identify 10 urines morphologically positive for HG transitional cell carcinoma 
with tumor available in surgical pathology for parallel 50 CGMP +Tert analysis
1. Urine samples with clinical information suggesting the presence of a HG transitional cell 
carcinoma will be divided in the cytology laboratory into two aliquots. 
a. One aliquot will be processed for routing laboratory cytomorphologic evaluation 
(i.e., Thin Prep)
b. A second aliquot will be stored in the refrigerator (-4 C)
c. The cytotechologist will make a note on the request form that a second aliquot 
exists/ has been saved
2. If routine cytologic evaluation confirms the presence of a HG transitional cell carcinoma
a. The cytopathologist will check whether the Pt’s tumor exists in surgical pathology 
b. If surgical pathology material exists – the cytopathologist will notify the 
cytotechnologist that the second aliquot should be centrifuged per laboratory 
routine to create a pellet and a supernatant
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
85i. Up to 5 ml of supernatant should be pi[INVESTIGATOR_555525] a conical tube labelled 
with the case number 
ii. The tube with the remaining cell pellet should also be labelled with the 
case number
3. Both tubes should be stored at -20 C (freezer to be determined)
4. When ten samples with corresponding surgical pathology material have been collected, 
these will be transferred to the Molecular Pathology Section for DNA extraction and 
CGMP50 +Tert analysis. 
[IP_ADDRESS] Tissue: UC Cohort 
Patient must be able to provide either archival tumor samples (H&E slides and one paraffin 
block or 15 unstained slides) or undergo tumor biopsy. If tissue was already collected for another 
CCR study run by [INVESTIGATOR_124]. Apolo, no additional tissue is needed. Biopsies are encouraged but 
voluntary.
o 10 unstained slides and 1 H&E for [CONTACT_555611]’s laboratory
o 5 unstained slides and 1 H&E for DTB Clinical Translational Unit’s laboratory
Biopsies obtained by [CONTACT_555592]’s laboratory. Three cores will be collected when 
possible (1-2 cores for pathology and 1 core for Don Bottaro). Fresh tumor obtained at NCI CCR 
will also be divided among the above [ADDRESS_729335]. Bottaro will use one core to 
perform the MET tumor assay. Biospecimens will be collected and processed using validated 
SOPs that will ensure both specimen quality and patient confidentiality. Using a computerized 
inventory system and a backup hardcopy process, all specimen collection and processing steps 
will be documented and the specific location of each specimen will be tracked. 
•Please contact [INVESTIGATOR_124]. Bottaro to notify of biopsy date and time at [PHONE_11545] (or Rene 
Costello at [PHONE_11546]) and to arrange for pi[INVESTIGATOR_9696]-up of sample during biopsy (1 core)
•1-2 biopsy cores will be submitted to pathology
•Tissue blocks and slides from outside pathology departments will be stored in the NIH 
pathology department with attention to [CONTACT_408286]. 
5.1.3 mCRPC Expansion Cohort
Correlative Studies: mCRPC cohort 
Patients will undergo one mandatory pretreatment biopsy and two optional research biopsies 
(timepoints assessed at PI [INVESTIGATOR_9106]) to assess the effect of response to olaparib plus EP0057.
Table 14. mCRPC Sample Collection Guidelines
Test Amount/Type/Tube Collection 
TimingContact [CONTACT_555593], Tube size: 10 
cc, 2 tubes, Draw 
volume: 20 ccBaseline, 
C4D1, and 
progressionCPC pi[INVESTIGATOR_555526] 
102-11964Immediately pack 
on wet ice
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729336] Amount/Type/Tube Collection 
TimingContact [CONTACT_555594]/Blue, Tube 
size: 8 cc, 2 tubes, 
Draw volume: 16 ccBaseline,
C2D1, and 
C3D1 DTB Clinical 
Translational 
Unit at 240-760-
6330Invert blood tubes 
3-4 times keep at 
room temperature 
Circulating Tumor 
Cells (CTC)Purple (LVV), Tube 
size: 7.5 cc Draw 
volume: 7.5 ccBaseline,
C2D1, and
progression DTB Clinical 
Translational 
Unit at 240-760-
6330Invert blood tubes 
3-4 times keep at 
room temperature
Nanostring 
Immune PanelPAX red, Tube size, 
2.5 cc, Draw volume 
2.5 ccBaseline,
C2D1, and 
progression DTB Clinical 
Translational 
Unit at 240-760-
6330Invert blood tubes 
3-4 times keep at 
room temperature 
or refrigerate
Nanostring DNA 
damage response 
panel PAXgene tube, Draw 
volume 2.5 ccBaseline, 
C2D1, and 
progressionDTB Clinical 
Translational 
Unit at 240-760-
6330Invert blood tubes 
3-4 times keep at 
room temperature 
or refrigerate
CTC (Epic 
Science)Brown/Black Streck 
tube, [ADDRESS_729337]. Figg’s lab 
to pi[INVESTIGATOR_555527]
[IP_ADDRESS] Tumor biopsies on mCRPC expansion cohort
Biopsy will be performed at the following time: mandatory-prior to treatment on cycle 1 day 1. 
Optional tumor biopsies may be obtained at 2 additional time points as determined by [CONTACT_1275](s) and/or the PI. 
Biopsies may be not performed on the specific dates and times due to the following reasons, 
including but not limited to, delayed recovery of hematologic toxicities, delayed clinic schedule, 
or national holidays.
At least 1 core biopsy specimen will be obtained via Interventional Radiology and members of 
the Kelly lab will be on call to receive the biopsies: [CONTACT_388224]’s lab representative: 240-760-
7121. 
[IP_ADDRESS] Exome sequencing for mCRPC expansion cohort
Exome sequencing will be done for mCRPC cohort on tumor tissue to investigate potential 
predictive biomarkers in responders and non-responders in collaboration with [CONTACT_555611] 
in the Genetics Branch/CCR/NCI. Additionally, culturing of patient-derived organoids (cell 
lines) will be performed in collaboration with Kathleen Kelly Siebenlist in the Laboratory of 
Genitourinary Cancer Pathogenesis/CCR/NCI, if there is biopsy core specimen available.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[IP_ADDRESS] Saliva sample collection for mCRPC expansion cohort
A one-time saliva sample will be collected anytime during the study as a source of normal tissue 
for genomics comparison. Saliva sample will be collected in one Oragene Saliva Kit at room 
temperature and page [CONTACT_62583]’s lab for pi[INVESTIGATOR_452629] 102-[ZIP_CODE]. [CONTACT_62583]’s lab will barcode the 
sample, remove patient identifier, and send the sample to [CONTACT_298853]’s lab via courier. Patients 
will be instructed not to eat, drink, smoke or chew gum for 30 minutes before giving their saliva 
sample. Sequencing of DNA will be performed by [CONTACT_555595]/CCR/NCI.
5.2 SAMPLE STORAGE, TRACKING AND DISPOSITION
All samples [except PK samples- which will be sent to Doug Figg’s lab; one core of research 
biopsy- which will be stored in the Laboratory of Pathology; hair samples which will be 
collected and processed by [INVESTIGATOR_124]. Redon, Developmental Therapeutics Branch] will be sent to and 
stored in DTB Clinical Translational Unit at NCI, Bldg 10, Bethesda, MD. Place all samples at 
room temperature, phone the Lab at [PHONE_3305] and a laboratory member will come to pi[INVESTIGATOR_555528]. 
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system. 
Should a CRIS screen not be available, the CRIS downtime procedures will be followed. 
Samples will not be sent outside NIH without appropriate approvals and/or agreements, if 
required. Any transfer of materials to other NIH or non-NIH investigators will occur following 
NIH Intramural Research Program guidelines. If the subject withdraws consent the participant’s 
data will be excluded from future distributions, but data that have already been distributed for 
approved research use will not be able to be retrieved.
5.2.[ADDRESS_729338] ID, name, 
trial name/protocol number, date/time drawn, as well as box and freezer location. Subject 
demographics associated with the clinical center patient number are provided in the system. For 
each sample, there are notes associated with the processing method (delay in sample processing, 
storage conditions on the ward, etc.). Access to personally identifiable information (PII) is 
limited to the PI [INVESTIGATOR_167851]. 
An additional layer of encryption will be added for samples undergoing genetic analysis in the 
DTB Clinical Translational Unit where a separate clinically annotated unique sample ID will be 
generated linked with the sample ID in Labmatrix. As additional clinical information is 
generated and linked to the unique patient ID, it is also electronically linked via Labmatrix to the 
sample ID. The DTB Clinical Translational Unit will proceed with sample analysis and record 
data under the unique sample ID. 
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80°C or in 
liquid nitrogen according to stability requirements. These freezers are located onsite, and access 
to stored clinical samples is restricted. Samples will be stored until requested by a researcher 
named on the protocol. All requests are monitored and tracked in the Labmatrix System. All 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
88researchers are required to sign a form stating that the samples are only to be used for research 
purposes associated with this trial (as per the IRB approved protocol) and that any unused 
samples must be returned to the NCI. It is the responsibility of the NCI Principal Investigator [INVESTIGATOR_83853] a manner consistent with IRB approval.
Samples will be stored in a freezer at either -4° C or -70° C behind a door locked after working 
hours. Samples will be tracked by a designated member of the laboratory who is responsible for 
notifying the PI [INVESTIGATOR_555529], for allocating the material to other 
members of the laboratory, for recording the disposition of the allocated material. 
5.2.2 Clinical Pharmacology Program (Figg Lab)
Upon arrival in the Clinical Pharmacology Program, samples will be centrifuged and the plasma 
transferred into cryovials for storage at -80 C until the time of analysis. In addition, samples will 
be barcoded.
All PK samples will be bar-coded, with data entered and stored in the Patient Sample Data 
Management System (PSDMS, aka Labmatrix) utilized by [CONTACT_195149]. This is a secure program, 
with access to PSDM System limited to defined CPP personnel, who are issued individual user 
accounts. The program creates a unique barcode ID for every sample and sample box, which 
cannot be traced back to patients with PSDMS access. The data recorded for each sample may 
include the patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, 
material type, as well as box and freezer locations. Patient demographics associated with the 
clinical center patient number are provided in the system. For each sample, there are notes 
associated with the processing method (e.g. delay in sample processing, storage conditions on the 
ward, etc.).
Bar-coded samples are stored in bar-coded boxes in locked freezers at either -20 C or -80 C 
according to stability requirements. These freezers are located onsite in the CPP and offsite at 
NCI Frederick Central Repository Services in Frederick, MD. Samples will be stored until 
requested by a researcher named on the protocol. All requests are monitored and tracked in 
PSDMS. All researchers are required to sign a form stating that the samples are only to be used 
for research purposes associated with this trial (as per IRB approved protocol) and that any 
unused samples must be returned to the CPP.
Following completion of this study, samples will remain in storage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting 
the rights to use the material.
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the 
samples will be destroyed (or returned to the patient, if so requested). The PI [INVESTIGATOR_555530] a deviation. Reporting will be per the requirements of 
section 7.2.
Sample barcodes are linked to patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the 
PSDMS. It is critical that the sample remains linked to patient information such as race, age, 
dates of diagnosis and death, and histological information about the tumor, in order to correlate 
genotype with these variables. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
895.2.3 Redon (Aladjem) Lab
At least [ADDRESS_729339]. Aladjem’s lab 
(DTB-LMP/CCR/NCI, Bldg 37/ Rm 5056) to inform him when samples will be taken (Tel: 240-
760-7338 (L); [PHONE_3304] (Cell); [EMAIL_3031]). [CONTACT_148430] will provide tubes for 
collecting the plucked hairs which contain ice cold PBS, and are labeled with the date/time of 
sampling, the protocol, and the unique identifier. [CONTACT_148430] should be notified of when the 
samples should be pi[INVESTIGATOR_100628]. 
All of the hairs from a patient will be placed in microfuge tubes containing cold PBS and stored 
on ice. Upon delivery in [CONTACT_148431]’s lab, hairs will be fixed with paraformaldehyde and 
analyzed under a dissection microscope to select those containing a full intact follicle and sheath. 
Plucked hairs will be fluorescently stained for γ-H2AX and images will be recorded by [CONTACT_2329] a 
confocal microscope.
5.2.4 Paul Meltzer Lab
All samples will be stored in monitored freezers/refrigerators in the Meltzer laboratory at 
specified temperatures with alarm systems in place. All samples will be tracked by [CONTACT_555596], using the Labmatrix software and the Genologic 
Clarity LIMS system. Secure computer database systems (Labmatrix and Clarity LIMS) will be 
used to track all samples collected on this protocol. The system will contain data that includes, 
but is not limited to the unique sample identifiers, storage locations and conditions, biologic 
study results, clinical information, and corresponding records of all derivatives generated from 
samples/tissues collected on this protocol. The system will employ mechanisms for restricting 
users to viewing only the level of data appropriate for each individual user, will provide the 
capability to audit any data modification, and will be maintained and backed up according to 
established standards.
5.2.5 Laboratory of Genitourinary Cancer Pathogenesis (Kathleen Kelly Siebenlist)
All samples will be assigned a unique barcode ID and entered into the Labmatrix system. Tissue 
will be processed immediately after biopsy and placed into organoid culture. Organoids that fail 
to grow will be destroyed. Organoids that are cultured successfully will be maintained in the 
Kelly lab. Viably frozen stocks of organoids will be stored in liquid nitrogen in the Kelly lab and 
tracked by [CONTACT_555597]. DNA and RNA derivatives will be added into the Labmatrix system, 
The system will contain data that includes, but is not limited to the unique sample identifiers, 
storage locations (freezer and box identifiers) and conditions, and corresponding records of all 
derivatives generated from samples/tissues collected on this protocol. Access to the tracking 
system is limited to appropriate personnel. Material will be stored in a monitored -80° C freezer, 
and access to material will be restricted to appropriate lab personnel.
5.2.6 Urologic Oncology Branch Molecular Therapeutics Facility (Donald Bottaro)
Each patient research sample will be assigned a unique patient identifier and relevant sample 
characteristics (such as timing of sample collection, treatment cycle and day identifiers) will be 
recorded. The location of all samples will be carefully tracked in the secure UOB database. All 
stored samples will be coded and no identifying patient information will be on placed on sample 
containers. Stored samples will be kept in freezers / refrigerators or secure containers located in 
the Urologic Oncology Branch research laboratories or in the laboratories of collaborators.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
90Samples will be stored until requested by [CONTACT_555598](s). All researchers are 
required to use the samples for research purposes associated with this trial (as per the NIH IRB 
approved protocol). Subjects will be given the option of consenting to future use of their research 
samples per the informed consent process with their option declared in the consent document. 
Samples from those patients who consent to this will be stored permanently. However, these 
samples will be used only for research studies on active NIH IRB approved protocols covered by 
a valid informed consent document. Samples will be destroyed at the completion of the study 
from those subjects who decline future use of their samples. Once primary research objectives 
for the protocol are achieved, intramural researchers can request access to remaining samples 
provided they have an IRB approved protocol and patient consent. Any unused samples must be 
returned to the UOB laboratories as appropriate. 
5.2.7 Laboratory of Pathology
Tissues designated for clinical diagnostics are transported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant portions are fixed, embedded in paraffin and 
sectioned and stained for diagnostic interpretation. Unutilized excess tissue that is not placed in 
paraffin blocks is stored in formalin for up to three months, in accordance with College of 
American Pathologists/Joint Commission on Accreditation of Healthcare Organizations 
(CAP/JCAHO) guidelines, and then discarded. Following completion of the diagnostic workup, 
the slides and tissue blocks are stored indefinitely in the LP’s clinical archives. All specimens are 
catalogued and retrieved utilizing the clinical laboratory information systems, in accordance with 
CAP/JCAHO regulations. The use of any stored specimens for research purposes is only allowed 
when the appropriate IRB approval has been obtained. In some cases, this approval has been 
obtained via the original protocol on which the patient was enrolled.
5.2.8 Laboratory of Pathology NCI COMPASS Program
Participants may undergo genetic analysis through the NCI COMPASS program for tumor-
normal exome and transcriptome. For additional information on consenting, ordering and results, 
refer to CCR SOP ADGC-5, Tumor/Normal Whole Exome Sequencing: Consenting, Ordering, 
and Obtaining Results found at 
https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=73203825. 
5.2.9 Future Use/IRB Reporting/Protocol Completion/Sample Destruction
Blood and tissue specimens collected in the course of this research project may be banked and 
used in the future to investigate new scientific questions related to this study, including 
gene/protein expression and germline analysis. However, this research may only be done if the 
risks of the new questions were covered in the consent document and the proposed research has 
undergone prospective IRB review and approval. If new risks are associated with the research 
(e.g., analysis of germ line genetic mutations.) the Principal Investigator [INVESTIGATOR_555531].
Following completion of this study, samples will remain in storage as detailed above only for those 
subjects that agreed to future use in the Optional Studies section of the consent form. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the 
rights to use the material. Currently, there is no plan to use these samples outside of the use 
described in the protocol. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729340] any loss or unanticipated destruction of samples as a deviation. Reporting will 
be per the requirements of section 7.2. 
5.3 SAMPLES FOR GENETIC/GENOMIC ANALYSIS
5.3.1 Description of the scope of genetic/genomic analysis
One of the exploratory endpoints of this protocol is to characterize genetic alterations which 
predict response and changes associated with the development of chemoresistance. To this end, 
whole and targeted genome sequencing may be performed on banked tumor samples collected 
pre-treatment and/or post-progression. Since analysis of germline variants is essential to fully 
characterize the somatic mutations identified in genome sequencing, these assays will involve 
both somatic and germline DNA. 
5.3.2 Certificate of Confidentiality
Refer to section 13.4.
5.3.3 Management of Results
The analyses that we perform in our laboratory are for research purposes only; they are not 
nearly as sensitive as the tests that are performed in a laboratory that is certified to perform 
genetic testing. Changes that we observe unrelated to our research may or may not be valid. 
Therefore, we do not plan to inform participants of the results of testing on the tissue and blood 
that is performed in our research lab. However, in the unlikely event that a clinically actionable 
gene variant is discovered, subjects will be contact[INVESTIGATOR_530]. Clinically actionable findings for the 
purpose of this study are defined as disorders appearing in the American College of Medical 
Genetics and Genomics recommendations for the return of incidental findings that is current at 
the time of primary analysis. (A list of current guidelines is maintained on the CCR intranet: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Incidental+Findings+Lists ) Subjects will 
be contact[CONTACT_148408] a request to provide a sample to be sent to a CLIA certified 
laboratory. If the research findings are verified in the CLIA certified lab, the subject will be 
referred to the NCI CCR Genetics Branch for the disclosure of the results. 
This is the only time during the course of the study that incidental findings will be returned. No 
interrogations regarding clinically actionable findings will be made after the primary analysis.
For samples undergoing analysis through the NCI COMPASS, results will be reported per CCR 
SOP ADGC-5, Tumor/Normal Whole Exome Sequencing: Consenting, Ordering, and Obtaining 
Results found at https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=73203825. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
926 DATA COLLECTION AND EVALUATION 
6.1 DATA COLLECTION
The PI [INVESTIGATOR_62482] a 21 CFR Part 11-compliant data 
capture system provided by [CONTACT_62550], consistency and 
timeliness. The principal investigator, associate investigators/research nurses and/or a contracted 
data manager will assist with the data management efforts. Primary and final analyzed data will 
have identifiers so that research data can be attributed to an individual human subject participant.
Document AEs from the first study intervention, Study Day 1, through [ADDRESS_729341] study drug administration 
and through the end of study participation, only adverse events which are serious and related to 
the study intervention need to be recorded.
An abnormal laboratory value will be considered an AE if the laboratory abnormality is 
characterized by [CONTACT_39132]:
•Results in discontinuation from the study
•Is associated with clinical signs or symptoms 
•Requires treatment or any other therapeutic intervention
•Is associated with death or another serious adverse event, including hospi[INVESTIGATOR_059]. 
•Is judged by [CONTACT_62551], the investigator will provide 
details about the action taken with respect to the test drug and about the patient’s outcome.
End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable. 
Loss or destruction of data: Should we become aware that a major breach in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per 
requirements in section 7.2.1. 
6.2 DATA SHARING PLANS
6.2.1 Human Data Sharing Plan
What data will be shared?
I will share human data generated in this research for future research as follows (check all that 
apply):
_x__ Coded and linked data in an NIH-funded or approved public repository. 
_x__ Coded and linked data in BTRIS (automatic for activities in the Clinical Center)
_x__ Coded and linked or identified data with approved outside collaborators under appropriate 
agreements.
How and where will the data be shared? 
Data will be shared through (check all that apply):
_x__ An NIH-funded or approved public repository: clinicaltrials.gov; dbGaP.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
93_x__ BTRIS (automatic for activities in the Clinical Center)
_x__ Approved outside collaborators under appropriate individual agreements.
_x__ Publication and/or public presentations.
When will the data be shared? 
_x__ Before publication.
_x__ At the time of publication or shortly thereafter.
6.2.2 Genomic Data Sharing Plan
Unlinked genomic data will be deposited in public genomic databases such as dbGaP in 
compliance with the NIH Genomic Data Sharing Policy.
6.3 RESPONSE C RITERIA
For the purposes of this study, patients should be re-evaluated for response every 2 cycles (every 
3 cycles for patients on mCRPC cohort as per section 6.3.5). In addition to a baseline scan, 
confirmatory scans should also be obtained 4 weeks (8 weeks for mCRPC) following initial 
documentation of objective response.
Response and progression will be evaluated in this study using the new international criteria 
proposed by [CONTACT_459] (RECIST) guideline 
(version 1.1) (61). Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 
criteria.
6.3.1 Definitions
Evaluable for toxicity: All patients will be evaluable for toxicity from the time of their first 
treatment with EP0057.
Evaluable for objective response: Only those patients who have measurable disease present at 
baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will 
be considered evaluable for response. These patients will have their response classified 
according to the definitions stated below. (Note: Patients who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.)
Evaluable Non-Target Disease Response: Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of measurable disease, have received at least one cycle 
of therapy, and have had their disease re-evaluated will be considered evaluable for non-target 
disease. The response assessment is based on the presence, absence, or unequivocal progression 
of the lesions. 
6.3.2 Disease Parameters
Measurable disease: Measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) as: 
•By [CONTACT_13190] x-ray: >20 mm; 
•By [CONTACT_3610]: 
oScan slice thickness 5 mm or under as >[ADDRESS_729342] scan
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
94oScan slice thickness >5 mm: double the slice thickness 
•With calipers on clinical exam: >[ADDRESS_729343] be recorded in millimeters (or decimal fractions of centimeters).
Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph node 
must be >[ADDRESS_729344] scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
and followed.
Non-measurable disease. All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered 
non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses 
(not followed by [CONTACT_462]), are considered as non-measurable.
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
[CONTACT_108], simple cysts.
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.
Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline. Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements. It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected. A 
sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum. The baseline sum diameters 
will be used as reference to further characterize any objective tumor regression in the measurable 
dimension of the disease.
Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline. Measurements of these lesions are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up. 
6.3.3 Methods for Evaluation of Measurable Disease
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by [CONTACT_460](s) being followed cannot be 
imaged but are assessable by [CONTACT_461].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
95Clinical lesions: Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and 10 mm diameter as assessed using calipers 
(e.g., skin nodules). In the case of skin lesions, documentation by [CONTACT_6775], including a 
ruler to estimate the size of the lesion, is recommended. 
Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776]. However, CT is preferable. 
Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is [ADDRESS_729345] slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. 
MRI is also acceptable in certain situations (e.g. for body scans). 
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement. Furthermore, the availability of MRI 
is variable globally. As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease. 
Furthermore, as with CT, the modality used at follow-up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the 
image acquisition protocol should be followed as closely as possible to prior scans. Body scans 
should be performed with breath-hold scanning techniques, if possible.
PET-CT: At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements. However, if 
the site can document that the CT performed as part of a PET-CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over time. Note, however, that the PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially 
performed. 
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the 
next. If new lesions are identified by [CONTACT_12153], confirmation by [CONTACT_118582]. If there is concern about radiation exposure at CT, MRI may be used instead of 
CT in selected instances.
Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is 
not advised. However, such techniques may be useful to confirm complete pathological response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete 
response (CR) or surgical resection is an endpoint.
Tumor markers: Tumor markers alone cannot be used to assess response. If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response. Specific guidelines for both CA-125 response (in recurrent ovarian cancer) and 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
96PSA response (in recurrent prostate cancer) have been published (62-64). In addition, the 
Gynecologic Cancer Intergroup has developed CA-[ADDRESS_729346]-line trials in ovarian cancer (65).
Cytology, Histology: These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain).
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of 
the treatment) and progressive disease.
FDG-PET: While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease). New lesions on the basis of FDG-
PET imaging can be identified according to the following algorithm: 
a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of 
PD based on a new lesion.
b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-
PET at follow-up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD. If 
the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, 
additional follow-up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal 
FDG-PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing 
site of disease on CT that is not progressing on the basis of the anatomic images, this 
is not PD.
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring. The use of FDG-PET in this circumstance should be prospectively described 
in the protocol and supported by [CONTACT_4623]-specific medical literature for the indication. 
However, it must be acknowledged that both approaches may lead to false positive 
CR due to limitations of FDG-PET and biopsy resolution/sensitivity.
 Note: A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.
6.3.4 Response Criteria
[IP_ADDRESS] Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm.
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729347] 5 mm. (Note: the appearance of one or more new lesions is also 
considered progressions).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters while on study.
[IP_ADDRESS] Evaluation of Non-Target Lesions
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).
Note: If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response.
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions. Unequivocal progression should not normally trump 
target lesion status. It must be representative of overall disease status change, not a single lesion 
increase. 
Although a clear progression of “non-target” lesions only is exceptional, the opi[INVESTIGATOR_12999], and the progression status should be 
confirmed at a later time by [CONTACT_463] (or Principal Investigator).
[IP_ADDRESS] Evaluation of Best Overall Response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started). The patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria.
For Patients with Measurable Disease (i.e., Target Disease)
Target 
LesionsNon-Target 
LesionsNew 
LesionsOverall 
ResponseBest Overall Response when 
Confirmation is Required*
CR CR No CR >4 wks. Confirmation**
CR Non-
CR/Non-PDNo PR
CR Not 
evaluatedNo PR
PR Non-
CR/Non-
PD/not 
evaluatedNo PR>4 wks. Confirmation**
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
98SD Non-
CR/Non-
PD/not 
evaluatedNo SD
Documented at least once >4 
wks. from baseline**
PD Any Yes or 
NoPD
Any PD*** Yes or 
NoPD
Any Any Yes PDno prior SD, PR or CR
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.
** Only for non-randomized trials with response as primary endpoint.
*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as 
disease progression.
Note: Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “symptomatic 
deterioration.” Every effort should be made to document the objective progression even after 
discontinuation of treatment.
For Patients with Non-Measurable Disease (i.e., Non-Target Disease)
6.3.5 Response Criteria for mCRPC Cohort
Changes in PSA and measurable lesions will be analyzed for efficacy according to the Prostate 
Cancer Clinical Trials Working Group 2 recommendations (63). PSA alone will not be utilized 
as a means to take a patient off-treatment. 
Patients will be assessed primarily by [CONTACT_200180], abdomen and pelvis and by 
[CONTACT_240761] 99 bone scan at baseline and every 12 weeks ( 66). Response and progression will be Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PD*
Not all evaluated No not evaluated
Unequivocal PD Yes or No PD
Any Yes PD
* ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used 
as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be 
measured is not advised
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
99evaluated in this study using the new international criteria proposed by [CONTACT_118444] (RECIST) guideline (version 1.1) (67) and Prostate Cancer 
Clinical Trials Working Group criteria (PCWG2) (66). Changes in the largest diameter 
(unidimensional measurement) of the tumor lesions and the shortest diameter in the case of 
malignant lymph nodes are used in the RECIST criteria.
Metastatic Bone Lesions
Disease progression is considered if a minimum of two new lesions is observed on bone scan. 
New lesions seen by [CONTACT_131808] 3 or before cycle 4 (after the first staging bone scan) may 
represent disease that was not detected on the pre-study scan, and a confirmatory scan will be 
required at the next scheduled staging bone scan. If confirmed, progression should be dated by 
[CONTACT_555599]. If new lesions are seen after cycle 3 but no 
additional lesions are seen on confirmatory scans, the scans from after cycle 3 would serve as the 
baseline scan to evaluate for disease progression (66).
6.3.6 Duration of Response
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started).
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented.
Duration of stable disease: Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements. 
6.3.[ADDRESS_729348].
6.3.8 Response Review
Tumor measurements will be performed in consultation with the Center for Cancer Research 
Radiology and Imaging Sciences image processing service. 
6.4 TOXICITY CRITERIA
The following adverse event management guidelines are intended to ensure the safety of each 
patient while on the study. The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_729349] access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1007 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN
7.1 DEFINITIONS
Please refer to definitions provided in Policy 801: Reporting Research Events found 
https://irbo.nih.gov/confluence/pages/viewpage.action?pageId=36241835#Policies&Guidance-
800Series-ComplianceandResearchEventReportingRequirements.
7.2 OHSRP OFFICE OF COMPLIANCE AND TRAINING / IRB REPORTING
7.2.1 Expedited Reporting 
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 
802 Non-Compliance Human Subjects Research found 
https://irbo.nih.gov/confluence/pages/viewpage.action?pageId=36241835#Policies&Guidance-
800Series-ComplianceandResearchEventReportingRequirements. 
Note: Only IND Safety Reports that meet the definition of an unanticipated problem or present 
new information that might affect the willingness of participants to enroll or remain on the study 
will need to be reported per these policies.
7.2.2 IRB Requirements for PI [INVESTIGATOR_62486] 801: Reporting Research Events found 
https://irbo.nih.gov/confluence/pages/viewpage.action?pageId=36241835#Policies&Guidance-
800Series-ComplianceandResearchEventReportingRequirements. 
7.3 NCI  CLINICAL DIRECTOR R EPORTING 
Problems expeditiously reviewed by [CONTACT_83940]/designee; therefore, a separate submission for these reports is not 
necessary. 
In addition to those reports, all deaths that occur within 30 days after receiving a research 
intervention should be reported via email unless they are due to progressive disease. 
To report these deaths, please send an email describing the circumstances of the death to 
[EMAIL_1229] within one business day of learning of the death.
7.4 NIH REQUIRED DATA AND SAFETY MONITORING PLAN
7.4.1 Principal Investigator/Research Team 
The clinical research team will meet on a regular basis when patients are being actively treated 
on the trial to discuss each patient. Decisions about dose level enrollment and dose escalation if 
applicable will be made based on the toxicity data from prior patients. 
All data will be collected in a timely manner and reviewed by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a lead 
associate investigator. Events meeting requirements for expedited reporting as described in 
section 7.2.[ADDRESS_729350] or supervise the 
investigation and provide appropriate delegation of responsibilities to other members of the 
research staff. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1018 SPONSOR PROTOCOL/SAFETY REPORTING
8.[ADDRESS_729351] a causal relationship with this 
treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product (ICH E6 (R2)).
8.1.2 Serious Adverse Event (SAE)
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
•Death (except if from progressive disease, see 8.4)
•A life-threatening adverse event (see 8.1.3)
•Inpatient hospi[INVESTIGATOR_83855]/admission that is pre-planned (i.e., elective or scheduled surgery 
arranged prior to the start of the study), a planned hospi[INVESTIGATOR_5912]-existing 
condition, or a procedure required by [CONTACT_760], without a serious deterioration in 
health, is not considered a serious adverse event.
oA hospi[INVESTIGATOR_059]/admission that is solely driven by [CONTACT_105]-medical reasons (e.g., 
hospi[INVESTIGATOR_138707]) is not considered a serious adverse event. 
oEmergency room visits or stays in observation units that do not result in admission to 
the hospi[INVESTIGATOR_62489] a serious adverse event. The reason for seeking 
medical care should be evaluated for meeting one of the other serious criteria.
•Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions
•A congenital anomaly/birth defect.
•Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.
8.1.3 Life-threatening 
An adverse event or suspected adverse reaction is considered "life-threatening" if, in the view of 
either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of 
death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a 
more severe form, might have caused death. (21CFR312.32).
8.1.4 Severity
The severity of each Adverse Event will be assessed utilizing the CTCAE version 4.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729352] assessed using the terms: related or not 
related. 
•Related – There is a reasonable possibility that the study product caused the adverse 
event. Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study product and the adverse event.
•Not Related – There is not a reasonable possibility that the administration of the study 
product caused the event.
8.[ADDRESS_729353] and alternate etiology (if not related to study product), date of 
resolution of the event, seriousness and outcome. The assessment of severity and relationship to 
the study product will be done only by [CONTACT_8703] a diagnosis 
and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637]-investigator. AEs 
occurring during the collection and reporting period will be documented appropriately regardless 
of relationship. AEs will be followed through resolution.
SAEs will be:
•Assessed for severity and relationship to study product and alternate etiology (if not 
related to study product) by a licensed study physician listed on the Form FDA 1572 as 
the site principal investigator [INVESTIGATOR_11637]-investigator.
•Recorded on the appropriate SAE report form, the medical record and captured in the 
clinical database.
•Followed through resolution by a licensed study physician listed on the Form FDA [ADDRESS_729354] be submitted immediately (within 24 hours 
of awareness) to OSRO Safety using the CCR SAE report form. Any exceptions to the expedited 
reporting requirements are found in section 8.4.
All SAE reporting must include the elements described in 8.2.
SAE reports will be submitted to the Center for Cancer Research (CCR) at: 
[EMAIL_1230] and to the CCR PI [INVESTIGATOR_32528]. CCR SAE report form and 
instructions can be found at: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Forms+and+Instructions
Following the assessment of the SAE by [CONTACT_62554], other supporting documentation of the event 
may be requested by [CONTACT_62555].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1038.4 WAIVER OF EXPEDITED REPORTING TO CCR/OSRO 
As death/hospi[INVESTIGATOR_452637] (DOR, OS and 
PFS), and captured as endpoints in this study, they will not be reported in expedited manner to 
the sponsor. However, if there is evidence suggesting a causal relationship between the study 
drug and the event, report the event in an expedited manner according to section 8.3.
The Sponsor might request case summaries for those events if, upon review, the Sponsor 
determines that an aggregate safety report is required (21CFR312.32(c)(1)(iv)).
8.[ADDRESS_729355] the relationship of each SAE to each specific study drug (if there is more than one 
study drug).
SAEs will be reported to: 
- Ellipses pharmacovigilance vendor, Simbec-Orion: 
[EMAIL_10561]  (Or alternatively by [CONTACT_12100] +[PHONE_11547] or 
Back-up SAE fax: +[PHONE_11548])
- Ellipses contacts: Rina Patel at [EMAIL_10562] Other Adverse Events of Special 
Interest
For all subjects, the following adverse events are categorized as Adverse Events of Special 
Interest (AESI) for EP0057:
•infusion-related hypersensitivity reaction(s) of any Grade
•any newly developed cystitis (including grade 1) in subjects without cystitis at baseline
The study team will report any occurrence of cystitis or patient hypersensitivity/allergic reactions 
a patient experiences associated with EP0057 to Ellipses (via Simbec-Orion) within 24 hours of 
learning of its occurrence using MedWatch 3500A or equivalent form. 
8.5.2 [COMPANY_008] Reporting Requirements
[IP_ADDRESS] To be performed by [CONTACT_555600] (each as defined in the 
protocol) that arise in relation to the study to (i) the relevant regulatory authorities in accordance 
with the applicable laws; and (ii) any overseeing ethics committee in accordance with its 
policies. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729356] dose of trial 
drug and/or until event resolution. All new AEs occurring during that period will be recorded (if 
SAEs, then they will be reported to the FDA and [COMPANY_008]). All study-related toxicities/ 
SAEs will be followed until resolution, unless in the Investigator’s opi[INVESTIGATOR_1649], the condition is 
unlikely to resolve due to the patient’s underlying disease.
The Sponsor will report to the Company per the following guidelines:
•The Sponsor will notify the Company of all Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) subject to expedited reporting under the Applicable Laws at the 
same time that the reports are sent to the FDA using a medwatch 3500A form or 
equivalent.
•The Sponsor will notify the company within 30 days of all other SAEs [non-expedited 
reports], plus any AE reports relating to topi[INVESTIGATOR_555532] [MDS/AML, new 
primary malignancy and pneumonitis] using a medwatch 3500A form or equivalent.
•The Sponsor will inform the Company of any other matter relating to safety, quality or 
efficacy of the Company’s medicinal product or which might affect the conduct of the 
study or the safety of subjects as soon as possible and at least in parallel with 
correspondence to regulators, IECs/IRBs and investigators.
•The Sponsor will provide the Company all adverse events (AEs and SAEs) on the Final 
Study Report upon completion of the Study.
•The Sponsor will respond to any query from the Company relating to SAEs, as part of the 
Company’s pharmacovigilance processes.
The sponsor will send reports described above to:
 [EMAIL_661]. 
Tata Consultancy Services (TCS) will be responsible for processing all SAEs onto the AZ 
Patient Safety Database. Reports can also be sent via FAX to [PHONE_169].
Overdose 
If an overdose on an [COMPANY_008] study drug occurs in the course of the study, then the sponsor 
will inform appropriate [COMPANY_008] representatives within one day, i.e., immediately but no 
later than the end of the next business day of when he or she becomes aware of it. 
For overdoses associated with SAE, standard reporting timelines apply. For other overdoses, 
reporting should be done within 30 days.
Pregnancies
If any pregnancy occurs in the course of the study, then the Sponsor will inform appropriate 
[COMPANY_008] and Ellipses representatives within one day i.e., immediately but no later than the 
end of the next business day of when he or she becomes aware of it. 
All outcomes of pregnancy should be reported to [COMPANY_008] and Ellipses.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1058.5.2.2 To be Performed by [CONTACT_555601] [INVESTIGATOR_555533]:
•Providing the Company with line listing of all adverse events reported in the study. These 
line listings will be sent when the investigator receives an e-mail from Company.
•A summary report of other AEs and SARs will also be sent at a frequency no less than 
once a year and in a format agreed upon at Study Start-up. Instructions on sending these 
additional reports will be agreed upon at Study Start-up.
8.6 REPORTING PREGNANCY 
All required pregnancy reports/follow-up to OSRO will be submitted to: 
[EMAIL_1230] and to the CCR PI [INVESTIGATOR_32528]. 
Forms and instructions can be found here: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Forms+and+Instructions 
8.6.1 Maternal  exposure
If a patient becomes pregnant during the course of the study, the study treatment should be 
discontinued immediately, and the pregnancy reported to the Sponsor no later than 24 hours of 
when the Investigator becomes aware of it. The Investigator should notify the Sponsor no later 
than 24 hours of when the outcome of the Pregnancy become known,
Pregnancy itself is not regarded as an SAE. However, congenital abnormalities or birth defects 
and spontaneous miscarriages that meet serious criteria (8.1.2) should be reported as SAEs. 
The outcome of all pregnancies should be followed up and documented.
8.6.2 Paternal exposure
Patients should refrain from fathering a child or donating sperm during the study and for (3 
months) after the last dose of EP0057 or olaparib.
Pregnancy of the patient’s partner is not considered to be an AE. The outcome of all pregnancies 
occurring from the date of the first dose until (3 months) after the last dose should, if possible, be 
followed up and documented. Pregnant partners may be offered the opportunity to participate in 
an institutional pregnancy registry protocol (e.g., the NIH IRP pregnancy registry study) to 
provide data about the outcome of the pregnancy for safety reporting purposes.
8.[ADDRESS_729357] and the adverse event. CCR will notify FDA and all participating investigators (i.e., all 
investigators to whom the sponsor is providing drug under its INDs or under any investigator’s 
IND) in an IND safety report of potential serious risks from clinical trials or any other source, as 
soon as possible, in accordance to [ADDRESS_729358] annually in a summary format.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1068.8 SPONSOR PROTOCOL DEVIATION REPORTING
A Protocol Deviation is defined as any non-compliance with the clinical trial Protocol, Manual 
of Operational Procedures (MOP) and other Sponsor approved study related documents, GCP, or 
protocol-specific procedural requirements on the part of the participant, the Investigator, or the 
study site staff inclusive of site personnel performing procedures or providing services in support 
of the clinical trial.
It is the responsibility of the study Staff to document any protocol deviation identified by [CONTACT_83943] (PDTS) online 
application. The entries into the PDTS online application should be timely, complete, and 
maintained per CCR PDTS user requirements. 
In addition, any deviation to the protocol should be documented in the participant’s source 
records and reported to the reviewing IRB per their guidelines. OSRO required protocol 
deviation reporting is consistent with E6(R2) GCP: Integrated Addendum to ICH E6(R1): 4.5 
Compliance with Protocol; 5.18.3 (a), and 5.20 Noncompliance; and ICH E3 16.2.2 Protocol 
deviations.
9 CLINICAL MONITORING 
Clinical site monitoring is conducted to ensure:
•that the rights of the participants are protected; 
•that the study is implemented per the approved protocol, Good Clinical Practice and 
standard operating procedures; and, 
•the quality and integrity of study data and data collection methods are maintained. 
Monitoring for this study will be performed by [CONTACT_83944] (OSRO) and Regulatory Oversight Support (SROS) Services contractor. Clinical site 
monitoring activities will be based on OSRO standards, FDA Guidance E6(R2) Good Clinical 
Practice: Integrated Addendum to ICH E6(R1) March 2018, and applicable regulatory 
requirements.
Details of clinical site monitoring will be documented in a Clinical Monitoring Plan (CMP) 
developed by [CONTACT_62554]. CMPs will be protocol-specific, risk-based and tailored to address human 
subject protections and integrity of the study data. OSRO will determine the intensity and 
frequency of monitoring based on several factors, including study type, phase, risk, complexity, 
expected enrollment rate, and any unique attributes of the study and the site. The Sponsor will 
conduct a periodic review of the CMP to confirm the plan's continued appropriateness. A change 
to the protocol, significant or pervasive non-compliance with GCP, or the protocol may trigger 
CMP updates.
OSRO SROS Monitoring visits and related activities will be conducted throughout the life cycle 
of each protocol. The first activity is before the study starts to conduct a Site Assessment Visit 
(SAV) (as warranted), followed by a Site Initiation Visit (SIV), Interim Monitoring Visit(s) 
(IMVs), and a study Close-Out Visit (COV).
Some monitoring activities may be performed remotely, while others will occur at the study 
site(s). Monitoring visit reports will describe visit activities, observations, and associated action 
items or follow-up required for resolution of any issues, discrepancies, or deviations. Monitoring 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
107reports will be distributed to the study PI, NCI CCR QA, CCR Protocol Support Office, 
coordinating center (if applicable), and the Sponsor regulatory file.
The site Monitor will inform the study team of any deviations observed during monitoring visits. 
If unresolved, the Monitor will request that the site Staff enter the deviations in the CCR 
Protocol Deviation Tracking System (PDTS) for deviation reporting to the Sponsor and as 
applicable per institutional and IRB guidance. 
10 STATISTICAL CONSIDERATIONS 
•Phase I: To determine the MTD/ recommended Phase 2 dose (RP2D) of EP0057 in 
combination with olaparib in patients with refractory cancers
•Phase II: To determine the antitumor activity of olaparib plus EP0057 with respect to 
progression free survival at 16 weeks in SCLC patients with resistant or sensitive relapse
•Expansion: To determine overall response rate of EP0057 plus olaparib in patients with 
mCRPC and urothelial carcinoma
10.[ADDRESS_729359] 3+3 design will be used, to determine the 
RP2D/MTD of EP0057 in combination with olaparib. The theoretical maximum number of 
subjects required to determine the MTD in the phase I portion of the study is 30 subjects (6 per 
dose level), although it is expected that as few as [ADDRESS_729360]-line therapy and to 
treatment-free interval (treatment-free interval longer or shorter than 60–90 days) ( 68). Although 
this definition was derived many years ago and based on a small patient series ( 69), first-line 
chemotherapy sensitivity has since been confirmed to be a prognostic factor to predict response 
to second line and further therapy in meta-analyses (3) and randomized studies (70, 71). 
Published results suggest that the median PFS for single agent therapy with topotecan (currently 
the only approved second line therapy) for previously treated patients which included a 
combination of sensitive and resistant /refractory SCLC patients was approximately 3 months 
(median 3.0-4.3 months for sensitive and 1.5-2.6 months for refractory; (68, 70-73) (refer to 
Table 15). 
A recent randomized study of PARP inhibitor plus chemotherapy in relapsed SCLC patients 
(both platinum-sensitive and resistant patients were included) found no significant difference in 
4-month PFS between temozolomide/veliparib (20 of 55; 36%) and temozolomide /placebo (13 
of 49; 27%; P  = .19) (74). Median PFS was 3.8 months and 2.0 months in the temozolomide 
/veliparib and temozolomide /placebo arms, respectively (log-rank P = .39; hazard ratio, 0.84; 
95% CI, 0.56 to 1.25). 
Patients with both sensitive and resistant SCLC will be enrolled in the phase II study and 
analyzed together. The phase II trial will be conducted using an optimal two-stage design in 
order to rule out an unacceptably low success rate of 25% (p0=0.25) in favor of an improved 
success rate of 45% (p1=0.45). With alpha=0.10 (probability of accepting a poor treatment=0.10) 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
108and beta = 0.20 (probability of rejecting a good treatment=0.20), this first stage will enroll [ADDRESS_729361] a success (that is, 0 to 4 make it to 16 weeks 
without progression), then no further patients will be accrued. If [ADDRESS_729362] success, then accrual would continue until a total of 27 evaluable resistant/refractory 
patients have been enrolled. As it may take up to 4 months to determine if a patient has 
experienced a success at 16 weeks, a temporary pause in the accrual may be necessary to ensure 
that enrollment to the second stage is warranted. If there are 5 to 9 patients with a success out of 
27 patients, this would be an uninterestingly low success rate. If there were 10 or more of 27 
(37%) who experienced a success, this would be sufficiently interesting to warrant further study 
in later trials. Under the null hypothesis (25% success rate), the probability of early termination 
is 68.7%. 
Patients who receive at least one dose of the study drug will be evaluable for safety. Patients who 
complete at least one cycle of treatment and have a follow up imaging study will be evaluable for 
efficacy. The maximum number of patients on the phase I portion of the trial is 30 and phase II 
SCLC may accrue up to 27 evaluable patients. Thus, the maximum number of evaluable patients 
which may enroll on the phase I and II cohorts is 57. In order to allow for a small number of in-
evaluable patients, the accrual ceiling will be set at 60 for these cohorts. It is anticipated that 
approximately 1 to 2 patients per month may enroll onto these cohorts.
Table 15. Selected randomized studies of cytotoxic agents for SCLC
No. Patients Treatment
sPrimary 
endpointMedian 
PFS- 
topotecanMedian 
OS- 
topotecanReference
1 Sensitive 
SCLCTopotecan 
(N=107) 
vs. CAV 
(N=104) ORR 3.3 months 
(sensitive)6.3 months 
(sensitive)(68)
2 Refractory or 
sensitive 
SCLC; 2nd 
lineTopotecan 
(N=213) 
vs. 
amrubicin 
(N=424)OS 4.3 months 
(sensitive)
2.6 months
(refractory) 9.9 months 
(sensitive)
5.7 months 
(refractory)(71)
3 Sensitive 
SCLC 
2:1Topotecan 
(N=26) vs. 
amrubicin 
(N=50)ORR 3.3 months
(sensitive)7.6 months 
(sensitive)(73)
4 Refractory or 
sensitive 
SCLCTopotecan 
(N=30) vs. 
amrubicin 
(N=29)ORR 3.0 months 
(sensitive)
1.5 months
(refractory) NA (70)
5 Sensitive 
SCLC; 2nd 
linePO 
(N=153) 
vs. IV ORR 3.7 months 
(sensitive)8.7 months 
(sensitive)(72)
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
109No. Patients Treatment
sPrimary 
endpointMedian 
PFS- 
topotecanMedian 
OS- 
topotecanReference
(N=151) 
topotecan 
10.2 PHASE II EXPANSION COHORTS
10.2.1 Expansion Cohort (Urothelial Carcinoma)
The primary objective of this cohort is to determine the clinical response rate to EP0057 and 
olaparib in patients with bladder cancer. Data from a single trial of 310 patients with metastatic 
bladder cancer receiving atezolizumb alone demonstrated an ORR of 15%. To establish at least 
slightly improved efficacy of this treatment combination compared to single agent atezolizumab, 
the primary objective would be to determine if using the proposed agents would rule out a 10% 
response rate and result in a response rate consistent with 25%. As such, this cohort of the trial 
will be conducted using a Simon optimal two-stage phase II trial design (75) to rule out an 
unacceptably low PR+CR rate of 10% (p0=0.10) in favor of an improved response rate of 25% 
(p1=0.25). With alpha=0.10 (probability of accepting a poor treatment=0.15) and beta = 0.20 
(probability of rejecting a good treatment=0.20), the first stage will enroll [ADDRESS_729363] been treated. As it may take up to several months to determine 
if a patient has experienced a response, a temporary pause in the accrual may be necessary to 
ensure that enrollment to the second stage is warranted. If there are 2 to 5 patients with a 
response out of 34 patients, this would be an uninterestingly low response rate. If there were 6 or 
more of 34 (17.6%) who experienced a response, this would be sufficiently interesting to warrant 
further study in later trials. Under the null hypothesis (10% response rate), the probability of 
early termination is 62.1%.
It is expected that approximately 1 to 2 patients per month may enroll onto this cohort in the 
trial. Thus, it is expected that 2 to 3 years may be required to enroll up to 34 evaluable patients. 
To allow for a small number of inevaluable patients, the accrual ceiling for this cohort will be set 
at 36 patients. Analysis of correlative studies will be exploratory.
10.2.2 Expansion Cohort (mCRPC)
The primary objective of this exploratory cohort is to determine the clinical response rate to 
EP0057 and olaparib in patients with prostate cancer who are identified as having one of several 
possible genetic mutations.
In a published study of [ADDRESS_729364] one of a set of specified 
mutations, 14 (87.5%) had experienced a clinical response when treated with olaparib alone. 
While it is unlikely that this could be improved upon, it would be of interest to explore if a 
similarly high response rate could be seen in patients treated at the NCI with EP0057 and 
olaparib.
Patients with prostate cancer will be enrolled onto this cohort and biopsied, and the patients who 
are found to have any of a set of defined genetic mutations (in the DNA damage repair 
pathways), will receive EP0057 and olaparib and be evaluated for clinical response by [CONTACT_555602]. It is anticipated that 25-30% of patients will be found to possess one of the 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729365] 5 patients who could be evaluated for response, 25 total 
patients will undergo procedures necessary to determine if they possess the appropriate 
mutations. If the true probability of a mutation were 30%, then with 25 patients, there is a 91.0% 
probability of identifying 5 or more with mutations, including a 32.3% probability of identifying 
9 or more patients with mutations. If the true probability of a mutation were 25%, with 25 
patients, there is a 78.6% probability of identifying 5 or more with mutations, and a 14.9% 
probability of obtaining 9 or more with mutations. Thus, by [CONTACT_79323] 25 patients, there should be 
between 79% and 91% probability of identifying 5 or more patients with mutations, and between 
15% and 32% probability of potentially identifying [ADDRESS_729366] criteria. The fraction with responses obtained will be reported 
along with 80% and 95% two-sided confidence intervals, and the results compared, at least 
informally, to those from the published study with similar patients treated with olaparib alone. 
While the actual number of these patients to receive EP0057 and olaparib is likely to between [ADDRESS_729367] mutations, only 1 of 5 responds, then no further 
patients will be enrolled since the upper one-sided 90% CI bound on 1/5 = 58.4%, which would 
be below the lower one sided 90% CI bound on 14/16 from the published study (70.0%), and 
thus be inconsistent with the prior results.
The remaining patients without a mutation in their DNA damage repair pathway will also receive 
the combination of EP0057 and olaparib. It is expected that out of [ADDRESS_729368] these mutations. For these patients, it would be 
desirable to determine if their response rate would exceed 5% and be consistent with 25% or 
greater. Using that as a guideline, if there are 16 patients without the proper mutations who 
receive the combination treatment, 3 responses in 16 would be associated with a two-sided 80% 
exact confidence interval of 7.1-37.1%, and 4 responses in 16 would be associated with a two-
sided 80% exact confidence interval of 11.4 to 43.9%. With 20 patients without the proper 
mutations, 3 responses in 20 is associated with the same confidence interval of 5.6 to 30.4%, and 
[ADDRESS_729369] a confidence interval of 9.0-36.1%. The values for [ADDRESS_729370] 
mutations, there will be no early stoppi[INVESTIGATOR_555534] 16 to 20 
patients.
It is expected that approximately 1 patient per month may enroll onto this cohort in the trial. 
Thus, it is expected that 2 years may be required in order to enroll up to 25 evaluable patients. To 
allow for a small number of inevaluable patients, the accrual ceiling for this cohort will be set at 
27 patients. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].3 SAMPLE SIZE D ETERMINATION
With up to 30+27+34+25= 116 evaluable participants needed for the phase 1 dose escalation and 
expansion phases, as well as planning for a small number of inevaluable participants (10), we 
intend to initiate intervention in up to 126 participants.  Note:  To allow for screen failures (10), a 
total of 136 will be set for the purposes of the NIH accrual ceiling.
Overall, 1 – 2 patients per month are expected to enroll across all of the cohorts. It is expected 
that enrollment will be completed in 6 – 8 years.
11 COLLABORATIVE AGREEMENTS 
11.1 COOPERATIVE R ESEARCH AND DEVELOPMENT AGREEMENT (CRADA)
11.1.1 BlueLink (CRADA #[ZIP_CODE])
The investigational study agent formerly named CRLX101 was being provided by [CONTACT_7904], 
BlueLink under a Collaborative Agreement [Cooperative Research and Development Agreement 
(CRADA)].
As of March 2020, the CRADA has been amended to switch the manufacturer from BlueLink to 
Ellipses and drug name [CONTACT_555607]101 to EP0057. 
11.1.2 Astra Zeneca (CRADA #[ZIP_CODE])
The investigational study agent, olaparib is provided by [CONTACT_7904], Astra Zeneca under a 
Collaborative Agreement [Cooperative Research and Development Agreement (CRADA)].
[ADDRESS_729371] SELECTION
As previously described, the subjects for this study will include all subjects who meet the 
eligibility criteria outlined in section 2.1. No gender, racial, or ethnic groups will be excluded 
from participation in this trial. 
The effects of EP0057 and olaparib on the developi[INVESTIGATOR_19241].  For this 
reason, participants will be required to use contraception
12.2 PARTICIPATION OF C HILDREN
Because no dosing adverse event data are currently available on the use of EP0057 in 
combination with olaparib in subjects <18 years of age, children are excluded from this study.
12.3 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS
12.3.1 Risks 
[IP_ADDRESS] Study drug risks
The risks associated with the specific study agents are described in sections 14.1.9 and 14.2.9. 
Subjects will be adequately monitored for the occurrence of any possible side effects. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729372] 
guidance may be used in obtaining biopsies.
[IP_ADDRESS] Conscious sedation risks
There is a possibility that conscious sedation may be used for the procedure. The common side 
effects of conscious sedation include drowsiness, delayed reflexes, hypotension, headache, and 
nausea. These are generally mild and last no more than a few hours.
[IP_ADDRESS] Radiation risks
Subjects will be exposed to radiation from 3 CT guided biopsies and up to 9 CTs. The amount of 
radiation exposure is equal to approximately up to 12.3 rem. 
Note: As accrual to cohort 4 (mCRPC) ended with amendment version 7/27/2021, CT c/a/p and 
bone scan every 3 weeks are not included in the calculated radiation dose above.
[IP_ADDRESS] Risks from CT scans
There is a chance of developi[INVESTIGATOR_555535], which may cause 
symptoms ranging from mild itching or a rash to severe difficulty breathing, shock or rarely, 
death. The contrast material may also cause kidney problems. Patients may feel discomfort when 
the contrast material is injected. 
[IP_ADDRESS] Risks related to blood sampling
Side effects of blood draws include pain and bruising, lightheadedness, and rarely, fainting. Up 
to 225 mL of blood may be drawn at any given visit, with a maximum of 529 mL in an 8-week 
period.
[IP_ADDRESS] Risk related to hair collection
The only risk associate with hair collection is pain. 
12.3.2 Benefits
The benefits include a possible decrease in the size of the tumor and the scientific knowledge 
that could be acquired through this trial.
12.4 CONSENT P ROCESS AND D OCUMENTATION
The informed consent document will be provided as a physical or electronic document to the 
participant for review prior to consenting. A designated study investigator will carefully explain 
the procedures and tests involved in this study, and the associated risks, discomforts and benefits. 
In order to minimize potential coercion, as much time as is needed to review the document will 
be given, including an opportunity to discuss it with friends, family members and/or other 
advisors, and to ask questions of any designated study investigator. A signed informed consent 
document will be obtained prior to entry onto the study.
The initial consent process as well as re-consent, when required, may take place in person or 
remotely (e.g., via telephone or other NIH approved remote platforms used in compliance with 
policy, including HRPP Policy 303) per discretion of the designated study investigator and with 
the agreement of the participant. Whether in person or remote, the privacy of the subject will be 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
113maintained. Consenting investigators (and participant, when in person) will be located in a 
private area (e.g., clinic consult room). When consent is conducted remotely, the participant will 
be informed of the private nature of the discussion and will be encouraged to relocate to a more 
private setting if needed. 
Consent will be documented with required signatures on the physical document (which includes 
the printout of an electronic document sent to participant) or as described below, with a manual 
(non-electronic signature) on the electronic document. When required, witness signature [CONTACT_62580].
Manual (non-electronic) signature [CONTACT_62581]:
When a manual signature [CONTACT_62582], this study will use the following to obtain the required signatures:
•Adobe platform (which is not 21 CFR Part 11 compliant); or, 
•iMedConsent platform (which is 21 CFR Part 11 compliant)
During the consent process, participants and investigators will view individual copi[INVESTIGATOR_62496] (if remote consent); the same 
screen may be used when in the same location, but is not required. 
Both the investigator and the participant will sign the document using a finger, stylus or mouse. 
Note: Refer to the CCR SOP PM-2, Obtaining and Documenting the Informed Consent Process 
for additional information (e.g., verification of participant identity when obtaining consent 
remotely) found https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=73203825. 
12.4.[ADDRESS_729373] the rights and welfare of the participants given 
that the activities are only intended to determine suitability for screening for participation in 
research protocols.  These activities could not practicably be carried out without the wavier as 
central recruiting services, utilized in the NIH Clinical Center, perform pre-screening activities 
for multiple studies and obtaining consent for each one is beyond their resources.  The 
participants will be provided with additional pertinent information after participation as they will 
be informed whether or not they are eligible to sign a consent for additional screening.
13  REGULATORY AND OPERATIONAL CONSIDERATIONS 
13.1 STUDY DISCONTINUATION AND CLOSURE
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_21224], 
investigator, funding agency, the Investigational New Drug (IND) sponsor and regulatory 
authorities. If the study is prematurely terminated or suspended, the Principal Investigator (PI) 
will promptly inform study participants, the Institutional Review Board (IRB), and sponsor and 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
114will provide the reason(s) for the termination or suspension. Study participants will be contact[INVESTIGATOR_530], 
as applicable, and be informed of changes to study visit schedule.
Circumstances that may warrant termination or suspension include, but are not limited to:
•Determination of unexpected, significant, or unacceptable risk to participants
•Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
•Insufficient compliance to protocol requirements
•Data that are not sufficiently complete and/or evaluable
•Determination that the primary endpoint has been met
•Determination of futility
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the sponsor, IRB and as applicable, Food and Drug Administration (FDA).
13.[ADDRESS_729374], data and biological 
specimen collection, documentation and completion. An individualized quality management plan 
will be developed to describe the site’s quality management.
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data 
anomalies will be communicated to the site(s) for clarification/resolution.
Following written Standard Operating Procedures (SOPs), the monitors will verify that the 
clinical trial is conducted and data are generated and biological specimens are collected, 
documented (recorded), and reported in compliance with the protocol, International Council for 
Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., 
Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)). 
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_12291].
13.[ADDRESS_729375] by [CONTACT_3486], 
their staff, and the sponsor(s). This confidentiality is extended to cover testing of biological 
samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729376] (IRB), and/or regulatory agencies may inspect all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The 
clinical study site will permit access to such records.
The study participant’s contact [CONTACT_148418]/each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by [CONTACT_3488], Institutional policies, or 
sponsor requirements.
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be stored at the NCI CCR. This will not include the participant’s contact [CONTACT_10415]. Rather, individual participants and their research data will be identified 
by a unique study identification number. The study data entry and study management systems 
used by [CONTACT_977](s) and by [CONTACT_148419]. At the end of the study, all study databases will be archived at the NIH.
To further protect the privacy of study participants, a Certificate of Confidentiality has been 
issued by [CONTACT_7681] (NIH). This certificate protects identifiable research 
information from forced disclosure. It allows the investigator and others who have access to 
research records to refuse to disclose identifying information on research participation in any 
civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or 
local level. By [CONTACT_100417], Certificates of Confidentiality help achieve 
the research objectives and promote participation in studies by [CONTACT_4205][INVESTIGATOR_52572].
14 PHARMACEUTICAL INFORMATION 
14.1 EP0057 (IND#130102)
14.1.1 Description 
EP0057 is a polymer drug conjugate composed of 20 (S)-camptothecin conjugated to a 
biocompatible polymer. The compound self assembles into soluble nanoparticles composed of 
several molecules when dissolved in aqueous solution. Camptothecin (CPT) is an antineoplastic 
that inhibits topoisomerase I resulting in cell death during the S phase of the cell cycle. EP0057 
nanoparticles are believed to be taken up by [CONTACT_555603] 20(S)-camptothecin.
14.1.2 Supplier/How Supplied
The EP0057 is provided by [CONTACT_7904], Ellipses, the manufacturer of the drug under a 
Collaborative Agreement [Cooperative Research and Development Agreement (CRADA)].
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729377] to the study patient. It is supplied as a lyophilized cakein 30 
mL single-use vial containing 35 mg of CPT equivalents (approximately 350 mg of polymer 
drug conjugate). 
14.1.[ADDRESS_729378] is dissolved by [CONTACT_399068] 
(do not shake) until a clear homogenous solution is achieved. The majority of the product cake 
will dissolve quickly, however complete dissolution to a clear, homogenous solution will take 
longer and may require up to [ADDRESS_729379] for completion of 
reconstitution every 2‐3 minutes. Reconstitution is complete when (i) foam head has dissipated 
down to a thin bubble ring along inner wall of vial, (ii) solids in solution and foam head are no 
longer visible, and (iii) translucent polymer “vapors” are no longer visible in solution and the 
solution is clear and uniform in appearance. Complete reconstitution of the vial may take up to 
30 minutes.
Each milliliter of concentrated solution contains 2.5 mg of camptothecin equivalents. 
Concentrated EP0057 solution is diluted to the recommended dose with 5% dextrose in water for 
injection (D5W) to a total volume of 500 mL. After determining the amount of EP0057 
concentrated solution required for dosing, an equivalent volume is aseptically withdrawn from a 
500 mL infusion bag or bottle of D5W with a calibrated syringe. The measured volume of 
concentrated EP0057 solution is then withdrawn with a calibrated syringe and injected into the 
prepared 500 mL D5W infusion bag or bottle. The solution is thoroughly mixed by [CONTACT_555604].
14.1.5 Storage and Stability
EP0057 vials should be stored at refrigerated conditions (2° - 8°C) and should only be accessible 
to authorized individuals. EP0057 is stable for at least 3 years when stored at refrigerated 
conditions (2° - 8°C). The reconstituted solution is stable for [ADDRESS_729380] solution from the reconstituted vials should be destroyed per 
the site’s standard operating procedures.
Formulated EP0057 (i.e., IV bag) should be used within [ADDRESS_729381] vials. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].1.6 Dosage and Administration
See Sections  3.2 and 3.3 for the dose levels and administration of EP0057 to be evaluated in this 
study.
See Section 3.3.4 for management of any EP0057 infusion related/hypersensitivity reactions. 
The second and subsequent dose of EP0057 may be delayed if related AEs have not resolved to 
grade 1 or better. If a dose of EP0057 is delayed, then the subsequent dose should be 
administered 2 weeks later to avoid significant carry-over of unconjugated plasma CPT from one 
dose to the next (see Section 3.3). However, the maximum delay for AEs to resolve is [ADDRESS_729382] hydration and additional 
prevention measurements to prevent hypersensitivity/infusion reaction have been described in 
Section [IP_ADDRESS].
14.1.8 Return and Retention of EP0057
Any used study drug vials, or partially used vials, remaining after trial is complete will be 
destroyed per institution drug destruction policy. Unused study drug vials may be destroyed in 
the same manner or returned if requested to Ellipses. 
14.1.9 Toxicity
Possible toxicities from EP0057 include: neutropenia, thrombocytopenia, anemia, nausea, vomiting, 
diarrhea, mucositis, anorexia, and cystitis. Commonly reported toxicities in clinical trials with 
EP0057 are anemia, fatigue, cystitis, nausea, hematuria, neutropenia, diarrhea, vomiting, dysuria, 
constipation, thrombocytopenia, decreased appetite, and infusion-related reaction.
For additional details, refer to section 1.2 and investigator brochure.
14.2 OLAPARIB (AZD2281;  OLAPARIB; IND#130102) 
(Please refer to the Investigator’s Brochure and the package insert for further details)
14.2.1 Source 
The olaparib is provided by [CONTACT_7904], Astra Zeneca under a Collaborative Agreement 
[Cooperative Research and Development Agreement (CRADA)].
Olaparib ([COMPANY_008] Pharmaceuticals LP) has been commercially Food and Drug 
Administration approved as monotherapy for the treatment of patients with deleterious or 
suspected deleterious germline BRCA mutated (gBRCAm) (as detected by [CONTACT_13247]-approved 
test) advanced ovarian cancer who have been treated with three or more prior lines of 
chemotherapy. 
As of 20 March 2015, >[ADDRESS_729383] received treatment with olaparib in clinical studies as 
either monotherapy or in combination with other chemotherapy/anti-cancer agents. Most new 
clinical studies are investigating the tablet formulation which delivers the therapeutic dose of 
olaparib in fewer dose units than the capsule.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].2.2 Pre-clinical experience
The pre-clinical experience is fully described in the current version of the olaparib Investigator’s 
Brochure (IB). 
14.2.[ADDRESS_729384]. There were no noticeable 
effects on the cardiovascular or respi[INVESTIGATOR_555536], autonomic or motor effects in the rat at the doses studied.
The toxicology studies indicate that the target organ of toxicity is the bone marrow. 
Further information can be found in the current version of the olaparib Investigator’s Brochure
14.2.4 Approved indications and clinical experience
Clinical experience with olaparib is fully described in the current version of the olaparib 
Investigator’s Brochure.
[COMPANY_008] is planning to voluntarily withdraw olaparib for the treatment of adult patients with 
deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian 
cancer who have been treated with three or more prior lines of chemotherapy (Dear ESR Sponsor 
Letter dated 8/10/22). This is currently an approved indication in the US. 
A recent subgroup analysis indicated a potential detrimental effect on overall survival (OS) for 
olaparib as a line of treatment compared to the chemotherapy control arm in patients who had 
received three or more prior lines of chemotherapy in the randomized Phase III study, SOLO3 
(D0816C00010; [STUDY_ID_REMOVED]). SOLO3 met its primary endpoint of ORR and the key 
secondary endpoint of progression-free survival (PFS). Safety data, other than OS, reported for 
olaparib in the SOLO3 study were consistent with that reported in other clinical trials with 
olaparib, and no new safety signals were identified.
14.2.5 Indications and Usage
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in 
patients with deleterious or suspected deleterious germline BRCA mutated (as detected by [CONTACT_108076]-approved test) advanced ovarian cancer who have been treated with three or more prior 
lines of chemotherapy.
The indication is approved under accelerated approval based on objective response rate and 
duration of response. Continued approval for this indication may be contingent upon verification 
and description of clinical benefit in confirmatory trials. 
14.2.6 Dosage and Administration
Please refer to section 3.2.2 for administration instructions. Dose will be according to assigned 
dose level (see section 3.1).
14.2.7 Tablet Dosage Forms and Strengths
Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 
mg, 150 mg or 200 mg of drug substance. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].2.8 Warnings and Precautions
• Myelodysplastic syndrome/Acute Myeloid Leukemia: (MDS/AML) occurred in patients 
exposed to olaparib, and some cases were fatal. Monitor patients for hematological toxicity at 
baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. 
• Pneumonitis: occurred in patients exposed to olaparib, and some cases were fatal. Interrupt 
treatment if pneumonitis is suspected. Discontinue if active pneumonitis is confirmed. 
• Embryo-Fetal toxicity: olaparib can cause fetal harm. Advise individuals of reproductive 
potential of the potential risk to a fetus and to avoid pregnancy. 
14.2.9 Adverse Reactions 
Table 16. Adverse Drug Reactions Reported in Clinical Trials
MedDRA SOC MedDRA term CIOMS descriptor/ 
overall frequency 
(All CTCAE grades)Frequency of CTCAE 
Grade 3 and above
Neoplasms benign, 
malignant and 
unspecified (including 
cysts and polyps)Myelodysplastic 
syndrome/acute myeloid 
leukaemiaUncommon Uncommon
AnaemiaaVery common Very common
NeutropeniaaVery common Common
LeukopeniaaVery common Common
ThrombocytopeniaaCommon CommonBlood and lymphatic 
system disorders
LymphopeniaaCommon Common
HypersensitivityaUncommon Rare Immune system 
disorders AngioedemabUncommon -
Metabolism and 
nutrition disordersDecreased appetite Very common Uncommon
Dizziness Very common Uncommon
Headache Very common UncommonNervous system 
disorders
DysgeusiaaVery common -
CoughaVery common Uncommon Respi[INVESTIGATOR_696], thoracic 
and mediastinal 
disordersDyspnoeaaVery common Common
Vomiting Very common Common
Diarrhoea Very common Uncommon
Nausea Very common Common
Dyspepsia Very common Rare
StomatitisaCommon UncommonGastrointestinal 
disorders
Upper abdominal pain Common Rare
RashaCommon Uncommon
DermatitisaUncommon RareSkin and 
subcutaneous tissue 
disordersErythema nodosumbRare -
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
120General disorders Fatigue (including 
asthenia)Very common Common
Blood creatinine 
increasedCommon Rare Investigations
Mean cell volume 
increasedUncommon -
Vascular disorders Venous 
thromboembolismaCommon Common
aAnaemia includes preferred terms (PTs) of anaemia, anaemia macrocytic, erythropenia, haematocrit 
decreased haemoglobin decreased, normocytic anaemia and red blood cell count decreased; Cough includes 
PTs of cough and productive cough; Dermatitis includes PTs of dermatitis and dermatitis allergic; 
Dysgeusia includes PTs of dygeusia and taste disorder; Dyspnoea includes PTs of dyspnoea and dyspnoea 
exertional; Hypersensitivity includes PTs of drug hypersensitivity and hypersensitivity; Leukopenia 
includes PTs of leukopenia and white blood cell count decreased; Lymphopenia includes PTs of 
lymphocyte count decreased and lymphopenia; Neutropenia includes PTs of febrile neutropenia, 
neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased; Rash includes PTs 
of exfoliative rash, generalized erythema, rash, rash erythematous, rash macular, rash maculo-papular, rash 
papular and rash pruritic; Stomatitis includes PTs of aphthous ulcer, mouth ulceration and stomatitis; 
Thrombocytopenia includes PTs of platelet count decreased, and thrombocytopenia; Venous 
thromboembolism includes PTs of deep vein thrombosis, embolism, pulmonary embolism, thrombosis, 
vena cava thrombosis and venous thrombosis.
bObserved in the post-marketing setting.
CIOMS = Council for International Organizations of Medical Sciences; CTCAE = Common Terminology 
Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; PT = Preferred term; 
SOC = System organ class.
MedDRA version 24.0.
Table 17. Serious Adverse Reactions for Olaparib Considered Expected for Safety Reporting 
Safety Reporting Purposes 
Number of patients exposed 
(N) = 4098MedDRAa SOC Preferred Term
CIOMS frequency indicator
Acute myeloid leukaemia Uncommon Neoplasms benign, malignant and 
unspecified (including cysts and 
polyps)Myelodysplastic syndrome Uncommon
Anaemia Common
Anaemia macrocytic Rare
Febrile neutropenia Uncommon
Leukopenia Rare
Neutropenia UncommonBlood and lymphatic system disorders
Thrombocytopenia Uncommon
Diarrhoea Rare
Nausea UncommonGastrointestinal disorders
Vomiting Uncommon
General disorders Fatigue Rare
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
121Asthenia Rare
Blood creatinine increased Rare
Haematocrit decreased Rare
Haemoglobin decreased Uncommon
Lymphocyte count decreased Rare
Neutrophil count decreased Uncommon
Platelet count decreased Uncommon
Red blood cell count decreased RareInvestigations
White blood cell count decreased Uncommon
Metabolism and nutrition disorders Decreased appetite Rare
Nervous system disorders Dizziness Rare
Cough Rare Respi[INVESTIGATOR_696], thoracic and mediastinal 
disordersDyspnoea Uncommon
Embolism Uncommon Vascular disorders
Pulmonary embolism Uncommon
aMedDRA version 24.0.
CIOMS = Council for International Organizations of Medical Sciences; DCO = Data cut-off;
MedDRA = Medical Dictionary for Regulatory Activities; PT = Preferred term; SAE = Serious adverse event.
For additional information, refer to investigator brochure.
14.2.10 Drug Interactions
• CYP3A Inhibitors: Avoid concomitant use of strong and moderate CYP3A inhibitors. If the 
inhibitor cannot be avoided, reduce the dose.
• CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers. If a 
moderate CYP3A inducer cannot be avoided, be aware of a potential for decreased efficacy. 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE] REFERENCES 
1. Murai J, Zhang Y, Morris J, Ji J, [COMPANY_005] S, Doroshow JH, et al. Rationale for poly(ADP-
ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or 
temozolomide based on PARP trappi[INVESTIGATOR_441588]. The Journal of pharmacology 
and experimental therapeutics. 2014;349(3):408-16.
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 
2011;378(9804):1741-55.
3. Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus 
refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. 
European journal of cancer. 2014;50(13):2211-8.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-
30.
5. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, et al. A phase II study 
of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. 
British journal of cancer. 2006;94(10):1395-401.
6. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G, et al. Phase 2 trial of 
epothilone B analog BMS-247550 (ixabepi[INVESTIGATOR_54575]) in advanced carcinoma of the urothelium 
(E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 2007;110(4):759-63.
7. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial 
of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 
1997;15(5):1853-7.
8. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of 
weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 
2002;20(4):937-40.
9. Keane TE, El-Galley RE, Sun C, Petros JA, Dillahey D, Gomaa A, et al. Camptothecin 
analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo 
model system. The Journal of urology. 1998;160(1):252-6.
10. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, 
et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who 
have progressed following treatment with platinum-based chemotherapy: a single-arm, 
multicentre, phase 2 trial. Lancet. 2016;387([ZIP_CODE]):1909-20.
11. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in 
metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-
arm, phase 2 trial. Lancet Oncol. 2017;18(3):312-22.
12. Cancer Genome Atlas Research N. Comprehensive molecular characterization of 
urothelial bladder carcinoma. Nature. 2014;507(7492):315-22.
13. Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, et al. Whole-exome 
sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and 
prognostic importance of DNA repair gene mutations on survival. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2014;20(24):6605-17.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729385] in bladder cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 
2014;20(18):4935-48.
15. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, et al. 
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment 
of sporadic human ovarian cancer. Molecular cancer therapeutics. 2013;12(6):1002-15.
16. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel 
and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair 
deficiency. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2013;19(18):5003-15.
17. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, et al. Enhanced 
killing of cancer cells by [CONTACT_52362](ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors 
reflects poisoning of both enzymes. J Biol Chem. 2012;287(6):4198-210.
18. Chaudhary UB, Verma N, Keane T, Gudena V. A phase II study of gemcitabine and 
irinotecan in patients with locally advanced or metastatic bladder cancer. Am J Clin Oncol. 
2014;37(2):188-93.
19. Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J. A phase II 
study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of 
transitional cell carcinoma of the bladder. Urologic oncology. 2013;31(6):878-82.
20. Yap KL, Kiyotani K, Tamura K, Antic T, Jang MR, Montoya M, et al. Whole-Exome 
Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and 
Prognostic Importance of DNA Repair Gene Mutations on Survival. Clinical Cancer Research. 
2014;20(24):6605-17.
21. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-
30.
22. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et 
al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 
1998;339(15):1036-42.
23. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and 
increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
24. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. 
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 
2013;368(2):138-48.
25. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. 
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 
2014;371(5):424-33.
26. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival 
with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
27. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. 
Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729386] CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited 
DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 
2016;375(5):443-53.
29. Beltran H. The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic 
Potential. Mol Cancer Res. 2014;12(6):815-22.
30. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair 
Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.
31. Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA 
damage primes the type I interferon system via the cytosolic DNA sensor STING to promote 
anti-microbial innate immunity. Immunity. 2015;42(2):332-43.
32. Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 
2015;15(12):760-70.
33. Akao Y, Kusakabe S, Banno Y, Kito M, Nakagawa Y, Tamiya-Koizumi K, et al. 
Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer 
LNCaP cells. Biochem Biophys Res Commun. 2002;294(2):363-70.
34. Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, et al. 
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and 
cancer cells. Antimicrob Agents Chemother. 1999;43(12):2862-8.
35. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, beta-cyclodextrin-
based polymers and their camptothecin conjugates. Bioconjug Chem. 2003;14(5):1007-17.
36. Chiang KC, Tsui KH, Chung LC, Yeh CN, Chang PL, Chen WT, et al. Topoisomerase 
inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen 
in prostate carcinoma cells. PLoS One. 2014;9(2):e89117.
37. Jayasooriya RG, Park SR, Choi YH, Hyun JW, Chang WY, Kim GY. Camptothecin 
suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in 
DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent 
induction of HO-1 expression. Environ Toxicol Pharmacol. 2015;39(3):1189-98.
38. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose) polymerase 
inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by [CONTACT_555605]. Clin Cancer Res. 2005;11(23):8449-57.
39. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of 
poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Bio. 2012;13(7):411-24.
40. By[CONTACT_115193], Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic 
Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic 
Targets Including PARP1. Cancer Discov. 2012;2(9):798-811.
41. Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, et al. Poly 
(ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in 
vitro and in vivo in small cell lung cancer. Cancer medicine. 2014;3(6):1579-94.
42. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, et al. Proteomic markers 
of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
125small cell lung cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research. 2013;19(22):6322-8.
43. Y. Feng RC, L.A. By[CONTACT_3727], B. Wang, Y. Shen. . Talazoparib (BMN 673) as single agent 
and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and 
gastric cancer models. . 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer 
Therapeutics (abstract) 2014.
44. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of 
temozolomide and topotecan growth inhibition and cytotoxicity by [CONTACT_452677](adenosine 
diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 2000;6(7):2860-
7.
45. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, et al. Enhanced 
Killing of Cancer Cells by [CONTACT_452678](ADP-ribose) Polymerase Inhibitors and Topoisomerase I 
Inhibitors Reflects Poisoning of Both Enzymes. J Biol Chem. 2012;287(6):4198-210.
46. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, et al. Safety and 
tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in 
combination with topotecan for the treatment of patients with advanced solid tumors: a phase I 
study. Invest New Drug. 2012;30(4):1493-500.
47. Kummar S, Chen A, Ji JP, Zhang YP, Reid JM, Ames M, et al. Phase I Study of PARP 
Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and 
Lymphomas. Cancer Res. 2011;71(17):5626-34.
48. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, et al. First-in-
human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin 
nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 
2013;31(4):986-1000.
49. Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, et al. Correlating 
preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. 
Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. 
2013;110(37):[ZIP_CODE]-32.
50. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting 
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 
2005;434(7035):917-21.
51. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in 
the repair of DNA damage by [CONTACT_466534](ADP-ribose) 
polymerase inhibition. Cancer Res. 2006;66(16):8109-15.
52. Menear KA, Adcock C, Alonso FC, Blackburn K, Copsey L, Drzewiecki J, et al. Novel 
alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Bioorg Med Chem Lett. 
2008;18(14):3942-5.
53. O'Connor LO, Wang AT, Jones DR, Odedra R, Spreadborough M, Wilson J, et al. A 
camptothecin-containing nanoparticle-drug conjugate combination with DDR agents provides a 
novel approach to increasing therapeutic index. Cancer Res. 2016;76.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE]. Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, et al. Alterations of 
DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. 
DNA Repair. 2015;28:107-15.
55. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative 
DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. 
Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. 
2012;109(37):[ZIP_CODE]-5.
56. Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, et al. SLFN11 is a 
transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing's sarcoma. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 
2015;21(18):4184-93.
57. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer 
chemotherapy. Nature reviews Immunology. 2008;8(1):59-73.
58. Tolstrup M, Johansen C, Toft L, Pedersen FS, Funding A, Bahrami S, et al. Anti-
inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. BMC 
immunology. 2013;14:51.
59. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, et al. c-Met 
ectodomain shedding rate correlates with malignant potential. Clinical Cancer Research. 
2006;12(14):4154-62.
60. McNeil BK, Sorbellini M, Grubb RL, Apolo AB, Cecchi F, Athauda G, et al. Preliminary 
evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. J 
Transl Med. 2014;12.
61. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer. 2009;45(2):228-47.
62. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: 
New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl 
Cancer Inst. 2004;96(6):487-8.
63. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and 
end points of clinical trials for patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2008;26(7):1148-59.
64. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility 
and response guidelines for phase II clinical trials in androgen-independent prostate cancer: 
recommendations from the Prostate-Specific Antigen Working Group. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 1999;17(11):3461-7.
65. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et 
al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. 
Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92(18):1534-5.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE]. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and 
End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels 
of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. 
Journal of Clinical Oncology. 2008;26(7):1148-59.
67. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J 
Cancer. 2009;45(2):228-47.
68. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. 
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent 
small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.
69. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of 
small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6(8):1264-70.
70. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized 
phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell 
lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26(33):5401-
6.
71. von Pawel J, Jotte R, Spi[INVESTIGATOR_43942], O'Brien ME, Socinski MA, Mezger J, et al. Randomized 
phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell 
lung cancer. J Clin Oncol. 2014;32(35):4012-9.
72. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study 
of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J 
Clin Oncol. 2007;25(15):2086-92.
73. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized 
phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with 
small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 
2011;29(3):287-93.
74. Pi[INVESTIGATOR_33006], Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. 
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either 
Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. 
Journal of Clinical Oncology. 2018;36(23):2386-+.
75. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 
1989;10(1):1-10.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE] APPENDICES
16.1  APPENDIX A: PERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
100Normal, no complaints, no 
evidence of disease.
0Normal activity. Fully active, able 
to carry on all pre-disease 
performance without restriction.90Able to carry on normal activity; 
minor signs or symptoms of 
disease.
80Normal activity with effort; 
some signs or symptoms of 
disease.
1Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).70Cares for self, unable to carry on 
normal activity or to do active 
work.
60Requires occasional assistance, 
but is able to care for most of 
his/her needs.2In bed <50% of the time. 
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities. Up and about 
more than 50% of waking hours. 50Requires considerable assistance 
and frequent medical care.
40Disabled, requires special care 
and assistance.
3In bed >50% of the time. Capable 
of only limited self-care, confined 
to bed or chair more than 50% of 
waking hours. 30Severely disabled, 
hospi[INVESTIGATOR_374]. Death 
not imminent.
20Very sick, hospi[INVESTIGATOR_373]. Death not imminent.
4100% bedridden. Completely 
disabled. Cannot carry on any 
self-care. Totally confined to bed 
or chair. 10Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].
5 Dead. 0 Dead.
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].2 APPENDIX B : LIST OF DRUGS THAT MAY HAVE POTENTIAL CYP3A4 INTERACTIONS
16.2.[ADDRESS_729387] 
Moricizine 
Nateglinide 
Nefazodone 
Nelfinavir 
Nevirapi[INVESTIGATOR_555537]: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].2.2 CYP3A4 Inhibitors
 In Vivo Inhibitors of CYP3A Probes
Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
Potent CYP3A Inhibitors (yielding substrate AUCr > 5)
VIEKIRA PAK2Antivirals See note2tacrolimus255.76 25708713 2015 May
indinavir /RIT Protease Inhibitors 800/100 mg BID (1 day) alfentanil 36.5 19225389 2009 Mar
tipranavir/RIT Protease Inhibitors 500/200 mg BID (2 days) midazolam 26.91 20147896 2010 Jun
ritonavir Protease Inhibitors 3 doses of 100 mg over 24 h midazolam 26.41 20002087 2009 Dec
cobicistat (GS-9350) None 200 mg QD (14 days) midazolam 19.03 20043009 2010 Mar
indinavir Protease Inhibitors 800 mg TID (7 days) vardenafil 16.25 NDA # [PHONE_11549] Aug
ketoconazole Antifungals 400 mg QD (4 days) midazolam 15.9 8181191 1994 May
troleandomycin Antibiotics 500 mg single dose midazolam 14.8 15536460 2004 Dec
telaprevir Antivirals 750 mg TID (16 days) midazolam 13.[ADDRESS_729388]
danoprevir / RIT Antivirals 200/100 mg QD (14 days) midazolam 13.42 23872824 2013 Nov
elvitegravir / RIT Treatments of AIDS 150/100 mg QD (10 days) midazolam 12.8 NDA # [PHONE_11550]
saquinavir / RIT Protease Inhibitors 1000/100 mg BID (14 days) midazolam 12.[ADDRESS_729389]
lopi[INVESTIGATOR_054] / RIT Protease Inhibitors 400/100 mg BID (2 days) alfentanil 11.47 24067429 2013 Dec
itraconazole Antifungals 200 mg QD (4 days) midazolam 10.8 8181191 1994 May
voriconazole Antifungals 200 mg BID (9 days) midazolam 9.[ADDRESS_729390]

Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
131Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
LCL161 Cancer Treatments 600 mg single dose midazolam 8.8 23585187 2013 Jun
clarithromycin Antibiotics 500 mg BID (7 days) midazolam 8.39 16432272 2006 Feb
posaconazole Antifungals 400 mg BID (7 days) midazolam 6.23 19302901 2009 Feb
telithromycin Antibiotics 800 mg QD (6 days) midazolam 6.2 NDA# [PHONE_11551]
grapefruit juice DS3Food Products 240 mL TID (2 days) and 90 min, 
60min, 30 min prior to midazolammidazolam 5.95 12953340 2003 Aug
conivaptan Diuretics 40 mg BID (5 days) midazolam 5.76 NDA # [PHONE_11552]
nefazodone Antidepressants 100-200 mg BID (12 days) midazolam 5.44 14551182 2003 Nov
nelfinavir Protease Inhibitors 1250 mg BID (14 days) midazolam 5.29 21406602 2011 Jun
saquinavir Protease Inhibitors 1200 mg TID (5 days) midazolam 5.18 10430107 1999 Jul
idelalisib Kinase Inhibitors 150 mg BID (8 days) midazolam 5.15 NDA # [PHONE_11553]
boceprevir Antivirals 800 mg TID (6 days) midazolam 5.05 NDA # [PHONE_11554]
Moderate CYP3A Inhibitors (AUCr ≥ 2 and < 5)
erythromycin Antibiotics [ADDRESS_729391]
atazanavir / RIT Protease Inhibitors 300/100 mg BID maraviroc 4.9 18333863 2008 Apr
darunavir Protease Inhibitors 1200 mg BID (14 days) saquinavir 4.9 NDA # [PHONE_11555]
diltiazem Calcium Channel Blockers 60 mg TID (2 days) midazolam 4.06 21209240 2011 Nov
darunavir / RIT Protease Inhibitors 400/100 mg BID (8 days) sildenafil 4.0 NDA # [PHONE_11555]
dronedarone Antiarrhythmics 400 mg BID (14 days) simvastatin 3.66 NDA # [PHONE_11556]
crizotinib Kinase Inhibitors 250 mg BID (28 days) midazolam 3.65 NDA # [PHONE_11557]
atazanavir Protease Inhibitors 400 mg QD (7 days) maraviroc 3.57 18333863 2008 Apr
aprepi[INVESTIGATOR_555538] 80-125 mg QD (5 days) midazolam 3.29 12891225 2003 Aug
casopi[INVESTIGATOR_555538] 120 mg QD (14 days) midazolam 3.[ADDRESS_729392]
amprenavir Protease Inhibitors 1200 mg BID (10 days) rifabutin 2.93 11158747 2001 Feb
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
132Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
faldaprevir Antivirals 240 mg BID (14 days) midazolam IV 2.92 25449227 2015 Apr
imatinib Antineoplastic Agents 400 mg QD (7 days) simvastatin 2.92 14612892 2003 Nov
verapamil Calcium Channel Blockers 80 mg TID (2 days) midazolam 2.[ADDRESS_729393]
nilotinib Kinase Inhibitors 400 mg BID (12 days) midazolam 2.4 25418605 2015 Apr
grapefruit juice Food Products 240 mL QD (4 days) midazolam 2.[ADDRESS_729394]
tofisopam Benzodiazepi[INVESTIGATOR_1651] 100 mg TID (9 days) midazolam 2.36 17989974 2008 Jan
cyclosporine Immunosuppressants Not provided (1-5 years) midazolam 2.[ADDRESS_729395]-178882 Renin Inhibitors 300 mg QD (14 days) midazolam 2.19 22849770 2013 Dec
ciprofloxacin4Antibiotics 500 mg single dose sildenafil 2.12 16372380 2005 Dec
schisandra 
sphenantheraHerbal Medications 3 capsules (= 11.25 mg 
deoxyschizandrin) BID (7 days)midazolam 2.05 19552749 2009 May
isavuconazole Antifungals clinical dose (detail not provided) midazolam 2.03 NDA # [PHONE_11558]
cimetidine H-2 Receptor Antagonists 200-400 mg QID (1.5 days) midazolam 2.02 6152615 1984 Sep
FK1706 Central Nervous System 
Agents60 mg QD (14 days) midazolam 2.01 19889885 2010 Feb
Weak CYP3A Inhibitors (AUCr ≥ 1.25 and < 2)
tabimorelin Hormone Replacement 2.86-3.21 mg QD (7 days) midazolam 1.93 12610745 2003 Feb
ranolazine Cardiovascular Drugs 1000 mg BID (7 days) simvastatin 1.89 NDA # [PHONE_11559]
amlodipi[INVESTIGATOR_555539] 10 mg QD (9 days) simvastatin 1.8 23965645 2014 Apr
lomitapi[INVESTIGATOR_555540] 60 mg QD (7 days) simvastatin 1.77 24734312 2014 Mar
fosaprepi[INVESTIGATOR_053] (IV) Antiemetics 150 mg single 30-min infusion midazolam 1.76 21209230 2011 Dec
Seville orange juice Food Products 240 mL single dose felodipi[INVESTIGATOR_050] 1.76 11180034 2001 Jan
amiodarone Antiarrhythmics 400 mg QD (4 days) simvastatin 
acid1.76 17301736 2007 May
chlorzoxazone Muscle Relaxants 250 mg single dose (part of a 6-drug 
cocktail)midazolam 1.68 11736864 2001 Nov
M100240 Antihypertensive Agents 50 mg single dose midazolam 1.66 15051745 2004 Apr
fluvoxamine Antidepressants 50-00 mg BID (12 days) midazolam 1.66 14551182 2003 Nov
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
133Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
ranitidine H-2 Receptor Antagonists 150 mg BID (1.5 days) midazolam 1.66 6135440 1983 Jun
fostamatinib5Anti-inflammatory Drugs 100 mg BID (7 days) simvastatin 1.64 26748647 2016 Mar
goldenseal Herbal Medications 1,323 mg (= 24.1 mg isoquinoline 
alkaloids) TID (14 days)midazolam 1.63 17495878 2008 Jan
clotrimazole Antifungals 10 mg TID (5 days) midazolam 1.61 20233179 2010 Feb
tacrolimus Immunosuppressants Not provided (1-5 years) midazolam 1.61 21753749 2011 Sep
palbociclib Kinase Inhibitors 125 mg QD (8 days) midazolam 1.58 NDA # [PHONE_11560]
cilostazol Antiplatelets 100 mg BID (7 days) lovastatin 1.56 10702889 1999
ticagrelor Antiplatelets 180 mg bid (7 days) simvastatin 1.56 NDA # [PHONE_11561]
peppermint oil Food Products 600 mg (= 300 uL peppermint oil) 
single dosefelodipi[INVESTIGATOR_050] 1.55 12235445 2002 Sep
ivacaftor Cystic fibrosis treatments 150 mg BID (6 days) midazolam 1.54 NDA # [PHONE_11562]
[COMPANY_004]2248761 Transcriptase Inhibitors 100 mg QD (12 days) midazolam 1.54 22288567 2012 Aug
Guan Mai Ning Herbal Medications 3 tablets TID (7 days) simvastatin 1.51 25801058 2015 Sep
AZD2327 Depression Treatments 15 mg QD (7 days) midazolam 1.49 26081137 2015 Nov
resveratrol Food Products 500 mg QD (10 days) carbamazepin
e1.48 25624269 2015 May
roxithromycin Antibiotics 300 mg QD (6 days) midazolam 1.47 7995324 1994
suvorexant Hypnotics - Sedatives 80 mg QD (14 days) midazolam 1.47 NDA # [PHONE_11563]
propi[INVESTIGATOR_555541] 15 mg BID (7 days) midazolam 1.46 16183781 2005 Dec
isoniazid Antibiotics 90 mg BID (4 days) triazolam 1.46 6140941 1983 Dec
berberine Herbal Medications 300 mg TID (14 days) midazolam 1.45 21870106 2012 Feb
oral contraceptives Oral contraceptives OC with low doses of estrogen (< 35 
ug ethinylestradiol) (> 3 months)triazolam 1.44 6149030 1984 Nov
delavirdine NNRTIs 400 mg TID (9 days) indinavir 1.44 9665503 1998 Jul
daclatasvir Antivirals 60 mg QD (7 days) simeprevir 1.44 NDA # [PHONE_11564]
simeprevir Protease Inhibitors 150 mg QD (11 days) midazolam 1.43 NDA # [PHONE_11564]
atorvastatin HMG CoA Reductase 
Inhibitors (Statins)10-40 mg/day (chronic treatment) midazolam IV 1.41 12911366 2003 Sep
tolvaptan Vasopressin Antagonists 60 mg single dose lovastatin 1.41 NDA # [PHONE_11565]
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
134Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
almorexant Hypnotics - Sedatives 200 mg QD (9 days) midazolam 1.37 22990330 2013 Mar
[COMPANY_004]1292263 Other Antilipemics 300 mg BID (9 days) simvastatin 1.36 23256625 2013 Jun
evacetrapid CETP inhibitors 300 mg QD (15 days) midazolam 1.35 26264702 2015 Dec
linagliptin Dipeptidyl Peptidase 
4Inhibitors10 mg QD (6 days) simvastatin 1.34 20497745 2010 Jun
lacidipi[INVESTIGATOR_555539] 4 mg QD (8 days) simvastatin 1.33 11259986 2001 Feb
cranberry juice Food Products 240 mL double strength juice, 1 glass 
q 15 min x 3midazolam 1.33 19114462 2009 Mar
pazopanib Kinase Inhibitors 800 mg QD (17 days) midazolam 1.32 20881954 2010 Nov
everolimus Immunosuppressants 10 mg QD (5 days) midazolam 1.31 23426978 2013 Apr
blueberry juice Food Products two doses of 300 mL, separated by 16 
hoursbuspi[INVESTIGATOR_5331] 1.31 22943633 2013 Apr
AMD070 Fusion Inhibitors 200 mg BID (8 days) midazolam 1.29 18362694 2008 Apr
alprazolam Benzodiazepi[INVESTIGATOR_1651] 1 mg TID (7 days) buspi[INVESTIGATOR_5331] 1.29 8300893 1993 Nov
Tong Xin Luo Herbal Medications 4 capsules TID (7 days) simvastatin 1.29 25801058 2015 Sep
bicalutamide Antiandrogens 150 mg QD (>3 months) m
i
d
a
z
o
l
a
m1.27 15509184 2004
sitaxentan Endothelin Receptor 
Antagonists100 mg QD (7 days) s
i
l
d
e
n
a
f
i
l1.27 20078609 2010 Jan
azithromycin Antibiotics 500 mg QD (3 days) m
i
d
a
z
o
l
a
m1.27 8720318 1996 Feb
ginkgo Herbal Medications 120 mg TID (28 days) m
i
d
a
z
o
l
a
m1.25 17050793 2006 Nov
teriflunomide Other Immunomodulators 14-70 mg QD (14 days) m
i
d
a
z
o
l
a
m1.25 NDA # [PHONE_11566]
[ADDRESS_729396].
When no study with midazolam was available, the AUCratio of another probe or sensitive substrate is presented.
2 VIEKIRA PAK = 150/100 mg paritaprevir/ritonavir + 25 mg ombitasvir + 800 mg dasabuvir for 28 days. Tacrolimus is also a substrate of 
OATP1B1/1B3 that can be inhibited by [CONTACT_555606].3 240 mL GFJ double-strength administered TID for 3 days
4 Of note, co-administration of ciprofloxacin (750 mg BID for 7 days) did not affect plasma concentrations of ivacaftor, which is also a 
sensitive substrate for CYP3A (KALYDECO Prescribing Information).5 Fostamatinib also inhibits BCRP, and BCRP inhibition likely participates to the increase in exposure of simvastatin
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
135Inhibitor Therapeutic Class Inhibitor dosing (oral)Object1 
(oral, unless 
otherwise 
specified)AUCratioPMID or NDA # Published
M and T Drug Interaction Database® - Copyright [ADDRESS_729397] (oral, 
unless 
otherwise 
specified)% ↓ AUC % ↑ oral CL Precipi[INVESTIGATOR_555542] (oral) PMID or NDA # Published
Potent Inducers (AUC decreased by ≥ 80% or CL increased by [CONTACT_726] 5 fold (400%))
rifampin Antibiotics budesonide 99.7 [ZIP_CODE].5 600 mg QD (7 days) 15726657 2005 Mar
mitotane Other 
Antineoplasticsmidazolam 94.5 Not Provided maximum of 3.5 g TID 
(chronic therapy) 21220434 2011 Apr
avasimibe Other Antilipemics midazolam 93.5 Not Provided 750 mg/day (7 days) 12766253 2003 Sep
phenytoin Anticonvulsants nisoldipi[INVESTIGATOR_050] 89.5 Not Provided 200-450 mg/day (chronic 
treatment)8917062 1996 Nov
carbamazepi[INVESTIGATOR_555543] 86.6 643.1 200 mg TID (26 days) 16390352 2006 Jan
enzalutamide Antiandrogens midazolam 85.9 Not Provided 160 mg QD (85±3 days) NDA # [PHONE_11567]
St John's Wort xtract Herbal Medications midazolam 80.0 Not Provided 300 mg TID (14 days) 16341856 2006 Jan
rifabutin Antibiotics delavirdine Not Provided 458.0 300 mg QD (14 days) 9224961 1997 Jun

Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729398] (oral, 
unless 
otherwise 
specified)% ↓ AUC % ↑ oral CL Precipi[INVESTIGATOR_555542] (oral) PMID or NDA # Published
phenobarbital Anticonvulsants verapamil 76.6 400.9 100 mg QD (21 days) 3392664 1988 Jul
Moderate Inducers (AUC decreased by 50-80% or CL increased by 2-5 fold (100-400%))
ritonavir and St. Johns 
wortNone midazolam 77.2 Not Provided ritonavir: 300 mg BID and 
SJW: 300 mg T ID (14 days)19924124 2010 Feb
semagacestat Alzheimer's 
Treatmentsmidazolam 76.4 324.6 140 mg QD (10 days) [ADDRESS_729399]
efavirenz NNRTIs alfentanil 76 369.4 600 mg QD (20 days) 22398970 2012 Apr
tipranavir and ritonavir Protease Inhibitors saquinavir 75.6 Not Provided tipranavir: 500 mg and 
ritonavir: 200 mg BID (14 
days)18176328 2008 Apr
bosentan Endothelin 
Receptor 
Antagonistssildenafil 69.0 239.8 62.5-125 mg BID (8 weeks) 15963102 2005 Jul
genistein Food Products midazolam 13.7 136.9 1000 mg QD (14 days) 21943317 2012 Feb
thioridazine Antipsychotics quetiapi[INVESTIGATOR_050] 68.7 104.5 100-300 mg QD (15 days) 22569350 2012 Jun
nafcillin Antibiotics nifedipi[INVESTIGATOR_050] 62.6 145.1 500 mg 4 times daily (5 
days)12814453 2003 Jun
talviraline NNRTIs indinavir 61.7 181.2 500 mg TID (14 days) [ADDRESS_729400]
lopi[INVESTIGATOR_555544] 59.7 Not Provided 400 mg BID (4 weeks) 15060509 2004 Apr
modafinil Psychostimulants triazolam 57.6 35.7 200-400 mg QD (28 days) 11823757 2002 Jan
etravirine NNRTIs sildenafil 56.7 Not Provided 800 mg BID (13.5 days) NDA# [PHONE_11568]
lersivirine NNRTIs midazolam 51.4 105.5 1000 mg BID (14 days) 22527351 2012 Nov
Weak Inducers (AUC decreased by 20-50% or CL increased by 20-100% (less than 2 fold))
eslicarbazepi[INVESTIGATOR_555545] 49.4 98.4 800 mg QD (14 days) 23726291 2013 Sep
telaprevir Antivirals darunavir 48.4 Not Provided 1125 mg BID (4 days) NDA# [PHONE_11569]
garlic Food Products saquinavir 44.7 Not Provided caplet of GarliPure BID (20 
days)11740713 2002 Jan
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729401] (oral, 
unless 
otherwise 
specified)% ↓ AUC % ↑ oral CL Precipi[INVESTIGATOR_555542] (oral) PMID or NDA # Published
bexarotene Other 
Antineoplasticsatorvastatin 45.3 Not Provided 400 mg/m2 QD (at least 
two 4-week cycles)22057855 2012 Feb
amprenavir Protease Inhibitors lopi[INVESTIGATOR_054] 43.0 Not Provided 700 mg BID (2-4 weeks) 15668539 2005 Jan
raltegravir HIV-Integrase 
Strand Transfer 
Inhibitorsdarunavir 42.0 Not Provided 400 mg BID 21958880 2012 Feb
lesinurad Antigout and 
Uricosuric Agentsamlodipi[INVESTIGATOR_050] 41.9 72.5 400 mg QD (24 days) NDA # [PHONE_11570]
vemurafenib Kinase Inhibitors midazolam 39.4 Not Provided 960 mg BID (15 days) NDA # [PHONE_11571]
troglitazone Thiazolidinediones simvastatin 37.7 Not Provided 400 mg QD (24 days) 11361054 2001 May
sorafenib Kinase Inhibitors sirolimus 36.9 Not Provided 200 mg BID (11 days) 21045832 2010 Nov
rufinamide Anticonvulsants triazolam 36.7 53.4 400 mg BID (11.5 days) NDA # [PHONE_11572]
sirukumab*** Immunomodulator
s Biologicsmidazolam 35.7 Not Provided 300 mg single dose 
subcutaneously26054042 2015 Dec
pleconaril Antivirals midazolam 34.6 52.8 400 mg TID (6 days) 16467135 2006 May
ginseng Herbal Medications midazolam 34.2 50.7 500 mg BID (28 days) 21646440 2012 Jun
boceprevir Antivirals darunavir 34.2 41.0 800 mg every 8 hrs (6 days) 23155151 2013 Mar
sulfinpyrazone Antigout and 
Uricosuric Agentscyclosporine 33.9 (change in 
Cavg)200 mg/day 11124491 2000 Dec
ginkgo Herbal Medications midazolam 33.7 52.6 120 mg BID (28 days) 18205997 2008 Feb
vinblastine Vinca Alkaloids midazolam IV 33.2 48.8 not provided (4 cycles) 20959500 2010 Nov
nevirapi[INVESTIGATOR_555546] 32.5 Not Provided 200 mg QD (14 days), then 
BID (19 da ys)10191212 1999 May
armodafinil (R-modafinil) Psychostimulants midazolam 32.2 54.7 100-250 mg/day (31 days) 18076219 2008
ticagrelor Anticoagulants and 
Antiplateletsmidazolam 31.7 46.5 400 mg QD (6 days) 23870610 2013 Jul
LCL161 Cancer Treatments midazolam 29.8 34.0 600 mg single dose 23585187 2013 Jun
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729402] (oral, 
unless 
otherwise 
specified)% ↓ AUC % ↑ oral CL Precipi[INVESTIGATOR_555542] (oral) PMID or NDA # Published
vicriviroc and ritonavir Treatments of AIDS ethinyl 
estradiol29.4 Not Provided 30 mg vicriviroc and 100 mg 
ritonavir QD (10 days)[ADDRESS_729403]
ritonavir Protease Inhibitors ethinyl 
estradiol29.2 Not Provided 100 mg QD (10 days) [ADDRESS_729404]
prednisone Corticosteroids tacrolimus 29.0 Not Provided 1.5 mg/kg/day 15787787 2005 Apr
oxcarbazepi[INVESTIGATOR_555547] 28.1 Not Provided 450 mg BID (7 days) 8451779 1993 Feb
danshen Herbal Medications midazolam 27.9 32.8 4 g TID (14 days) 20565457 2010 Jun
clobazam Benzodiazepi[INVESTIGATOR_555548] 27.7 Not Provided 40 mg QD (15 days) 22422635 2012 Apr
echinacea Herbal Medications midazolam 27.3 37.5 500 mg TID (28 days) 20653355 2010 Aug
ticlopi[INVESTIGATOR_555549] 27.0 50.0 250 mg BID (4 days) 23361846 2013 Mar
brivaracetam Anticonvulsants ethinyl 
estradiol26.8 37.3 200 mg BID (21 days) 24386664 2013 Dec
Stribild* Treatments of AIDS ethinyl 
estradiol26.2 31.3 150 mg ELV + 150 mg COB 
+ 200 mg EMT+ 300 mg 
TENNDA # [PHONE_11550]
pi[INVESTIGATOR_555550] 26.0 Not Provided 45 mg QD 7 days Actos ® Product 2004 Aug
VIEKIRA PAK** Antivirals darunavir 25.7 Not Provided See note** NDA # [PHONE_11573]
dexamethasone Corticosteroids aprepi[INVESTIGATOR_053] 25.0 Not Provided 8 mg/day (5 days) NDA # [PHONE_11574]
terbinafine Antifungals midazolam 24.5 Not Provided 250 mg QD (4 days) 8527290 1995 Sep
quercetin Food Products midazolam 23.6 Not Provided 500 mg QD (13 days) 21680781 2012 Jun
glycyrrhizin Herbal Medications midazolam 23.0 Not Provided 150 mg BID (15 days) 20393696 2010 Aug
aprepi[INVESTIGATOR_555551]-1 
Receptor 
Antagonistsmidazolam IV 22.1 28.5 125/80 mg QD (3 days) 14973304 2004 Mar
pretomanib (PA-824) Antibiotics midazolam 22.1 20.7 400 mg QD (14 days) 23689718 2013 Aug
oritavancin Antibiotics midazolam 18.7 23.9 1200 mg IV single infusion NDA # [PHONE_11575]
AZD 7325 Anxiolytics midazolam 18.7 22.6 10 mg QD (12 days) 22122233 2012 Jul
methylprednisolone Corticosteroids cyclosporine 15.8 35.0 16 mg/day (12 days) then 8 
mg/day (6 months)12164891 2002 Sep
topi[INVESTIGATOR_555552]12.0 20.2 50 mg/day (21 days) 12681003 2003 Apr
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/[ADDRESS_729405] (oral, 
unless 
otherwise 
specified)% ↓ AUC % ↑ oral CL Precipi[INVESTIGATOR_555542] (oral) PMID or NDA # Published
1- Ritonavir has dual effects of simultaneous CYP3A inhibition and induction, and the net pharmacokinetic outcome during chronic 
ritonavir therapy is inhibition of CYP3A activity.2- All the substrates presented in the table are sensitive CYP3A substrates (see definition in FDA guidance) except verapamil, 
cyclosporine, ethinyl estradiol, and delavirdine.
* Stribild is a combination of elvitegravir, cobicistat, emtricitabine and tenofovir DF
** VIEKIRA PAK = paritaprevir/ritonavir/ombitasvir 150/100/25 mg QD + dasabuvir 250 mg BID for 14 days
 *** Sirukumab is not a CYP inducer per se. It reverses the IL-6 mediated suppression of CYP3A activity in patients with active rheumatoid 
arthritis 
M and T Drug Interaction Database® - Copyright 2016 www.druginteractioninfo.org Database Searched in April 2016
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE].3 APPENDIX C : PATIENT’S PI[INVESTIGATOR_142990]: OLAPARIB 
Today’s date ________________________________ 
Patient Name_______________________________ Patient Study ID ______________________ 
Cycle #__________ Days 1-14
(initials acceptable for patient’s name) 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each cycle (28 days). 
2. You will take each dose twice a day 12 hours apart on days 3 – 13* and days 17 -26*. Each dose is 
___150mg tablets and ___ 100mg tablets. You must take the tablets with a large glass of water. A light snack 
(biscuits/ toast) is also recommended to help reduce nausea.
3. Record the date, the number of tablets you took, and when you took them. (*You will be given additional 
instructions about the timing of the doses on Days 13 and 26 each cycle.)
4. If you have any comments or notice any side effects, please record them in the Comments column. 
5. Please bring your pi[INVESTIGATOR_148369]. 
DAY DATE # TABLETS 
AND WHEN 
TAKEN: 
OLAPARIB 
AM PM
12 HOURS 
APARTCOMMENTS (side effects or missed doses)
1 Do not take 
olaparib
2 Do not take 
olaparib
3 _________AM 
_________PM
4 _________AM 
_________PM
5 _________AM 
_________PM
6 _________AM 
_________PM
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
1417 _________AM 
_________PM
8 _________AM 
_________PM 
9 _________AM 
_________PM 
10 _________AM 
_________PM
11 _________AM 
_________PM 
12 _________AM 
_________PM 
13 _________AM 
14 Do not take 
olaparib
Patient’s Signature: ________________________________________ Date: _________________________ 
The Study Team will complete this section: 
1. Date patient started protocol treatment______________ Date patient was removed from study _____________
2. Patient’s planned daily dose___________________ Total number of pi[INVESTIGATOR_555553] 1-14 __________________
Physician/Nurse Signature ____________________________________________________________________ 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
142Appendix C: Patient’s Pi[INVESTIGATOR_13355]: Olaparib
Today’s date ________________________________ 
Patient Name_______________________________ Patient Study ID ______________________
Cycle #__________ Days 15-28
(initials acceptable for patient’s name) 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each cycle (28 days). 
2. You will take ___ tablets twice a day 12 hours apart on days 3 – 13* and days 17 -26*. Each dose is 
___150mg tablets and ___ 100mg tablets. You must take the tablets with a large glass of water. A light snack 
(biscuits/ toast) is also recommended to help reduce nausea. (*You will be given additional instructions about 
the timing of the doses on Days 13 and 26 each cycle.)
3. Record the date, the number of tablets you took, and when you took them. 
4. If you have any comments or notice any side effects, please record them in the Comments column. 
5. Please bring your pi[INVESTIGATOR_148369]. 
DAY DATE # TABLETS 
AND WHEN 
TAKEN: 
OLAPARIB 
AM PM
12 HOURS 
APARTCOMMENTS (side effects or missed doses)
15 Do not take 
olaparib
16 Do not take 
olaparib
17 _________AM 
_________PM 
18 _________AM 
_________PM
19 _________AM 
_________PM
20 _________AM 
_________PM 
Abbreviated Title: EP0057 in Advanced Cancers
Version Date: 08/16/2024
[ZIP_CODE] _________AM 
_________PM 
22 _________AM 
_________PM 
23 _________AM 
_________PM
24 _________AM 
_________PM 
25 _________AM 
_________PM
26 _________AM 
27 Do not take 
olaparib
28 Do not take 
olaparib
Patient’s Signature: ________________________________________ Date: _________________________ 
The Study Team will complete this section: 
1. Date patient started protocol treatment______________ Date patient was removed from study _____________
 
2. Patient’s planned daily dose___________________ Total number of pi[INVESTIGATOR_555553] 15-28 _______________
3. Total number of pi[INVESTIGATOR_555554] (Days 1-28)___________
Physician/Nurse Signature ____________________________________________________________________ 